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Abstract 
 PepT1 (SLC15A1) is a low affinity high capacity, di- and tri-peptide transmembrane 
transporter primarily located in the brush border membrane in the small intestines.  As well as 
transporting oligopeptides, PepT1 has been discovered to transport a wide range of xenobiotics 
including, β–lactams and ACE inhibitors. This broad substrate capacity makes PepT1 ideal as a 
vehicle for the targeted delivery of xenobiotic prodrugs. It has been shown that our hydrolysis 
resistant thiodipeptide PepT1 substrates (e.g. A and B) can be used as ‘carriers’ for the prodrug 
targeting of poorly bioavailable drugs towards PepT1 via the strategy illustrated below.  
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 In this thesis, using this approach, the xenobiotics attached to our carriers will be 
expanded from commercially available drugs to new chemical entities which display undesirable 
physiochemical properties, such as the Aurora kinase inhibitor C.  
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 The discovery that PepT1 is over-expressed in pancreatic adenocarcinoma cell lines, AsPc-
1 and Capan-2,4 has also led to research being undertaken into targeted anti-cancer therapy via 
our thiodipeptide carriers.   The use of PepT1 targeting in cancer therapy has the potential to 
reduce side effects due to the minimisation of off target delivery. Pancreatic cancer often has a 
poor prognosis, with only a 5% survival rate 5 years after diagnosis.  Thiodipeptide D will be 
shown in this research to significantly reduce cell proliferation and vitality in AcPc1 cells. This is 
the first time that reduced cell proliferation by ibuprofen or an ibuprofen prodrug has been 
reported in this cell line. The use of our thiodipeptides to improve the oral bioavailability of an 
oncology drug through PepT1 targeting will also be explored.   
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The development of new hydrolysis resistant dipeptide carriers will also be explored as the 
presence of a sulfur atom in our present carriers has historically resulted in non-crystalline 
prodrugs being synthesised, which is not ideal for formulation.  
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1.1 Drug delivery via the oral route 
 Oral administration is often the favoured route of drug delivery.  The simplicity of 
swallowing a pill allows the patient to administer the dose at home without the need for training 
or special apparatus and increases the likelihood of patient compliance.1 However, the 
development of drugs for the oral route can be particularly challenging. Any drug administered 
orally faces obstacles before it can pass into the bloodstream and become effective. How much of 
this dose is absorbed and becomes available at the site of action is often referred to as 
bioavailability.  Drugs administered intravenously have a 100% bioavailability by this definition.  
 Oral bioavailability is determined by whether the drug is stable in the gastrointestinal 
tract, how water soluble it is, its dissolution rate, how well it is able to pass though gut wall 
mucosa of the gastrointestinal tract into the hepatic portal vein, whether it is an efflux 
transporter substrate and whether it is able to remain intact during first pass metabolism.1 
Absorption of the drug through the gut wall of the gastrointestinal tract is the primary 
determinant of bioavailability, as this determines what quantity of the initial dose will reach the 
bloodstream.    
 
Figure 1 Mechanisms of absorption across a cell membrane. 
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Drugs which can passively diffuse through the cell are thought to generally follow Lipinski’s 
‘rule of 5’.2 These are; 1) a molecular weight less than 500 gmol-1, 2) no more than five hydrogen 
bond donors, 3) no more than ten hydrogen bond acceptors, 4) a LogP (partition co-efficient, a 
measure of lipophilicity) of less than five.  
1.2 Strategies to improve oral bioavailability 
 During drug development compounds are optimised for maximum efficacy at a target, 
with the lead compounds having the best in vitro action. However, they may display a poor in vivo 
pharmacological effect due to their physiochemical properties.  This may be low bioavailability, 
rapid metabolism and/or excretion. The strategies to overcome these issues can be grouped into 
three main categories; Formulation, bioactivity compromise in order to include good oral 
absorption features into the drug design and prodrug design.1  
1.2.1 Prodrugs 
 A prodrug is a chemical precursor of a drug which undergoes enzymatic or chemical 
biotransformation in cells before eliciting a pharmacological effect.1 As an example, acid groups 
add to the hydrophilicity of a molecule and are often ionised at physiological pH. This can impede 
the drugs ability to cross a cells lipid bilayer. By changing the acid group to an ester group 
lipophilicity is increased and in vivo hydrolysis releases the original active drug.1 By utilising the 
prodrug strategy to change the physiochemical properties of a drug, oral bioavailability can be 
improved. This may occur by: increased solubility and stability; the reduction of drug degradation 
through metabolism; allowing the drug to be passively absorbed and targeting the drug towards 
an active transporter.1  Although the use of prodrugs can significantly improve oral bioavailability 
it is not without its drawbacks.   Finding a suitable prodrug form can be time consuming and 
therefore expensive.  By changing the structure of the molecule the pharmacokinetics and 
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pharmacodynamics may also be altered. Any by-products of the prodrugs breakdown into the 
active form must also be fully assessed.   
1.2.2 Targeting transporters 
 More than 400 membrane transporters have been annotated in the human genome.3 
These can be classified into two superfamilies; ATP-binding cassette (ABC) and solute carrier (SLC). 
Many of these transporters are localised into important barrier tissues such as the luminal and/ or 
basolateral membranes of enterocytes, hepatocytes and renal tubular epithelial cells as well as 
the blood-brain, blood-testis and placental barriers.3 Their role is to control the uptake and efflux 
of essential compounds such as amino acids, inorganic ions, nucleotides, sugars and xenobiotics. 
This may occur via either a facilitated or active mechanism.3 Facilitated transport allows solutes to 
move through the cell membrane down their electrochemical gradient without energy expense. 
Active transport involves a substrate moving across the membrane at an energy cost to the cell. 
This energy can be obtained from adenosine triphosphate (ATP) hydrolysis, or by the co-transport 
of another molecule (i.e. a proton) down its chemiosmotic gradient.  
The transporters involved in drug uptake in the small intestines are detailed in Figure 2 and 
Table 1. When targeting a drug towards a transporter, a drugs natural affinity can often be taken 
advantage of.  For example, peptidomimetics such as penicillins often display affinity for and are 
transported by PepT1. When this is not the case, prodrugs can be used to mimic the structural 
requirements needed for transport. There are several excellent recent reviews of the use of active 
transporters as a route for drug delivery.4-6 The use of PepT1 as a vehicle for drug delivery is a 
major area of research in our group. 
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Figure 2 The uptake transporters expressed in the intestinal enterocytes which are involved in 
drug transport. 
Table 1 Drug uptake transporters identified in the small intestine.3 
Transporter Substrate speci ficy Example substrate
OATPs Organic anions Ciprofloxacin
OCTs Low molecular weight 
organic cations
Metformin
OCTNs Carnitine and organic 
cations
Pyri lamine
MCT1 Unbranched a l iphatic 
and subs ituted 
monocarboxylates
Sal icyl ic acid
PepT1 Di- and tri -peptides Penici l ins
PMAT Organic cations Dopamine
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1.3 PepT1 
1.3.1 Location and transport 
PepT1 is primarily expressed in the brush border of the absorptive enterocytes which line 
the small intestine.  Its function is to transport the di- and tri-peptides, which are the result of the 
hydrolytic breakdown of dietary proteins, from the gastrointestinal tract into the blood stream.4  
As a result it is a high capacity transporter.7 Within the gastrointestinal tract expression is at its 
highest in the duodenum and jejunum, with lower levels being present in brush border membrane 
of the ileum.7 In comparison, the large intestine contains low levels of PepT1 unless small 
intestine trauma has occurred and no expression has been found in the stomach. PepT1 is also 
expressed, at low concentrations, in the liver, bile duct and nasal epithelium8 as well as in the 
kidneys where it plays a role in the re-absorption of proteins from the glomerular filtrate.9 PepT1 
has also been found to be over expressed in gastric, pancreatic and prostate cancer cells,10 this 
opens up the possibility of tumour specific drug delivery via the PepT1 transporter.   
Transport occurs across the cell membrane as a result of electrogenic H+-coupled 
oligopeptide co-transport (Figure 3).11  The symporting of a H+ ion down its concentration 
gradient, by way of facilitated diffusion, creates an electrochemical potential difference. This 
drives the di- and tri- peptides to move across the membrane against their concentration 
gradient. This co-transport was first demonstrated by Ganapathy et al.,12,13 whose further work 
went on to prove a mechanism that is now widely accepted.14-16 The inward H+ gradient is 
maintained by the apically located Na+/H+ transporter NHE317 and is indirectly dependent on 
extracellular Na+.18 With PepT1, generally only relatively weak binding of a substrate is seen. This 
is due to the necessary rapid release of substrates after transport. A high affinity substrate for 
PepT1 is classed as having a binding affinity less than 1 mM and a medium affinity substrate has a 
binding affinity less than 5mM whereas typical enzymatic binding is in the nM range.   
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Figure 3 The mechanism of transport for a PepT1 substrate. 
 
 The indirect dependence of peptide transport on Na+ was first proposed by Ganapathy et 
al. in 1983.11 Thwaites et al.19, 20 have since demonstrated this model using Caco-2 cell monolayers 
loaded with the dye 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein (BCECF). It was shown that H+/ 
peptide co-transport resulted in intracellular increase in pH. This reduces the H+ electrochemical 
gradient and therefore inhibits further peptide uptake.  H+ influx is minimised by the NHE3 Na+/H+ 
exchanger, which utilises the energy stored in the Na+ gradient to efflux H+ ions.  This was 
demonstrated by Thwaites et al. who showed that inhibition of NHE3 reduced peptide 
transport.16 The net result of the H+ cycling mechanism is a microclimate surrounding the 
microvilli of the brush boarder membrane of pH 6, which is not affected by the pH of the small 
intestine.21  
There are several other transporters within the human body which display proton-
coupled oligopeptide transport.  These are the renal peptide transporter PepT2 and the peptide/ 
histidine transporters PhT1 and PhT2, which alongside PepT1 are classified as the SLC15 family.  
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PepT1 is structurally most similar to PepT2 which is found mainly in the epithelial cells of the 
kidney tubule, where its role is to recover peptides from urine. Due to its location in areas that 
generally have low peptide concentrations, unlike PepT1, it is a low capacity transporter.  PepT2 
also displays a much higher affinity for di- and tri-peptides, as necessitated by its protein 
scavenging role.22  
When transporting a substrate PepT1 is able to mediate electrogenic substrate influx, 
independent of net charge.23 However, the rate and capacity of PepT1 to transport neutral and 
charged peptides is thought to be affected by extracellular pH.  This was first proposed 
independently in 1996 by the Leibach23 and Daniel24 research groups, before being expanded by 
Irie in 2005.25 The Daniel group24 observed that neutral and charged substrates differently 
affected both the Michaelis-Menten affinity constant (Km) and the maximal inward current (Imax) 
values as a function of membrane potential (Vm) and external pH. Utilising rabbit mRNA 
expressing Xenopus laevis oocytes it was found that a decrease in external pH induced an increase 
in the rate of transport of anionic species, and to a lesser extent neutral species.  In contrast an 
increase in external pH induced an increase in the rate of uptake of cationic species. The proton 
stoichiometry of transport was investigated by Temple et al.26 and alluded to by Leibach.23 Two 
protons are co-transported alongside anionic species, whereas neutral and cationic peptides are 
only transported with a singular proton, thus maintaining the membrane potential (Figure 4).  
 
Figure 4 Model to show how PepT1 mediates electrogenic substrate influx at varying pH. 
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Once a substrate has been transported into the cell, any di- and tri peptides can be 
hydrolysed into their constituent amino acids by peptidases located within the cytosol.  The 
resultant amino acids are transported out of the cell and into the blood stream via basolateral 
amino acid transporters.27 Available information suggests that at least six amino acid transporters 
fulfil this role.28-30 Not all peptides, such as Gly-Sar, are susceptible to hydrolysis which makes 
them ideal as controls in transport experiments.  Dyer et al.31 was the first to study peptide 
transport through the basolateral membrane.  Using Caco-2 cells Berthelson et al.32 showed that 
the uptake kinetics had a Michaelis-Menten like relationship which is indicative of carrier-
mediated transport. There is disagreement as to whether PepT1 transport is proton dependant, 
with several papers being published suggesting this is not the case.33-35 However, Thwates,19 
Dyer31 and Berthelsen32 all agree that transport is in fact proton dependant. Berthelsen offers the 
explanation that the differing views may be due to experimental set up, with the apical pH of 6.0 
used by Irie,34 Saito,35 and Terada33 resulting in a lower proton gradient across the basolateral 
membrane. All studies agree that the basolateral peptide transporter has a lower capacity than 
PepT1, but broad substrate specificity to include not only peptides but peptidomimetics. No 
specific transporter has been universally accepted as fulfilling the role of basolateral peptide 
transporter. Shepard et al.36 has suggested a 112 kDa protein but little other characterisation at 
the molecular level has been carried out. 
1.3.2 Regulation 
When considering PepT1 as a vehicle for oral drug delivery attention must be paid to 
regulation of the protein in the small intestines. Any changes could significantly impact oral 
bioavailability which is particularly significant in prodrugs with small therapeutic windows.   The 
regulation of PepT1 intestinal expression could emanate from pathological, pharmacological and 
physiological factors. These changes may be nonspecific such as nutritional status or a disease 
state which changes expression and/or membrane surface area. Specific inhibition of the 
transport mechanism may occur either by blocking the PepT1 protein or by altering any of 
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chemiosmotic gradients necessary for transport. Attention must also be paid to any substance 
that alters the expression of PepT1 this includes transcription and translation which affects the 
levels found in the enterocytes. There are several in depth reviews of the regulation of PepT1, 
primarily from an in vitro perspective.4,36,38 Highlighted below are the aspects which potentially 
play a significant role in the oral bioavailability of PepT1 transported drugs. 
Upregulation of PepT1 has been reported in bowel subjected to inflammation, starvation 
and a high protein diet. Ziegler et al.39 reported that humans with Short Bowel Syndrome, small-
bowel resection or a combination of small-bowel plus colonic resection, displayed a 5 fold 
increase in colonic PepT1 expression. This shows that the bowel is able to mitigate peptide 
absorption dysfunction after small intestine damage. Increased colonic PepT1 expression has also 
been reported in patients with chronic ulcerative colitis (chronic inflammation of the colon) and 
Crohn’s disease (an inflammatory disease of the intestines).40 The colon has a significantly higher 
bacterial population than the small intestines, resulting significantly higher concentrations of 
bacteria derived di- and tri-peptides. These small peptides are transported by PepT1 and have 
been shown to contribute to colonic inflammation.41,42 If in these cases PepT1 can be inhibited or 
downregulated in the colon, then patients could potentially see an ease in some symptoms. 
Habold et al.43 showed that in male Winsor rats subjected to prolonged fasting, upon the 
mobilisation of stored fats PepT1 expression significantly increased.  Ma et al.44 has since shown 
in vivo that this can occur in as little as 16 hours. The expression of intestinal PepT1 has also been 
found to increase in response to high dietary protein levels,45 and has been shown to have a  
diurinal rhythm based on habitual feeding times.46 
Hormonal expression has been found to both up regulate and inhibit PepT1 expression in 
the small intestine. Ashida et al.47 showed decreased PepT1 expression in the small intestines of 
rats after hyperthyroidism was induced.  The same group also demonstrated reduced PepT1 
expression in Caco-2 cells upon treatment with the thyroid hormone 3,3’,5-triido-L-thyronine.48 
Stimulation of PepT1 activity by insulin has also been found in Caco-2 cells. Thamotharan et al.49 
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showed that physiological concentrations of insulin stimulated Gly-Gln uptake 30-60 minutes after 
dosing. This is thought to occur as a result of insulin binding to a receptor in PepT1 as the 
stimulation was blocked with an inhibitor. Remarkably, increased expression of PepT1 is also 
noted in a sex dependant manner in rats induced with diabetes. In female rats an increase in 
mRNA lead to increased PepT1 expression. However, in male rats an increase in mRNA lead to a 
decrease in PepT1 expression. It was thought that this difference may be due to a sex dependent 
hormone such as oestrogen.50  
Zinc, iron and copper ions have also been shown to have an inhibitory effect on the PepT1 
transporter.51 This suggests that supplements or medications containing these ions may alter the 
uptake of PepT1 transported drugs.  This inhibition can most likely be attributed to the cations 
competitively inhibiting H+ binding. Similarly, any drugs which affect the chemiosmotic gradient of 
a cell can affect PepT1 transport. This usually occurs via inhibition or stimulation of the sodium-
proton antiporter. Known drugs which do this include calcium channel blockers such as 
nifedipine52 and the diuretic amiloride.53 Caffeine,54 as well as several naturally occurring 
flavonoids55 have also been shown to affect PepT1 transport via interaction with the sodium-
proton antiporter. This may have significance for PepT1 drug substrates with narrow therapeutic 
windows and is a much underexplored area. 
1.3.3 Discovery 
In 1978 Kimura et al.56 discovered that the abnormally high bioavailability of penicillin β-
lactam antibiotics was due to a mechanism of absorption which was the same as dipeptides. This 
led not only to the discovery of PepT1, but also to its potential as a vehicle for targeted delivery. 
Up until this point it was only known that dipeptides were transported via a separate mechanism 
to amino acids, which were known to be actively transported. The discovery centred around β-
lactams as they have a high bioavailability, even though are ionised at physiological pH and have 
low lipid solubility so therefore should not be absorbed.    
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Hou and Poole57 were the first to note the physio-chemical similarities between amino 
acids and β-lactams (which have a peptide like core structure).  This led to the theory that the 
absorption of both may occur via the same process. This speculation was further strengthened by 
Levine,58 who discovered that drug absorption by active mechanisms is limited to compounds 
bearing a structural resemblance to the products of the gastrointestinal break down of food.   
Utilising the everted gut sac technique, in which a rat intestine is used to study intestinal 
absorption, Dixon and Mizen59 investigated the transport of several β-lactams. Although no 
relationship between the transport of amino acids and β-lactams was discovered, the transport of 
cyclacillin became saturated once a certain concentration was reached.  It was also noted that the 
forward flux of cyclacillin was far greater than its backward flux. It had been recently discovered60 
that dipeptides were transported via a separate mechanism to amino acids.  Dixon and Mizen59 
postured that it would be interesting to see if cyclacillin uptake was via the same mechanism as 
dipeptides.  This work was in fact carried out by Kimura et al.56 using in situ perfusion, leading to 
the discovery of PepT1.  
1.3.4 Structure 
The knowledge that PepT1 could transport substrates other than natural dipeptides 
prompted research into the pharmacophoric pattern required for PepT1 substrates. This has been 
conducted utilising both biological and chemical characterisation, as no crystal structure has yet 
been generated. By understanding the physical structure of PepT1, its binding site and the 
conformational change involved in transport, greater understanding can be applied to the limits 
of size and spatial arrangement for PepT1 targeted drugs.   
PepT1 is a member of both the proton-dependent oligopeptide transporter (POT) and 
major facilitator superfamily (MFS) and is encoded by the SLC15A1 gene. It was first functionally 
characterised and cloned from a rabbit small intestine in 1994 by Fei et al.61 and later that year by 
Boll et al.62   Human PepT1 (hPepT1) was subsequently cloned by Liang et al.63 in 1995. It was 
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found to contain 708 amino acid residues and be a 81% match to rabbit PepT1, which contains 
707 amino acid residues.  In the first paper to be published on the structure of PepT1, utilising a 
hydropathy plot based on the Kyte-Doolittle algorithm, Fei61 predicted the presence of 12 
transmembrane spanning domains.  This was subsequently confirmed by Covitz et al.64 using EE 
epitope tagging. Covitz65 also showed that the C-terminus of hPepT1 was intracellular and a large 
extracellular loop existed between transmembranes 9 and 10. The role of this large loop is still 
unknown, but it has been shown to contain several putative glycosylation sites.  
The first attempt to elude the structure of PepT1 via computer modelling came with 
Vincent Lee’s group.66-67 Models of hPepT1 were generated based on minimising the facial 
interactions of paired transmembrane domains. This was based on a study by Fei et al.68 that 
predicted that the α-helical transmembrane domains are important for substrate/ H+ binding.  In 
their models both Bolger and Yeung arranged the transmembrane sequences of PepT1 helically, 
so that each had 7 faces and therefore 49 possible interactions. After minimising and modelling 
the 12 transmembrane domains, taking into consideration amphipathicity and hydrophobicity, 
they predicted the arrangement of the domains around a central channel.  Bolger also modelled 
the presence of the PepT1 substrates Gly-Gln and Gly-Gly-Gly in the created channel. Through this 
work several amino acid residues that have a potential interaction with bound substrates were 
identified (Figure 5).  
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Figure 5 Lee’s models of the substrate binding site of PepT1. Left: A schematic view looking at 
the computationally modelled transmembrane domains buried in the phospholipid 
membrane.67 Middle:  A schematic view of the lipid-bilayer showing the arrangement of all 12 
transmembrane domains.69  Right: The vestibule model showing the amino acid residues 
identified as potentially interacting with a substrate. 69 Reproduced with the kind permission of 
the publishers, © Elsevier Ltd.  
 
Lee’s group69 further refined their model in 1999, with the prediction of the presence of a 
vestibule in the centre of the modelled channel large enough to hold a dipeptide.  To test the 
vestibule model, site directed mutations were made to the residues identified by Bolger as being 
potentially involved in substrate interaction. This work was primarily performed by the Lee and 
Meredith research groups and showed that if mutated all residues identified in the vestibule 
model, except E26 and Y588, have a detrimental effect on rabbit and/or human PepT1 function. 
Despite the mutation of Y588 having no effect on transport, when several other tyrosine residues 
were systematically mutated effects were seen in affinity and transport rate.70 Interestingly, 
mutation of both R282 and D341 have been shown to alter the pH profile of PepT1 without 
affecting transporter function.71,37 However, the double mutant R282D-D341R had no effect on 
pH profile suggesting that these residues are involved in a salt bridge.   
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Several studies have shown that histidyl residues participate in proton and substrate 
recognition,37 but are not included in Lee’s model. Of note is H57, located on transmembrane 
domain 2.  When Fei et al. 72 mutated this residue they found the mutant PepT1 was no longer 
able to transport substrates.  To find out if the residue was responsible for H+ binding and 
therefore initiating co-transport, Chen et al.73 mutated the aromatic residues tyrosine 56 and 
tyrosine 64 which are located near H57.  They concluded that by interacting with H57 the 
aromatic tyrosine residues stabilize the charge on the H+, confirming that H57 is essential for the 
normal function of PepT1.   
Other site directed mutagenesis work of note is the investigation of the residues in 
transmembranes 3,74 575 and 776 for involvement in the putative central channel of PepT1. Each of 
the amino acid residues in these transmembrane domains were systematically changed to a 
cysteine so that the effect of each residue could be assessed.  Several residues were theorised to 
play an important structural role in transporter function (Figure 6) as negligible Gly-Sar uptake 
was seen in PepT1 which had these residues mutated. Two of the mutated transporters Y287C- 
and M292C-hPepT1 were not found to express at the plasma membrane, suggesting that these 
residues may be integral for transcription and/or translation. By assessing the solvent accessibility 
of the various residues the orientation of transmembrane domains 3, 5 and 7 could be eluded and 
all were predicted to lie diagonal to the plane of the membrane. 
The site directed mutagenesis of PepT1 is an expanding area of research and plays a 
critical role in the identification of the function of areas and residues within the transmembrane 
domains and loops. This includes the residues responsible for substrate binding and recognition, 
as well as salt bridges and the conformational changes that are involved in transport.    There are 
several comprehensive reviews on the work determining function of domains using site directed 
mutagenesis.77,78 
17 
 
 
Figure 6 The secondary structure of human PepT1. 
 
The uses of chimeras have also been important in elucidating the function of each 
transmembrane domain, whereby different regions of human PepT1 are spliced with rat PepT2.   
Transmembrane domains 7-9 have been found by Fei et al. 68 to be important in the structure of 
the binding site, as they play a role in determining the affinity profile.  As PepT2 has a much 
higher affinity than PepT1, it was hoped that by increasing the quantity of PepT2 from the C-
terminus end binding affinity would be increased. It was discovered that the replacement of 
transmembrane domains 10 ½ to 12 with PepT2, did not affect the affinity profile, suggesting that 
they do not play a role in substrate binding.  However, once the chimera contained 50% PepT2 it 
displayed increased affinity similar to wild type rat PepT2.  Expanding this research, Terada et al.79 
reasoned that substrate specificity was located in the N-terminus.  Döring et al.80 concluded that 
the N-terminus was not involved in pH dependency. However, transmembrane domains 2 and 3 
did appear to be. This is in line with the placement of H57, which is thought to be involved in the 
binding of H+ for co-transport. 
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1.3.5 PepT1 homologues  
Further insight into the structure of PepT1 was obtained by comparison of the published 
crystal structures of LacY81 and GlpT82 which are homologous 12 membrane domain POT 
transporters. The similarity in the structures of LacY, a proton-coupled lactose permease 
transporter, and GlpT, a phosphate coupled glycerol-3-phosphate antiporter, was shown by 
Ambramson et al.83 When both 3D structures were superimposed only the transmembrane 
domains 2 and 8 were displaced.  This displacement may be due to the fact that unlike GlpT, LacY 
was crystallised while bound to a substrate.  
As PepT1 is also a member of the major facilitator superfamily, Meredith and Price84 
decided to homology model rabbit PepT1 against the crystal structures of LacY and GlpT.  As 
PepT1 contains a large extracellular loop that neither LacY or GlpT contains, this was removed and 
a modified form of the rabbit PepT1 overlaid on both structures. The modified PepT1 (rPepT1-
trunc) was then run through the transmembrane prediction program MEMSAT3.  In the model 
proposed by Meredith many of the transmembrane domains are not adjacent to their 
predecessor (Figure 7). This is contrast to Lee’s model which was based on the assumption that 
there is 3D restriction of the transmembrane domains. Meredith’s model also predicts that 
several of the transmembrane domains lie diagonal to the plane of the membrane.    
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Figure 7 Meredith model of the arrangement of rPepT1-trunc’s 12 transmembrane domains. 
Left: A cartoon showing several of the domains lying diagonal to the plane. Right: A helical 
wheel plan of r-PepT1-trunc. Reproduced with the kind permission of the publishers and 
authors, © Springer Science and Business Media, LLC (2007)84 
The first topology model of a POT transporter with a similar substrate recognition pattern 
to PepT1 was published by Weitz et al.85 in 2007. YdgR, a POT transporter found in E. coli, was 
found to transport both di- and tri-peptides and aminocephalosporins with similar affinities to 
that of PepT1. By representing a substrate recognition pattern which corresponds to mammalian 
PEPT1, the architecture of the substrate binding domain should be the same. However, YdgR does 
not contain a histidine reside in the area of H57, which is thought to be essential for the normal 
function of PepT1.  H121 is also absent in YdgR, although there is a histidine residue located 
nearby.  This suggests that the identification of the residues in YdgR which are responsible for 
transport activity would aid in understanding the mechanisms of PepT1. YdgR also lacks a large 
extracellular loop between the transmembrane domains 9 and 10, suggesting this region of PepT1 
is unlikely to be essential for the transport process.     
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Figure 8 Homology model of human PEPT1 overlaid with corresponding YdgR residues. 
 
The recently published crystal structures of four different prokaryotic POT transporters, 
has given insight into the alternating access transport cycle of PepT1. The first to be crystallised 
was PepTso
86 which is found in Shewanella oneidensis, an anaerobic bacterium, and has a 30% 
identity with to Pep1.  Newstead87 concluded that there was a central ligand binding site 
equidistant to the intracellular and extracellular sites which, when bound to a ligand, presented a 
novel occluded conformation. In contrast PepTst
87 found in Streptococcus oneidensis, was 
crystallised in an inward facing conformation. Two pairs of salt bridges R53-E312 and R33-E312 
were found to facilitate the close packing of gate helices at the extracellular end of the 
extracellular cavity, which are proposed to facilitate closure of the extracellular gate. The 
intracellular gate is thought to be controlled by a salt bridge between K126 and E400. It is 
proposed that the binding of a substrate and proton with the central ligand site disrupts this salt 
bridge and therefore facilitates the release of the intracellular gate. E400 corresponds to E594 in 
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human PepT1 and has been suggested by Meredith’s research group as being involved in 
transport. The third and fourth POT homologues GkPOT,88 from Geobacillus kaustophilus, and 
PepTso2,
89  found in Shewanella oneidensis, were crystallised in the inward open state with a 
peptide in the peptide binding site.  This only leaves the crystal structure of a substrate bound 
POT transporter in the outward open conformation to be captured for the sequence to be 
completed.  
 
Figure 9 The crystal structures of POT transporters which have given insight into the alternating 
access transport cycle of PepT1. Blue donates N-terminus and red the C-terminus. 90 Reproduced 
under the creative commons attribution licence.   
 PepT1 is able to accommodate a wide range of ligands whilst maintaining specificity for 
peptides two or three residues in length within the central ligand binding site. To better 
understand the mechanisms behind this, Lyons et al.91 determined the crystal structure of PepTst 
in complex with physiologically relevant di- and tri- peptides. L-Ala-L-Phe was found to sit laterally 
in the binding site, with the amino terminus forming a hydrogen bond with N328 and interaction 
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occurring with E400.  Coordination of the dipeptides carboxy terminus with N156 forms a ligand-
coordinated bridge between the C- and N-terminal bundles of PepTst. Two elongated cavities in 
the ligand binding site were observed. The first being 16 x 7 x 11 Å at the N-terminal end of the 
ligand and the second a hydrophobic pocket 10 x 10 x 3 Å accommodating the phenyl side chain.  
The position of the phenyl side chain brings it into close proximity to the side chain of Y68, causing 
π-π stacking interactions. This suggests that Y68 is involved in determining substrate specificity 
and corresponds to Y64 in human PepT1, which has been identified as being essential for 
transport. In contrast, L-Ala-L-Ala-L-Ala was found to sit vertically in the ligand binding site. 
However, poor electron density of the crystal structure means it cannot be established whether 
the C-terminus is orientated towards the cyctoplasmic or periplasmic space. 
 
Figure 10 Topology model showing amino acid residues similarities between; PepT1, PepTso, 
PepTst, GkPOT and PepTso2. 
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1.3.6 Identifying PepT1 substrate structural features. 
As there is no known structure for PepT1, the structural requirements of a PepT1 
substrate have had to be ascertained through extensive in vitro, in vivo and in-situ screening.92 
This has hindered the structure-based approach to targeted drug discovery as computer models 
cannot be made of the binding site. This would allow investigation into the capacity of PepT1 for 
drugs of varying size, hydrophobicity and functional groups, although the crystallisation of both a 
dipeptide and tripeptide in PepTst
91
 is a promising development.  
It was initially assumed that active transport was limited to compounds with structural 
resemblance to the products of dietary digestion. This was strengthened with the discovery that 
penicillin class β-lactam antibiotics, which contain an α amino group, are PepT1 substrates. 
However, the discovery that cephalosporin class β-lactam antibiotics, which lack an α-amino 
group are also transported, prompted research into other drugs that may be substrates.   As a 
result ACE inhibitors, bestatin, thyrotropin-releasing hormone and some renin inhibitors were 
shown to be actively transported by PepT1 (Figure 11).    
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Figure 11 Examples of the classes of drugs that are PepT1 substrates. 
24 
 
How closely a substrate must resemble a peptide and still be transported was further 
called into question with the discovery that 4-aminophenylacetic acid93 and subsequently ω-
amino fatty acids80 were able to bind and be transported by PepT1. This was the first indication 
that the presence of a peptide bond was also not a structural requirement for transport.  Döring 
et al.80 found that affinity of PepT1 for the substrates tested increased with increasing number of 
hydrogen bonding sites.  To assess whether the N- or C-terminus played a role in transport, the 
terminal amino or carboxylic groups of known substrates were removed. No transport occurred 
although binding affinity was maintained, suggesting that they both play a role in substrate 
recognition. 
The necessity of a terminal carboxylic acid group within a substrate was further 
investigated by Börner et al.94 utilising peptidomimetic alanyl anilides.  Removal of the terminal 
carboxylic group from known PepT1 substrates still resulted in molecules with medium binding 
affinities.  The introduction of a phenyl group in the carboxy terminal region was shown to 
improve binding affinity, which was further improved with the introduction of nitro group or a 
second benzene group. This shows that carboxyl group is not necessary in this area and can be 
replaced with a group which can participate in hydrogen bonding.  Interestingly, Börner also 
found that insertion of a CH2 group between the peptide NH and benzene ring in alanine-4-
nitroanilide (7) resulted in a greatly reduced binding affinity Ki = >30 mM. This suggests that a 
directional vector of the carboxylate site may be important for high affinity binding.   
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Figure 12 Peptomimetics used by Börner94 which are substrates of PepT1, but do not possess a 
free terminal carboxylic acid group. 
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 The necessity of a free amino terminus was demonstrated with the acetylation of the 
amino terminus of Phe-Tyr.95 Upon acetylation, the binding affinity of phenylalanine-tyrosine was 
significantly reduced.  The same molecules were also amidated at the carboxy terminus, resulting 
in a comparatively small decrease in transport affinity. This indicates that the amino terminus is 
the primary binding feature.  
In an attempt to further assess the structural features required for transport Vig et al.96 
used high throughput screening to test 79 di- and tri-peptides and 2 amino acids for PepT1 
activation. Surprisingly 20 of these did not induce PepT1, which contradicts the assumption that 
all di- and tri-peptides are PepT1 substrates.  Of these five were dibasic, which encompasses all of 
the dibasic peptides tested except His-His. This suggests that the bulky side chains of Arg, Lys and 
Orn are responsible for their lack of transport, rather than their charge.   Lys-Pro and Pro-Lys were 
also not transported. The study also attempts to suggest a model of the PepT1 channel by 
overlaying the lowest energy conformations of four dipeptides. They propose that substrates with 
aromatic side chains are subject to π stacking interactions with aromatic residues within the 
PepT1 binding site.  This is found to occur in PepTst.  
Within nature the L form of amino acids dominates.  It is therefore assumed that di- and 
tri-peptides containing two and three L- amino acids respectively would have the highest affinity 
binding.  Experimentally this has always been the case, with dipeptides which have L-
stereochemistry at the N-terminus showing the highest affinity. To probe the reason behind this 
preference the Bailey group97 synthesised and tested a series of constrained dipeptide analogues. 
In each case, surprisingly, the binding affinity was found to be higher in peptidomimetics with D- 
stereochemistry at the N-terminus.  This suggests that high affinity binding is achieved when the 
amino group is directed to the back of the plane.  
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Figure 13 The constrained dipeptide analogues used by Bailey97 to demonstrate high affinity 
binding when the free N-terminus is directed back in the plane. 
 To further probe the reason for the low binding affinity seen in D-conformation N-
terminus peptides, the half position of the N-terminus created by an α-aminoisobutyric (Aib) 
peptide was investigated. Working on the assumption that the oxygen on the 3rd atom of the 
molecule in Figure 14 forms a salt bridge with a specific histidine residue, its positioning becomes 
fixed within the PepT1 central ligand binding site. The bond between atoms 2 and 3 must 
therefore rotate to find the optimum conformation of the three substituents on atom 2 within the 
binding site.  
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Figure 14 The conformational arrangement of the N-terminus D- or L- tripeptide conformational 
isomer used in Baileys experiment.97 
By placing a methyl group on atom 4 gauche interactions occur between that methyl 
group and the two functional groups on atom 2. To avoid this and minimise the energy of the 
system, rotation of the bond between atoms 2 and 3 must occur. This alters their optimum 
positioning within the binding pocket.  Through the placement of either a hydrogen and a methyl 
or two methyl groups on atom 2 the D- or L-conformers or Aib analogue can be created. To avoid 
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gauche interactions and therefore reach an energy minimum, no rotation is required in the L-
residue. However, a rotation of approximately 120° must occur in the D-residue and 
approximately 60° in the Aib analogue. In these rotated positions the amino group of the L-
conformer (11) is in the experimentally deduced optimum position of being directed to the back 
of the plane; in the D-conformer (12) it is forward of the plane and in the Aib analogue (13) it is 
with the plane. It could therefore be assumed that the L-conformer (11) would have good binding 
affinity, the D-conformer (12) would have poor and the Aib analogue (13) would have a binding 
affinity somewhere between the two.  However, no significant difference in binding affinity was 
seen between the D-conformer (12) and Aib analogue (13).  This suggests that D-isomers have a 
lower binding affinity due to spatial constraints as the dipeptide makes its way down the binding 
pocket, not due to the positioning of the amino group. 
When an amide bond is in its partial double bond form, rotation of the bond is inhibited 
and either the cis and trans isomer can form.98 Rapid interconversion between these two isomers 
often occurs giving a specific cis/trans ratio. Favouritism for the trans isomer was first 
demonstrated by Brandsch et al.98 By using a thiodipeptide to stabilise the peptide bond, they 
were able to show that the trans isomer was preferentially transported. Caco-2 cells were 
incubated with Ala(S)Pro in a 62% trans/38% cis ratio.  After 60 minutes the intracellular content 
of the Caco-2 cells were analysed and found to contain 92% of the trans isomer.   Reanalysed after 
2 days the intracellular content was found to have re-equilibrated, showing that transport rates 
for the trans isomer are much higher than for the cis isomer.   The findings of this study was 
supported by the Bailey group99 using pH controlled thiodipeptides and Niida et al.100 using 
fluoroalkene and alkene containing dipeptide mimics.  
The presence of a D-amino acid at the carboxy terminus is tolerated, although lower 
transport rates are seen than if it is of the L-conformation.101   If the positioning of the carboxylate 
is absolutely fixed due to hydrogen bonding a histidine residue, then the difference in binding 
affinities seen for L- and D- residues must be explained in the side chain positioning (Figure 15).  
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Under the assumption that the L-conformation at the C-terminus has the highest binding affinity, 
as there is no interaction of the side chain with the binding pocket, it can be proposed that the 
side chain points out of the binding pocket.   The drop in binding affinity for the D-amino acids 
could therefore be proposed as being due to interaction of the side chain with the residues at the 
mouth of the binding pocket. Peptides that have pure D- stereochemistry have the lowest binding 
affinity of all enantiomers.97 
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Figure 15 Side chain positioning in L- and D- carboxy-terminus dipeptides. 
 
The Bailey group was the first to collate all of the published PepT1 substrate data, 
enhancing the pool with in vitro investigations of over 100 substrates.  This lead to the first 
template that attempted to encompass all of the substrate specificities.102 This work was later 
enhanced to give a predictive indication of how well a potential substrate would be transported 
by PepT1.103  
 
Figure 16 The Bailey PepT1 substrate template, showing the four key binding sites.104 
Reproduced with the kind permission of the publishers, ©2000 WILEY-BCH Verlang GmbH. 
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1.3.7 QSAR studies 
Prior to Newstead et al.91 determining the crystal structure of PepTso in complex with 
physiologically relevant di- and tri- peptides, quantitative structure affinity relationship (QSAR) 
modelling was used to assess the optimum binding conformation of a PepT1 substrate. Using a 
comparative molecular field analysis (CoMFA) and comparative molecular similarity indices 
analysis (CoMSIA), Gebauer et al.104 developed a pharmacophore model, which is supported by 
independent study in 2005 by Våbenø et al.4 Using CoMSIA standard deviation coefficient contour 
plots for steric properties, Gebauer was able to show that the poor binding affinity of D-
conformers was due to the side chains occupying disfavoured steric regions (Figure 17). Binding 
affinity was found to increase with dipeptides which largely occupied favoured regions i.e. L-trans 
conformers with bulky side chains. These favoured regions correspond to the same positions as 
the two elongated cavities in the ligand binding site of PepTst. It was also found that at the 
carboxy terminus all that was required for appreciable affinity was an area of high electron 
density, rather than a specific carboxylate group.  This is in keeping with previous groups work 
that alteration to the carboxy terminus has only a small affect on affinity.   CoMSIA standard 
deviation coefficient contour plots, showing lipophilic properties, indicated an overlapping region 
with C-terminus sterically favoured region.  This suggests, as in Bailey’s template, that a C-
terminus lipophilic side chain is favoured for high affinity binding.    
 
 
 
 
30 
 
                             
 
Figure 17 CoMISA standard deviation coefficient contour plots. Top: For steric properties. Green 
isopleths indicate regions where bulky groups enhance affinity. Yellow isopleths are regions 
that should be left unoccupied. Bottom: Electrostatic properties. The blue contour donates a 
region where positively charged groups enhance affinity.  The red contour group donated a 
region where negatively charged groups increase affinity.  Reproduced with the kind permission 
of the publishers, © 2015 American Chemical Society.104 
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2.1 Targeting drugs towards PepT1. 
 There have been two major routes undertaken in an attempt to improve the 
bioavailability of drugs through PepT1 targeting. Both routes involve turning the drug in question 
into a prodrug.  However, one approach focuses on turning the whole drug into a PepT1 
substrate, whilst the other involves attaching the drug to a standardised hydrolysis resistant 
PepT1 substrate.   
2.1.1 Changing the drug to make it a substrate.  
 Several successful PepT1 transported prodrugs have been created though the attachment 
of amino acids to drugs which already contain some peptidomimetic characteristics. L-dopa was 
one of the first drugs to which this prodrug method was applied. L-dopa is a naturally occurring 
psychoactive drug found in foods such as the velvet bean and is used primarily for the relief of 
Parkinson’s disease symptoms.  However, it undergoes metabolism by a decarboxylase enzyme in 
the gut wall causing variable bioavailability and poor absorption. Tamai et al.105 attempted to 
improve the bioavailability of L-dopa by attaching it to L-phenylalanine.  This created a dipeptide 
that was found to be recognised and transported in Caco-2 cells. Phenylalanine, the second amino 
acid moiety, can be metabolised by aromatic amino acid hydroxylases the body into L-dopa, and 
eventually to the target compound adrenaline. This means that by using phenylalanine, to create 
a PepT1 targeted prodrug, the number of L-dopa molecules per dose is doubled.  This prodrug 
approach has also been applied to several other drugs displaying poor bioavailability, as 
summarised in Table 2. In most cases the PepT1 prodrug is created through the addition of an 
amino acid or dipeptide via an ester linkage. This involves time consuming and expensive high 
throughput screening of potential monoester and diester prodrugs. When using this strategy 
consideration must be given to whether the prodrug can undergo PepT1 transport, as well as to 
the stability of the prodrug linkage to enzymatic cleavage in vivo prior to transport.  
34 
 
Table 2 Prodrugs which display improved bioavailability through PepT1 targeting. Parent drug 
displayed as black. 105-111 
Parent name and 
bioavailability 
Function Prodrug name and 
bioavailability 
Structure 
L-dopa             
Variable105  
Relieves 
Parkinson 
disease 
symptoms 
L-dopa-L-
phenylalanine x 40 
uptake in Caco-2105  HN
OH
O
O
H2N
OH
OH
18
 
DMAE                          
50%106 
Treats 
orthostatic 
hypotension 
Midodrine                                
93%106 
O
O O
N
H
O
NH2
19  
Eglumegad                          
10% in rat106 
Teats anxiety 
and drug 
addiction 
Talaglumetad                        
84% in rat106 
OH
O
HO
O
HN
O
NH2
20  
Alendronate                         
1.7% in rat106 
Used treat 
and prevent 
osteoporosis 
Pro-Phe-alendronate                        
75% in rat106 
N
H PO3H2
PO3H2
H2O3P
O
HN
O
N
H
21
 
Olenolic acid              
0.7%107 
Exhibits 
antitumor 
and antiviral 
properties 
L-valyl diester of 
olenolic acid                              
2.21-fold improvement 
in rats107 
H
H
H
HO
O
O
O
OHCl
.
H2N
22
 
Oseltamivir                   
4%108 
An antiviral 
licensed for 
influenza A+B 
virus 
GOC-L-Val                                 
48% in fasted and 23% 
in fed in mice108 
O
O
O
O
NH2O
HN
O
HN
NH2
NH
23
 
Acyclovir                      
12-20%106 
Treatment of 
viral herpes 
Valacyclovir                             
54%106 HN
N N
H
N
O
H2N
O
O
O
H2N
24  
Ganciclovir                   
6%106 
Treatment of 
viral herpes 
Valganciclovir                        
61%106 HN
N N
H
N
O
H2N
O
OH
O
H2N
25  
2'-C-methylcytidine              
10%109 
Anti-viral Val-2'-C-
methylcytidine                  
34%109 HN
O
O
O
OH
OH
O
O
NH2
26  
Vidarabine                       
~2%110 
Anti-viral Vidarabine-Ile                  
x 10 uptake in Caco-
2110 
N
N
N
N
H2N
O
HO OH
O O
H2N
27  
Didanosine                   
7.9% in rat106 
Treatment of 
HIV 
L-valyl ester of 
Didanosine                                          
47.1% in rat106  N N
N
N
H2N
O
O O
H2N
28  
Cidofovir                         
<5%111 
Anti-viral MeSer-Val Cidofovir  
x 20 uptake in rat 
perfusion111 
O
O
P
N
N
O
H2N
O
O
O
O
O
H2N
29  
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2.1.2 Attaching a substrate carrier. 
As very few drugs resemble oligopeptides, turning the whole drug into a PepT1 substrate 
has limited applicability. Utilisation of an easily hydrolysable, standardised, PepT1 recognised 
attachment is a more pertinent approach. This concept was first put forward by Taub’s group with 
the attachment of benzyl alcohols to the amino side chain of several dipeptides112-3 (Figure 18). All 
dipeptides were transported by PepT1, with the L-dipeptides Glu(OBn)Sar (30) and Asp(OBn)Sar 
(31) having the highest affinity.  However, D-Glu(OBn)Ala (32) and D-Asp(OBn)Ala (33) were found 
to be much more stable than their L-dipeptide counterparts. Both 32 and 33 were shown to 
qualitatively release benzyl alcohol as a result of hydrolysis, whereas both benzyl alcohol and 
cyclisation products were formed from 30 and 31. This suggests that the L-dipeptides are 
hydrolysed by two parallel pathways.  
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Figure 18 Standardised dipeptide carriers investigated by Taub’s group.112, 113 
 
 In an attempt to examine if this method could be applied to larger molecules, the group 
expanded their research by attaching glucose-6-phosphatase inhibitors.114 Glucose-6-phosphatase 
inhibitors of the 4-(4-chlororphenyl)-4,5,6,7-terahydrothieno[3,2-c]pyridin-5-yl-phenylmethanone 
(34) type (figure 19) are active inhibitors of G-6-Pase, but lack in vivo activity. This is thought to be 
due to physiochemical characteristics that prevent passive diffusion and/or give poor aqueous 
solubility. It was hoped that attaching of an enzymatically stable dipeptide would cause an 
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increase in permeability. A selection of derivatives were therefore synthesised and tested for G-6-
Pase inhibitory activity.  The modified compounds 36 and 37 (Figure 19) still showed significant 
inhibitory activity, whilst 38 did not. However, when tested using Caco-2 cells 38 was the only 
compound found to be transported. Interestingly, whilst compound 36 was not subjected to 
efflux, its parent compound was. Efflux is the mechanism by which compounds are removed from 
a cell and can seriously affect the oral bioavailability of a drug. This study suggests the attachment 
of a dipeptide to a compound can potentially alter the ability of the resultant prodrug to be 
recognised and transported by efflux pumps. The group did not pursue this method further, 
deeming that there is a restriction on the size of molecule that can be attached to a peptide whilst 
still being a PepT1 substrate.  
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Figure 19 The 4-(4-chlororphenyl)-4,5,6,7-terahydrothieno[3,2-C]pyridin-5-yl-phenylmethanone 
derivatives and their prodrug counterparts used by Taub.114 
The greatest limitation of this work was the use of a D-Glu-Ala linker.  This was chosen as 
N-terminal D-amino acids are more enzymatically stable than their L- arranged counterparts.  
However, N-terminus D-amino acids are subject to spatial constraints as the peptide moves down 
the PepT1 binding pocket, resulting in lower binding affinities (section 1.3.6). The attachment of 
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the compound to the N-terminus R group means that the compound must be accommodated 
within the ligand binding site. Although a pocket has been shown to exist in this position in 
PepTst
91 (section 1.3.5), it is much too small to accommodate the moieties attached in this case. 
This means that the required arrangement of the dipeptide within the binding pocket cannot 
occur preventing transport.  If the linker chain was doubled back across the dipeptide, the 
attached moiety could be placed in a favourable region outside the PepT1 pocket.  Although this 
is an unlikely high energy conformation it would allow the required arrangement of the dipeptide 
to take place and may have been why 38 was transported.   
2.2 Using thiodipeptides as carriers. 
The transport of thiodipeptides by PepT1 had been demonstrated in 1998 by Brandsch et 
al.98 and later by our group (the Bailey group)99 in experiments to understand if PepT1 could 
differentiate between the cis-trans isomers of dipeptides (section 1.3.6).  During these 
experiments our group99 found that the inclusion of a sulfur atom on the N-terminus amino acid 
had no significant effect on PepT1 binding affinities when compared to its oxygen counterpart.  
Our group went on to create a series of thiodipeptides which were patent protected in 2005.115 
We were surprised to find that not only did the thiodipeptides bind efficiently to PepT1, but they 
were rapidly transported in vivo. As thiodipeptides do not contain a ‘classical’ peptide bond they 
are resistant to hydrolysis by peptidases within the gastrointestinal tract. This eliminates the need 
to use an N-terminal D-amino acid to ensure that the dipeptide reaches the enterocytes intact. 
Two thiodipeptide analogues, Ala(S)Ser (39) and Ala(S)Asp (40), with good binding affinities were 
proposed for the use as carriers to improve the bioavailability of drugs.  
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The carriers both display L-dipeptide configuration and have free N- and C-terminus. This 
allows optimum configuration within the PepT1 binding pocket, thereby increasing the chance of 
high binding affinity.  Drug moieties can be attached via an ether or ester linkage through the R2 
position on the C-terminus amino acid. Both carriers were tested in vivo using a range of benzyl or 
cyclohexyl ester or ether analogues and were found to give favourable binding affinities.115 To 
date 39 and 40 have been attached to several model drugs and commercially available drugs 
resulting in prodrugs which are transported by Pept1. Some of the work that had been completed 
within the group prior to the commencement of this project are highlighted below.  
Attachment of poorly soluble dehydrocholic acid to the Ala(S)Ser carrier (39) by Dr. R. 
Pettecrew resulted in a prodrug (41) which was both recognised and transported by PepT1 
(unpublished). This demonstrated for the first time the potential of the thiodipeptide prodrug 
method as a route for drug delivery. Unfortunately, the resultant prodrug was also poorly soluble, 
demonstrating that you cannot necessarily increase the solubility of a compound by attaching it to 
a dipeptide. 
O O
O
Ki = 0.05 mM
H2N
H
N
OH
S
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In order to activate the parent compound in the thiodipeptide prodrug, the ester or ether 
link between the carrier and the attached moiety must be hydrolysed in vivo. The toxicity of the 
carrier, as well as the parent drug, must therefore be assessed. Ala(S)Ser (39) was measured in rat 
using a single oral dose of 700 mg/kg. After 15 days no intercurrent deaths or weight loss 
occurred, suggesting that the carrier causes no negative pharmacodynamic effects.115    
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The first papers showing proof of concept with commercially available drugs were 
published by our group in 2009. In the first paper published, the carrier method was used in an 
attempt to improve the bioavailability of nabumetone (42) (Scheme 1).116 An attempt to couple 
the hydroxyimine directly to the Ala(S)Asp carrier (40) resulted in a compound that was too 
unstable to isolate or use, so to circumvent this, a glycol spacer was used. Not only did this 
improve the water solubility of the prodrug, but it allowed investigation into the effect of chain 
length on transport. 
 
 
 
 
 
 
 
 
 
 
Prodrugs 44 and 45 were tested in Xenopus lavis oocytes expressing rabbit PepT1 and 
were found to competitively inhibit the transport of D-Phe-L-Gln. They were also both found to be 
transported by PepT1 in Caco-2 cells.  The transport of both prodrugs was compared to the known 
thiodipeptide PepT1 substrate Thio-Phe-Ala. 44 was found to be transported 6.3 times faster than 
Thio-Phe-Ala and 45 1.3 times faster.  This is the first example of targeting a ketone drug towards 
PepT1.  
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Scheme 1 The metabolism of the nabumetone hydroxyimine prodrug in vivo and the 
two nabumetone hydroxyimine-carrier prodrugs tested in vitro. 
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The use of a glycol spacer was further investigated by our group in a second 2009 
paper.117 We were intrigued that the use of a longer glycol chain in nabumetone prodrugs 
resulted in higher binding affinity and wished to explore this further. Benzoic acid and benzoic 
alcohol, separated from our carriers by various chain lengths, were assessed for binding affinity.  
The use of a triethylene glycol spacer between drug moiety and carrier significantly decreased 
transport rate when compared to the diethylene glycol spacer counterparts. This suggests that 
there is a limit in the tolerance of PepT1 to accommodate hydrophobic groups placed at 
considerable distance.  Other than aiding the coupling of a drug to the carrier, a benefit of using a 
spacer may be to set the drug slightly away from the mouth of the binding pocket. Large drugs, 
especially if branched, attached directly to the carrier may cause negative interactions with the 
binding pocket. This may either decrease binding affinity or prevent transport from occurring.  By 
setting the drug slightly away from the pocket PepT1 is likely to recognise the presence of only 
the carrier, not the attached drug.  As a result, the mechanism of transport will already be in 
motion before the attached drug is detected and in a ‘piggy backing’ method the drug will be 
pulled through.   
Our group believes that through the use of the PepT1 carrier method a wider range of 
pharmaceuticals may be brought to the market via the oral route. By determining the limits of the 
PepT1 transporter for drug moiety attachments it is hoped that not only can new drugs be 
formulated using this technique, but that existing drugs can be reassessed.  With this in mind a 
collaboration was formed with AstraZeneca. The main purpose of the collaboration was not only 
to further explore the limits of a PepT1 substrate, but also to use the thio-dipeptide prodrug 
stratagy in an attempt to improve the bioavailability of existing AstraZeneca compounds. This was 
the main focus of my research. 
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2.3 Synthesis of thiodipeptide carriers. 
 Ala(S)Asp (40) and Ala(S)Ser (39), the thiodipeptide carriers used in my research, were 
synthesised using methodology previously published by our group (Scheme 2).117 Each carrier is 
synthesised on a multi-gram scale taking approximately two weeks. The first step in the synthesis 
is the protection of the free carboxylic acid in commercially available N-Fmoc side chain protected 
O-Bn amino acids. This is accomplished using tert-butyl 2,2,2-trichloroacetimidate in DCM:Et2O to 
give the tert-butyl ester. The free amine is generated through the removal of the Fmoc group with 
TBAF in THF.  This is not the standard method of Fmoc deprotection, but must be employed as the 
use of pyridine had previously been found by the group to cause side reactions. Boc-Ala-OH is 
then coupled to the deprotected amino acid using DPPA/TEA in DMF.  The amide carbonyl then 
undergoes selective sulfur-oxygen exchange using Lawesson’s reagent in reflux conditions.  The 
last step involves deprotection of the benzyl ether or ester using dissolving metal conditions.  
FmocHN
X
OH
O
FmocHN
X
OtBu
O
H2N
X
OtBu
O
BocHN
O
H
N
X
OtBu
O
BocHN
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N
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(i) (ii)
(iii) (iv)
(v)
46 Ser X = OBn
47 Asp X = CO2Bn
48 Ser X = OBn (93%)
49 Asp X = CO2Bn (91%)
50 Ser X = OBn (78%)
51 Asp X = CO2Bn (80%)
52 Ser X = OBn (87%)
53 Asp X = CO2Bn (83%)
54 Ser X = OBn (84%)
55 Asp X = CO2Bn (89%)
56 Ser Y = OH (95%)
57 Asp Y = CO2H (94%)
 
Scheme 2 Synthesis of the protected thiodipeptide carriers. (i) tert-butyl-2,2,2-
trichloroacetimidate, DCM/Et2O, 3 days (ii) TBAF in THF, 3h (iii) Boc-Ala-OH, DPPA, TEA, DMF, 
18h (iv) Lawesson’s reagent, Toluene, 4h reflux (v) Na/NH3 in THF, 2h, -78°C. 
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 The preferred method of benzyl deprotection, hydrogenation, cannot be used due to the 
presence in the sulfur group in the thiodipeptides which would poison the catalyst. Although the 
dissolving metal reduction reaction used gives good yields and a clean compound, it is expensive 
and not suitable for scale up conditions. It was therefore speculated that benzyl hydrogenation 
may be performed prior to the sulphur exchange step. This was performed for both the Ala(S)Asp 
and Ala(S)Ser carriers, to yield the deprotected dipeptides in 90% yields. The deprotected 
dipeptides were then subjected to oxygen-sulfur exchange, using Lawesson’s reagent. In both 
cases however, no desired thio-dipeptide product could be seen in the crude NMR, and column 
chromatography resulted in isolation of (4- methoxyphenyl)(thioxo)phosphane oxide and several 
very polar fractions. Upon the commencement of this project the column chromatography 
purification utilised in the purification of 48 & 49 and 54 & 55 involved the use of chlorinated 
solvents. Therefore, to make the process more ‘green’ the solvent system for 48 & 49 was 
changed to 2:8 EtOAc: petroleum ether and the solvent system for 54 & 55 was changed to 1:9 
EtOAc: petroleum ether. Throughout this research project the use of chlorinated solvents has 
been avoided where possible. 
 In order to reduce the cost associated with making the thio-dipeptide carriers from di-
protected amino acids an alternative route was envisioned involving the mono protection of the 
H-X(OBn)-OH starting material. This method had been successfully performed by AstraZeneca, 
using condensed isobutylene and catalytic H2SO4 in Et2O and has been recently described for the 
protection of H-Ser(Bn)-OH in a patent lodged by Whomsley et al.118 However, this method 
involves the shaking of the reaction mixture under pressure and these facilities were not available 
in our laboratory.  
 An alternative route using tert-butyl acetate was therefore considered. This involves the 
addition of catalytic perchloric acid to a cooled mixture of the amino acid and excess tert-butyl 
acetate. This method had been demonstrated using 2-bromo-2-phenylacetic acid by Arndt et al.119 
Initially this reaction was performed using H-Ser(OBn)-OH using the procedure as set out by 
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Arndt. However, a 1H NMR of the crude reaction mixture showed only starting material to be 
present. Attempts were made to change the reaction conditions by altering the number of 
equivalents of HClO4 used as well as the time and temperature (Table 3). Optimisation of these 
conditions gave H-Ser(OBn)-OtBu in a near quantitative yield (99%) and use of these reaction 
conditions with H-Asp(OBn)-OH also gave the desired di-protected amino acid.  
Table 3 Reaction conditions tried in the mono protection of H-Ser(OBn)-OH 
eq of                
t-
BuOAc 
eq of 
HClO4 Temperature 
(°C) 
Time  
(h) NMR 
Time 
(h) NMR 
Time 
(h) NMR 
30 0.2 RT 24 Starting 
material 
48 Starting 
material 
72 Starting 
material 
30 0.2 30 24 Starting 
material 
48 Starting 
material 
72 Starting 
material 
30 0.2 50 24 Starting 
material 
48 Starting 
material 
72 Starting 
material 
30 0.5 RT 24 Starting 
material 
48 Starting 
material 
72 Starting 
material 
30 0.5 30 24 Starting 
material 
48 Starting 
material 
72 Starting 
material 
30 0.5 50 24 Starting 
material 
48 Starting 
material 
72 Starting 
material 
30 1.1 RT 24 Starting 
material 
48 Starting 
material 
72 Starting 
material 
30 1.1 30 24 Starting 
material 
48 Some 
product 
72 Fully 
converted 
30 1.1 50 24 Some 
product 
48 Fully 
converted 
    
 
 This optimised protection procedure gave an overall yield of ~69% in 5 days compared to 
the previous methodology of ~50% in 9 days. However, this method was not pursued due to a 
price increase of 280% for H-Asp(OBn)-OH (£422 per 25g) compared to Fmoc-Asp(OBn)-OH and a 
500% increase for H-Ser(OBn)-OH (£660 per 25g) compared to Fmoc-Ser(OBn)-OH.  This route 
may be pertinent should industrial scale up be required as amino acid costs would be reduced by 
buying in bulk. Any increased costs should be offset through both improved overall yield and the 
reduction of steps. 
 
44 
 
2.4 Synthesis of alternatively protected thiodipeptide carrier. 
Doxorubicin (58) is an anthracycline antibiotic used in the treatment of haematological 
malignancies, carcinomas and soft tissue carcinomas.  Poor bioavailability of the parent 
compound (5%) is due to due to low permeability, substrate specificity to the efflux pump P-gp 
and acid catalysed hydrolysis in the stomach.120 This therefore necessitates intravenous 
administration. However, due to the wide usage as an oncology drug several strategies have been 
undertaken to deliver the drug orally.120 As doxorubicin (58) is a known substrate of the P-gp 
transporter we were interested to assess whether the thiodipeptide prodrug method would allow 
this mechanism to be bypassed, therefore increasing bioavailability. This has been shown to be 
the case with quinidine which is actively effluxed by P-gp. L-valine-quinidine is both actively 
transported by PepT1 and is no longer a P-gp substrate.106 Work to synthesise a Ala(S)Asp-
doxorubicin prodrug was carried out by Dr R. Pathak and is summarised in scheme 3.  
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Scheme 3 Attempted synthesis of Ala(S)Asp-doxorubicin prodrug by Dr. R. Pathak (i) (57), DCC, 
NHS, DIPEA, THF 
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Despite the utilisation of a variety of mild conditions, Dr Pathak encounted problems with 
the final deprotection of the prodrug due to the degradation of doxorubicin in acidic conditions.  
As these problems may be encountered in the future with other acid sensitive drugs, it was 
decided to establish methodology for our carriers utilising an alternative protecting group 
strategy. This work was carried out as part of this research project. The protecting groups chosen 
needed to be robust to the conditions used during the synthesis of the carriers and be cleaved 
cleanly using non acidic conditions in a single final step. Due to the commercial availability of 
serine and aspartate amino acids with tert-butyl protected side chains, these were used as the 
starting point for the synthesis. Several protecting groups were assessed for the protection of the 
amine and carboxylic groups. For the alanine amino acid Fmoc-Ala-OH was initially used as the N-
terminus residue. However Fmoc deprotection occurred when DMAP was used as the base in the 
coupling reaction between alanine and the second residue.  This could be mediated by using a 
base other than DMAP, but would severely limit the options available when coupling the carrier to 
drug.  As alternative amino protecting groups, both methyl and ethyl carbonate were considered 
as they can be readily removed by KOH or K2CO3. For the serine or aspartate amino acid, the 
commercial availability of Cbz-Asp(OtBu)-OH and Cbz-Ser(tBu)-OH made us consider these 
protected amino acids as the starting point for the protection of carboxylic acid group.  However, 
most carboxylic acid protecting groups are cleaved under acidic conditions, risking the 
deprotection of tert-butyl.  We could not find a nontoxic carboxylic acid protecting group that 
would both withstand hydrogenation and cleave under KOH/ K2CO3 conditions. 
It was ultimately decided to use benzyl type protection as Cbz-Ala-OH is commercially 
available and benzyl protection of the free carboxylic acid on the second residue could be 
achieved using commercially available Fmoc-Asp(OtBu)-OH or Fmoc-Ser(tBu)-OH. Benzyl 
protection is robust enough to withstand the acidic conditions needed to cleave the tert-butyl 
side chain and the basic conditions used during coupling reactions. In our thiodipeptides the 
benzyl protection must be cleaved in the relatively harsh conditions of dissolving metal reduction. 
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This is due to the presence of a sulphur atom which would poison the catalyst. However, if this 
strategy is utilised in sulfur free alternative PepT1 carriers (Chapter 3) the usual mild conditions of 
hydrogenation with a palladium catalyst could be used.  
Initial attempts were made to protect Fmoc-Asp(OtBu)-OH using benzyl-2,2,2-
trichloroacidimidate. This is a similar method used for the tert-butyl protection of Fmoc-
Asp(OBn)-OH in the original synthesis ((i) in scheme 2). However, using this method after 4 days 
only a small amount desired product (6%) was obtained.  This was thought to be due to an 
increase in the activation energy of reaction, as when this reaction is performed with tert-butyl-
2,2,2-trichloroacidimidate high yields are only obtained after 3 days in a very concentrated 
solution.  Benzyl bromide was therefore used to give the desired product (64) in a 83% yield.  
Fmoc deprotection of 64 was carried out using TBAF in THF to give 66, followed by coupling with 
Cbz-Ala-OH using DPPA and TEA in DMF to give 68. Sulphur-oxygen exchange was carried out 
using Lawesson’s reagent prior to tert-butyl deprotection using TFA in DCM to give 72. 
Deprotection of the benzyl type protecting groups was successfully carried out using dissolving 
metal reduction to give 73 (scheme 4). Unfortunately, when the stability of doxorubicin (58) to 
dissolving metal reduction conditions was assessed, degradation was found to occur and so this 
protecting group strategy could not be utilised in this case. It does however remain an option for 
acid sensitive drugs encountered in the future.  
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Scheme 4 Synthesis of the benzyl protected thiodipeptide carriers.  (i) BnBr, NaHCO3,  DMF, 3 
days (ii) TBAF in THF, 3h (iii) Cbz-Ala-OH, DPPA, TEA, DMF, 18h (iv) Lawesson’s reagent, Toluene, 
4h reflux (v) TFA in DCM, 8h (vi) Na/NH3 in THF, 2h, -78°C. 
2.5 PepT1 targeted prodrugs using commercially available drugs. 
2.5.1 Propofol (2,6-diisopropylphenol). 
Propofol (74) is used for the induction and maintenance of general anesthesia.121 As it has a low 
solubility it is currently administered intravenously as an oil-in-water emulsion.  If used at a sub-
sedative dose there is evidence that propofol can be effective in treating: Delirium tremens 
associated with alcohol withdrawal;122 trigeminal neuralgia;123 spinal cord injury pain;124 central 
post-stroke pain;125 intractable migraines121 and post-chemotherapeutic nausea and vomiting.121   
OH
74
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 An oral formulation of propofol is therefore medically desirable. This has been attempted 
by the Xenoport incorporation121 using amino acid and dipeptide attachments to target 
unspecified gastrointestinal transporters.  The structurally unspecified amino acid attached 
prodrug, XP20925, has been shown, in a patent, to appear in systemic circulation in both rat and 
dog after oral administration126 although no measure of bioavailability was given.   
 The Ala(S)Asp-2,6-diisopropylphenol prodrug (76) had previously been created within our 
group (Dr. R. Price and Dr. D, Foley, unpublished).127  In vitro testing showed that the prodrug had 
high binding affinity for PepT1 and was transported moderately well in Caco-2 cells. Part of the 
collaboration between our group and AstraZeneca involved my use of their facilities for Caco-2 
testing. Ala(S)Asp-2,6-diisopropylphenol was therefore synthesised to use as a standard to ensure 
consistency with Caco-2 work previously carried out at Oxford Brookes. In my hands, when 
propofol (74) was coupled to Boc-Ala(S)Asp(OH)-OtBu using the established methodology127 no 
desired product was obtained. Initial attempts were made to change the reaction conditions by 
increasing the equivalents of DMAP in both DMF and DCM. The use of DMAP as a full equivalent, 
rather than catalytically, often results in successful coupling conditions, despite its role as a 
catalyst in the reaction. Indeed, when the equivalents of DMAP used was increased from 0.15 to 1 
and the coupling reagent was changed from DCC to EDC successful coupling was observed by 
crude NMR.  
 Purification was performed via dry loaded column chromatography using the established 
conditions; DCM followed by gradual change to 9:1 DCM: EtOAc. However, fractions collected 
showed the presence of propofol (74) as well as the desired product 75 which have very different 
Rf values. Repeated attempts to optimise the eluting mixture still resulted in propofol being 
present in the fractions containing the product. It was therefore hypothesised that propofol was 
becoming “baked on” when absorbed onto the silica for dry loading. To counteract this, the 
volume of propofol added to the reaction mixture was reduced from 1.25 to 0.95eq and the crude 
reaction mixture wet loaded onto the column. Using a gradual change in the solvent system of 
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petroleum ether to 9:1 petroleum ether: EtOAc the product was successfully separated. 
Subsequent acidolysis of the Boc and tert-butyl protecting groups gave the desired prodrug. 
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Scheme 5 Synthesis of Ala(S)-Asp-2,6-diisopropylphenol. (i) (57), EDC, DMAP, DMF, rt, 3 days. 
(ii) HCO2H, reflux, 3h. 
2.5.2 Ibuprofen 
 Unlike propofol, ibuprofen (77) does not suffer from low bioavailability. However, it can 
cause gastric and intestinal ulceration. This is especially prominent in patients on a long-term 
dose for chronic pain conditions.  
77
O
OH
 
 By attaching a thiodipeptide carrier it was envisioned that gastric damage would be 
limited as, prior to uptake, the drug would not be available in its free form. A thiodipeptide 
prodrug of ibuprofen (79) had previously been created in our group.117 In vitro testing had 
previously shown that the prodrug had high binding affinity for PepT1 and high permeability in 
Caco-2 cells. In vivo testing had shown that the prodrug is rapidly absorbed into circulation 
without any short term gastrointestinal or systemic toxicity (unpublished).127 Ala(S)Ser-ibuprofen 
(79) was therefore synthesised (1.5g) for use in a full pharmacokinetic study and taste assessment 
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in rat (sections 3.3.1 and 3.3.2).  Repeated difficulty was encountered with the final acidolysis step 
to give the desired prodrug 79.  It was found that the standard tert-butyl type deprotection 
conditions of TFA in DCM gave unpredictable results. Deprotection of the Boc and tert-butyl 
groups to give a pure sample is vital as the resulting deprotected prodrug salt is very polar and 
therefore cannot be separated from any impurities.  Attempts to find conditions using TFA which 
consistently gave quantitative deprotection were made by reducing reaction times and distilling 
the TFA. Successful cleavage of the tert-butyl groups was hypothesised to be trace water 
dependent as certain bottles of TFA after a period of time would give quantitative deprotection. 
As the use of TFA could not guarantee a successful result, formic acid was used as an alternative 
reagent and consistently gave 79 in quantitative yields after 3 hours.  
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Scheme 6 Synthesis of Ala(S)Ser-ibuprofen. (i) (56), HBTU, DIPEA, DMF, rt, 4 days. (ii) HCO2H, 
reflux, 3h. 
2.5.3 Aspirin. 
 Belonging to the same class of drugs (non-steroidal anti-inflammatory) as ibuprofen (77), 
aspirin (80) is also considerably toxic to the gastrointestinal tract.  As well as for pain relief, aspirin 
(80) is widely used in primary and secondary preventive treatments of cardiovascular disease.   
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 The development of a benign prodrug is therefore of considerable commercial interest. 
Ester and amide derivatives of aspirin (80) are expected to be less pernicious to the 
gastrointestinal tract.128 Previous attempts in the group, by Dr. F. Foley, to attach aspirin (80) 
directly to the protected Ala(S)Ser carrier (56) using a variety of mild esterification conditions 
proved unsuccessful.127 This was unsurprising as esters of aspirin reported in literature are 
generally made using an aspirin acid chloride, methodology we discounted as it would damage 
our carrier. A glycol ester of aspirin (81) was therefore synthesised by Dr. F. Foley, using 
concentrated Mitsonobu conditions and sonication. Although 81 showed good binding affinity in 
vitro, it was found to be unstable in acidic media.   
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 In vivo aspirin ester prodrugs are hydrolysed by plasma butyrylcholinesterase (BuChE). 
This presents an obstacle to prodrug development as the competing hydrolysis to the salicylate 
ester (84) is usually the fastest pathway (Figure 20). This means that for an ester prodrug to 
successfully release aspirin (80), the ester must undergo hydrolysis at a greater rate than the 
acetyl group.  
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Figure 20 Routes of aspirin ester hydrolysis. Adapted from Moriarty et al.128 
 
 Recently a diasprinate ester of isosorbide has been published which has been shown to 
preferentially release acetyl salicylate (83) after interaction with BuChE. ISDA (86) has been shown 
to produce aspirin in vivo,128 but due to competing hydrolysis pathways only 7% hydrolyses 
directly to aspirin (80).128 This is due to the presence of two acetates and therefore two 
competing processes. Aspirin production is the result of either a direct hydrolysis of the isosorbide 
in either the 2 or 5 position, or hydrolysis of the resultant monoasprinate.  However, there is also 
a preferential competing pathway whereby either one or both of the aspirin moieties are 
hydrolysed to the salicylate ester. In this pathway the acetyl group of the 5-asprinate is 
hydrolysed first to give ISAS (87).  When the hydrolysis pathways of ISAS were studied, 
surprisingly it was found to be an excellent substrate for BuChE. This outcompetes the usual fast 
route of the enzymes which hydrolyse the phenylacetate group. As a result ~70% of ISAS is 
directly hydrolysed to aspirin (80).  
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 Although ISDA (86) has been shown to have oral bioavailability129 this may not necessarily 
be the case with ISAS (87) as there is currently no published transport data. The presence of the 
free phenoxy group may also cause gastrointestinal toxicity, rendering the purpose of the prodrug 
futile. It was theorised that attachment of the Ala(S)Asp carrier (40) through the free phenoxy 
group may address both of these issues. The published synthesis for ISAS (87) is through 
isosorbide mononitrate, commonly used to treat angina.  This is not commercially available due to 
the highly explosive isosorbide dinitrate also being formed during synthesis.  The purpose of using 
isosorbide mononitrate in the published synthesis127 appeared to be from a protecting group 
perspective only, so an alternative starting material was considered. Huynh et al.130 had 
previously shown that the correct hydroxyl group on isosorbide (90) could be selected for 
monobenzylation using LiH/LiCl. This presumably occurs through lithium ion chelation control as 
the use of sodium hydride preferentially selects for the exo hydroxyl group.131 A synthetic route 
was therefore postured using isosorbide (90) as a starting material (Scheme 7). 
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Scheme 7 Theorised synthesis of thiodipeptide aspirin prodrug. (i) K2CO3, TBAB, BnBr, THF, rt (ii) 
LiH, LiCl, DMSO (iii) BnCl (iv) (80), DCC, DMAP, DCM (v) H2, Pd/C, rt (vi) (89), DCC, DMAP, DCM, rt 
(vii) H2, Pd/C, rt (viii) (57), DCC, DMAP, DCM, rt (ix) HCO2H 
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 The monobenzylation of isosorbide (90) was successfully achieved in a 58% yield and no 
exo enantiomer was found to be present in the crude reaction mixture. However, upon coupling 
the monobenzylated isosorbide 91 to aspirin (80) using established methodology,129 92 was not 
obtained. Rather than the aspirin (80) coupling to the free hydroxyl group, deacetylation of the 
aspirin and acetylation of the isosorbide benzyl ester (91) was seen.  
O
O
HO H
H O
91
(i)
O
O
O H
H O
O
98
 
Equation 1 Synthesis of 65 (i) Aspirin (80), DCC, DMAP, DCM. 
 
 Pre-forming the DCC-isosorbide benzyl ester complex prior to the addition of aspririn (80) 
also resulted in transesterification occurring, with no coupled product seen.  This method of 
perfoming a copupling reaction is called pre-charging method.  When all of the reagents are 
added at the same time it is refered to the one-pot method.  
 DMAP can promote the acetylation of alcohols, so HOBt was used as an alternative base. 
Transesterification did not occur, but no desired ester was obtained. Using EDC and HATU as 
alternative coupling reagents also failed to give 92 as the desired product. Salicylic acid (88) was 
therefore used as the reactive species as acetylation to aspirin (80) could be undertaken 
subsequent to coupling (scheme 9). Using the pre-charged DCC DMAP conditions salicylic acid (88) 
was coupled to 91 in an 86% yield. Initial attempts were made to find conditions to acetylate 99 
to give the desired aspirin product 92. However, this avenue could not be fully explored due to 
this research being undertaken in the final few weeks of this research project. 
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Scheme 8 Synthesis of modified salicylic prodrug. (i) LiH, LiCl, DMSO (ii) BnCl (iii) Salicylic acid 
(88), DCC, DMAP, DCM (iv) H2, 10% Pd/C, MeOH:EtOAC rt (v) (57), DCC, DMAP, DCM, rt. 
 99 was instead successfully deprotected using a 1:1 mix of MeOH: EtOAC as a solvent and 
10% palladium on carbon as the catalyst to give 100. As both the salicylic and isosorbide alcohols 
are deprotected in 100, coupling of this compound to benzyl protected salicylic acid (89) would 
result in the formation of several products (scheme 8). It is therefore unlikely that the desired 
product 101 would be formed in the yields necessary to explore further synthesis using this 
intermediate. Therefore, in an effort to make a model aspirin like prodrug which could be used in 
vitro testing it was decided to couple the protected Ala(S)Asp carrier (57) directly attached to the 
free isosorbide alcohol on 100 (scheme 8). It was hoped that enough of 102 would be able to be 
isolated from the resultant mix of coupled products that, after deprotection, biological testing 
could be carried out.  
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 Using pre-charged DCC conditions, the only product that could be isolated was the 
protected Ala(S)Asp carrier (57) attached both to the salicylic ester and the free isosorbide 
alcohol. This project was therefore abandoned due to the prioritisation of other work and the 
difficulties previously encountered in the group by Dr. Foley127 in making a thiodipeptide aspirin 
prodrug. It is not known why in my hands transesterification was found to occur, when using 
DCC/DMAP conditions the Trinity college group successfully coupled aspirin (80) to a protected 
isosorbide. Perhaps the mononitrate group on the isosorbide used by Trinity plays a role other 
than as a convenient protecting group. Extensive screening of coupling conditions between aspirin 
(80) and mono-protected isosorbide to find a successful method which does not cause 
transesterification to occur would be the next step in moving this synthesis along. These same 
conditions could hopefully be used for all coupling reactions in the synthetic sequence. If this is 
achieved and the original target 97 is found to be a PepT1 substrate, in vivo work would need to 
be undertaken to assess whether aspirin is preferentially released. 
2.6 AstraZeneca new chemical entities 
As the PepT1 prodrug strategy had been proven within the group for commercially 
available drugs, a collaboration was created with AstraZeneca to assess if existing new chemical 
entities could be taken further in the development process. Due to the financial cost involved in 
drug development, only the most promising candidates will be taken through drug discovery, pre-
clinical research and into clinical trials. Designing a drug to have both favourable target efficacy 
and pharmacokinetics can be challenging and many valuable compounds are shelved due to 
bioavailability issues. Two AstraZeneca developed compounds were identified from two different 
classes of drugs to see if the PepT1 prodrug strategy could be successfully applied to improve 
their bioavailability. These are an Aurora kinase inhibiter and an α1β5 integrin inhibitor. Both of 
the structures are in the public domain and are not the lead development compounds, although 
they are of interest. The compounds are structurally very different from each other and from drug 
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moieties already attached to our carriers. This is to further assess PepT1’s ability to transport 
drugs of varying size, hydrophobicity and functional groups.  
2.6.1 Aurora kinase inhibitor 
Aurora kinase inhibitors play an important role in the regulation of mitosis and are highly 
expressed in the thymus, testis, spleen, intestine and bone marrow132 and are commonly 
overexpressed in human tumours.133 There are three Aurora kinase paralogues expressed in 
mammals, Aurora A, B and C.   Aurora A regulates mitotic spindle assembly and stability from 
prophase to telophase. Overexpression of Aurora A has been shown to inhibit cytokinesis and 
overrides the mechanism that monitors spindle assembly.134 Aurora B is a chromosome passenger 
protein which regulates chromosome segregation and cytokinesis. The function of Aurora C is still 
unknown, but it has the same subcellular location as Aurora B. It is overexpressed in somatic 
cancer tissues and hematologic cancers where it has been shown to interfere with the spindle 
checkpoint by promoting the degradation of Aurora B.135 Disregulation of the Aurora kinase 
inhibitors ultimately leads to chromosome instability. This, combined with the overexpression of 
Aurora kinase inhibitors in cancer cells, suggests that they are involved in tumorgenesis.  
Several compounds have been reported to inhibit both Aurora A and B and have allowed 
the validation of Aurora kinases as a target for cancer drug discovery. The most advanced of these 
are Alisertib 103, developed by Millennium, and Barasertib 104, developed by AstraZeneca.  
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 Alsertib (103) is currently in US and UK Phase-III clinical trials for relapsed or peripheral T-
cell lymphoma. The half maximal inhibitory concentration (IC50) for Aurora A is 0.0067μm and for 
Aurora B is 1.534μm.136 Barasertib (104) is an acetanilide-substituted pyrazole-amino-quinazoline 
prodrug and is in phase II/III clinical trials for acute myeloid leukaemia. The IC50’s are 1.369μm for 
Aurora A, 0.00036μm for Aurora B and 0.017μm for Aurora C.137 Barasertib is the phosphate 
derivative of the structure activity relationship optimised analogue of 105, which was based on 
one of the first reported Aurora kinase inhibitors ZM447439 (106).  
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 105 Suffers from low solubility (0.035 mg/mL).132 It was hoped that by attaching our 
carrier, solubility and therefore bioavailability would be improved. After an extensive range of 
coupling conditions were employed, the desired product was obtained with DCC and a 
combination of HOBt and DMAP as base. DMAP is generally needed in catalytic amounts in 
coupling conditions, although this has not been found to be the case in the course of this 
research. This was again found here with 0.5 equivilents only generating a trace of product 
(observed by TLC) that could not be isolated. Interestingly, reasonable yields (32%) were not 
achieved until 2 equivalents of HOBt were also used in the reaction. However, when used without 
DMAP no reaction was found to occur.  
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Scheme 9 Synthesis of Aurora kinase inhibitor thiodipeptide prodrug. (i) (57), EDC, DMAP, HOBt, 
DMF, 3 days (ii) HCO2H, reflux, 3h. 
 Solubility testing of 108 showed that solubility had been improved from 0.035mg/mL 
(105) to ~6 mg/ml.  This was carried out by saturating 1ml of pH 7.4 HBSS/0.1% BSA/HEPES buffer 
with prodrug. Concentration of the centrifuged solution was then calculated based on mass 
spectrometer peak area assuming linearity at concentrations greater than the standards. 
 To assess the effect of chain length between the Aurora kinase inhibiter (105) and 
Ala(S)Asp carrier (40) on PepT1 transport, a series of polyethylene glycolic acid spacers were 
created.  It was also hoped that solubility of the final prodrug would be improved, which had 
previously been seen when Dr. F. Foley attached glycol linkers between the Ala(S)Asp carrier (40) 
and nabumetone (42) (section 2.1.2). Benzyloxyacetic acid (110) was created from benzyl alcohol 
(109) and chloroacetic acid using modified Williamson ether synthesis (scheme 10). To synthesise 
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113 and 116 the monobenzyl protected glycols 112 and 115 were first created from their 
corresponding glycols in good yields using standard sodium hydride based desymmetrisation 
chemistry (scheme 10).  2-(2-Phenylmethoxyethoxy)acetic acid (111) and 2-[2-(2-
phenylmethoxyethoxy)ethoxy]acetic acid (114) were then synthesised through oxidation of their 
corresponding monobenzyl protected glycols with Jones oxidation.  
OH BnO
OH
O
(i)
(ii)
109 110
92%
HO
O
OH
n
(iii)
111 n=1 
114 n=2
HO
O
OBn
n
112 n=1 (58%)
115 n=2 (70%)
(iv)
HO
O
OBn
n
113 n=1 (73%)
116 n=2 (71%)
O
 
Scheme 10 Synthesis of glycol acid spacers. (i) Na, BnOH (ii) chloroacetic acid, BnOH (iii) NaH, KI, 
BnBr (iv) Cr3O, H2SO4, H2O, (CH₃)₂CO. 
 Initial synthesis of an Aurora kinase glycol acid benzyl ether was attempted using 113 and 
the DCC, DMAP, HOBt conditions used to synthesise 108, but unfortunately this failed to give the 
desired product 118.  After trying various coupling reagents a yield of 27% was achieved with 1eq 
DIPEA and 1.1eq HATU in DMF. This was then successfully applied to the other two glycol acid 
benzyl ethers (Scheme 11). It was envisioned that deprotection of the glycol benzyl ethers 117, 
118 and 119 could be achieved through palladium hydrogenation as the sulphur in the thiazole 
ring would be sufficiently conjugated to prevent poisoning of the catalyst, as is the case with the 
thiazolidine ring in penicillins.138   
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Scheme 11 Intended synthesis of Ala(S)Asp glycol Aurora kinase prodrugs (i) (126, 127 or 128), 
DIPEA, HATU, DMF (ii) Palladium hydrogenation (iii) (57), coupling conditions (iv) HCO2H, reflux, 
3h. 
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 Attempts to remove the benzyl ether by hydrolysis were unsuccessful, with only starting 
material recovered from reactions. This was initially assumed to be the result of the starting 
materials being inert to the reaction conditions, so extensive screening of catalytic conditions was 
therefore carried out (Table 4). These could only be undertaken under atmospheric conditions as 
facilities for hydrogenation at multiple atmospheres were not available. The addition of a second 
quantity of 10% Pd(OH)2/C after 30 minutes to 118 when dissolved in ethanol  and when dissolved 
in acetic acid gave a second spot by TLC. This could not be isolated due to scale (5 mg) as full 
conversion did not occur. It was theorised that poisoning of the catalysis was occurring so 
hydrogenation attempts were abandoned. The benzyl protecting group used in the synthesis of 
our thiodipeptide carriers is removed by dissolving metal reduction (section 2.3). However, when 
this method was used with 118 multiple products were observed by TLC. Literature searches of 
benzyl protected thiazole compounds showed that benzyl ether deprotection was most often 
undertaken with either boron trichloride or trimethylsilyl iodide. Due to the presence of other 
ether and ester bonds in 117, 118 and 119 these methods could not be employed as they do not 
allow for selective hydrolysis. It was however hoped that the much milder condition of NaOH in 
MeOH would give the desired product.  Multiple spots were seen on TLC after 15 minutes with 
118, but due to scale (5 mg) could not be isolated. As so much time had been dedicated to this 
research, with little success, it was decided to shelve this area of the research project to allow 
progression on other areas of work. If re-examined in the future, the use of tert-butyl ether rather 
than a benzyl ether on the glycolic acid linkers may afford a more easily hydrolysable product 
which could be removed using formic acid. 
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Table 4 Hydrolysis conditions attempted to remove the benzyl ester protecting groups in 
compounds (117) and (118). 
Starting 
material  Solvent Catalyst Additive Temperature Result (TLC) 
117 MeOH 10% Pd/C   Rt Starting material 
 
EtOH 10% Pd/C 
 
Rt/ Reflux Second spot after 
second addition of 
catalyst 
 
AcOH 10% Pd/C 
 
Rt Starting material 
 
MeOH 
10% 
Pd(OH)2/C 
 
Rt Starting material 
 
EtOH 
10% 
Pd(OH)2/C 
 
Rt/ Reflux Starting material 
  
AcOH 10% 
Pd(OH)2/C 
  
Rt Second spot after 
second addition of 
catalyst 
118 MeOH Pd/C HCl Rt/ Reflux Multiple spots 
 
MeOH Pd/C HCO2NH4 Rt Starting material 
 
EtOH Pd/C 
 
Rt Starting material 
 
AcOH Pd/C 
 
Rt/ Reflux Multiple spots 
 
MeOH 5% Pd/C AcOH Rt/ Reflux Starting material 
 
MeOH 5% Pd/C 
 
Rt Starting material 
 
AcOH 5% Pd/C 
 
Rt Starting material 
 
MeOH 10% Pd/C 
 
Rt Starting material 
 
MeOH 10% Pd/C AcOH Rt Starting material 
 
EtOH 10% Pd/C 
 
Rt/ Reflux Starting material 
 
EtOAc 10% Pd/C 
 
Rt Starting material 
 
THF 10% Pd/C 
 
Rt Starting material 
 
AcOH 10% Pd/C 
 
Rt Starting material 
 
MeOH 
20% 
Pd(OH)2/C 
 
Rt/ Reflux Starting material 
 
EtOH 
20% 
Pd(OH)2/C 
 
Rt/ Reflux Starting material 
 
EtOH 
20% 
Pd(OH)2/C AcOH Rt/ Reflux Starting material 
 
MeOH 
10% 
Pd(OH)2/C 
 
Rt Starting material 
 
MeOH 
10% 
Pd(OH)2/C AcOH Rt Starting material 
 
EtOH 
10% 
Pd(OH)2/C 
 
Rt Starting material 
 
EtOAc 
10% 
Pd(OH)2/C 
 
Rt Starting material 
 
AcOH 
10% 
Pd(OH)2/C 
 
Rt Multiple spots 
 
DCM Pd(OAC)2 1 eq Et3SiH, 
Cat. Et3N 
Reflux Starting material 
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2.6.2 α1β5 Integrin inhibitor. 
 Integrins are transmembrane heterodimeric proteins which are present in a wide variety 
of cells and play a crucial role in normal cell function. Alongside other receptors, integrins 
modulate the signalling pathways of cells through microclimate sensing, thereby maintaining 
tissue homeostasis.139 In mammals 24 subtypes have been identified, which are constituted from 
18 α and 8 β subunits.  Many of these have been found to be overexpressed in cancer cells 
impacting proliferation, metastasis, resistance to therapies and recurrence.140 Three of these; 
αvβ3, αvβ5 and α5β1 have been shown to mediate angiogenesis which is a key path physiology in 
cancer.141 The increased nutrient and oxygen demands of an enlarging tumour necessitates new 
blood vessel formation, inhibiting this pathway would therefore have a significant effect on 
tumour progression.  The overexpression of α5β1 in colon, breast, ovarian, lung and brain 
tumours is particularly associated with poor patient prognosis,139 inhibition of this pathway is 
therefore an attractive target for cancer therapy.   
 Intracellular signalling by α5β1 is initiated through the formation of an adhesion complex 
with the extracellular matrix molecule fibronectin via the tripeptide motif Arg-Gly-Asp. Disruption 
of α5β1-fibronectin binding has been investigated using three main classes of antagonists, specific 
antibodies, small peptides and Arg-Gly-Asp like molecules. Clinically the most advanced of these is 
voloximab, a chimeric antibody, which has completed phase II trials for advanced epithelial 
ovarian and peritoneal cancer in combination with liposomal doxorubicin.139  
 α5β1, αvβ3 and αIIbβ3 are all able to recognise the Arg-Gly-Asp motif of fibronectin, 
making   selective antagonist design a challenge. As a crystal structure of α5β1 in complex with 
fibronectin was not published until 2012142 initial Arg-Gly-Asp like antagonists were developed 
using a homology model based on αvβ3. This led to the development of several structure affinity 
relationship optimised non peptidic α5β1 antagonists by different pharmaceutical research 
groups.139 One of these was by AstraZenca, using both a homology model and literature 
precedence of pharmacophores for α5β1 selectivity.143-4 Structure affinity relationship 
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optimisation of the dibasic R1 group gave 131 and 132 as the most potent in an human 
immortalised myelogenous leukemia cell line (K562 IC50 0.003 and 0.007μm respectively with 2,6 
dichlorophenyl (130) R2 group).  Amide optimisation using 132 as the dibasic group gave 130, 133, 
134 and 135 as the most potent amides. 
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Figure 21 Side chains identified through structure affinity optimisation of a non peptidic α51 
antagonist.143-4 
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 Integrin inhibitor 136 was selected by AstraZeneca for attachment to our carriers. It was 
envisioned that this could be achieved through direct attachment of the serine carrier (56) to the 
carboxylic acid of 136 (Scheme 12). Solvation of 136 proved challenging and could only be 
achieved upon the addition of an organic base. Unfortunately, even upon addition of a base, 
solvation was not found to occur in DCM. Coupling conditions could therefore not be screened in 
this solvent. The coupling conditions that were screened are shown in Table 5. 
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Scheme 12 Original proposed synthesis of Ala(S)Ser-Integrin prodrug (i) coupling conditions (ii) 
HCO2H, reflux, 3h. 
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Table 5 Conditions used for the coupling of Boc-Ala(S)Ser-OtBu (56) to the integrin inhibitor 
(136). 
Coupling 
reagent Eq. Additive Eq. Additive Eq. Solvent 
EDC 1.1 DMAP 1 
  
DMF 
 
1.2 DMAP 2 
  
DMF 
 
1.1 DIPEA 2 
  
DMF 
 
1.1 DMAP 1 HOBt 1 NMP 
 
1.1 DMAP 2 HOBt 2 DMF 
 1.2 HOBt 1     EtOAc 
DCC 1.1 DMAP 2     DMF 
 
1.1 DMAP 2 HOBt 1 DMF 
 
1.2 DIPEA 2 HOBt 1.1 DMF 
 
1.1 DIPEA 2 HOBt 1.1 THF 
 1.2 HOBt 1.2     DMF 
COMU 1.1 
Oxyma 
Pure 1.1     DMF 
 
1.2 DIPEA 1.5 
  
DMF 
 1.2 DIPEA 5   DMF 
TBTU 1.1 HOBt 2 DIPEA 1.5 THF 
 
1.1 DIPEA 1.5 
  
EtOAc 
 1.1 DIPEA 2   DMF 
HATU 1.1 DIPEA 1.2     DMF 
 
1.2 DIPEA 2 
  
DMF 
 
1.2 DIPEA 2 HOBt 2 DMF 
 1.2 TEA 2     EtOAc 
HBTU 3.5 TEA 3.5     DMSO 
 
1.2 TEA 2 
  
DMF 
 
1.2 DIPEA 2   DMF 
 
1.2 DIPEA 2     THF 
 1.2 DIPEA 5     DMF 
CDI 1.3 
m-
terphenyl 0.25 Imidazole 1.5 NMP 
  1.2 TEA 1.2     THF 
DPPA 1.1 TEA 2     DMF 
TFFH 1 DIPEA 1 
  
DMF 
 
1 DIPEA 2 
  
DMF 
              
 Oxyma Pure has been brought to the market as a replacement additive in carbodiimide 
coupling reactions. This was in response to HOBt and HOAt being removed from sale due to 
explosive properties. It has been shown to possess coupling efficiency superior to that of HOBt 
and at least comparable to HOAt, whilst inhibiting racemisation.145 COMU is an uronium salt 
derived from Oxyma Pure and contains morpholino group.146 A benefit in using COMU is that the 
course of the reaction can be monitored due to a change in colour of the reaction mixture. The 
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other unusual reagent used was TFFH. TFFH is a non-hydroscopic salt fluorinating agent which, 
when used in conjunction with DIPEA, can be used to generate acid fluorides.147 It is especially 
suited for the coupling of sterically hindered amino acids, which is why it was selected for use 
with the integrin inhibitor.  
  Despite extensive screening of coupling conditions for the coupling of Boc-Ala(S)Ser(OH)-
OtBu (56) to the integrin inhibitor (136), no successful condition could be found (Table 5).  It was 
thought that this may be due to steric hindrance of the reaction site as both molecules are quite 
bulky. It was therefore theorised that coupling a less bulky polyethylene glycol linker to the 
integrin inhibitor may be more successful (Scheme 13).   
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Scheme 13 Revised synthesis of Ala(S)Asp-linker-Integrin prodrug. (i) NaH, KI, BnBr (ii) (136), 
coupling conditions (iii) TosCl, pyridine, -5°C, 24h (iii) Pd(OH)2, MeOH (iv) (57), coupling 
conditions (v) HCO2H, reflux, 3h. 
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 Adding a polyethylene linker to the integrin inhibitor would give the added benefit of 
assessing the effect of chain length on transport and hopefully improve the solubility of the very 
insoluble 136. However again, extensive screening failed to give the desired product (Table 6). 
Table 6 Conditions used for the coupling of (112) to the integrin inhibitor (136). 
Coupling 
reagent Eq. Additive Eq. Additive Eq. Solvent 
EDC 1.1 DMAP 2 
  
DMF 
 
1.1 DMAP 3 
  
DMF 
 
1.1 DIPEA 2 
  
DMF 
 
1.1 DIPEA 2 
  
EtOAc 
 1.1 HOBt 2   EtOAc 
DCC 1.1 DMAP 2     DMF 
 
1.1 DMAP 2 HOBt 1 DMF 
 
1.1 DIPEA 2 
  
DMF 
 
1.1 DIPEA 2 HOBt 1 DMF 
 1.1 HOBt 2     DMF 
COMU 1.2 DIPEA 1.5     DMF 
  1.1 HOBt 2     DMF 
TBTU 1.1 HOBt 2     DMF 
 
1.1 DBU 2 
  
DMF 
 1.1 DIPEA 2   DMF 
HATU 1.1 DIPEA 2     DMF 
 
1.1 DIPEA 3 
  
DMF 
 1.1 TEA 2   DMF 
HBTU 3.5 TEA 3.5     DMSO 
 
1.1 TEA 2 
  
DMF 
 1.1 DIPEA 2   DMF 
TFFH 1 TEA 5 DMAP 1 DMF 
 
  In addition to the coupling conditions listed (Table 6), Mitsnoubu conditions (PPh3 and 
DIAD) were utilised. It was thought that these reaction conditions may have failed due to the acid 
group on the integrin inhibitor being too sterically hindered to form a complex with the coupling 
reagent. Therefore, methyl protection was attempted on the carboxylic acid group.  As methyl 
iodide is a very small molecule there should be no steric impediment to the reaction occurring. 
However, reaction conditions failed to give the methyl ester. In 136 the secondary amine on the 
1,2,3,4-tetrahydro-1,8-naphthyridine is able to sit very close to the carboxylic acid, possibly 
participating in hydrogen bonding. This interaction would be eliminated through amine 
protection, hopefully enabling the carboxylic acid to react. Protecting the amine may also give the 
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added benefit of improving the solubility of 136, allowing coupling to be carried out in a wider 
variety of solvents (Scheme 14).  
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Scheme 14 Attempted secondary amide protection of integrin inhibitor. (i) tert-Butyl carbamate 
protection (ii) carboxybenzyl carbamate protection (iii) acetyl protection. 
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 Unfortunately, despite the utilisation of several protecting group strategies no conditions 
could be found to protect the amine (Table 7).  
Table 7 Conditions employed for the secondary amine protection of the integrin inhibitor (136). 
Protecting group Reagent Eq. Additive Eq. Solvent Temperature 
tert-Butyl carbamate  Boc2O 1.2 DMAP Cat. THF 40°C 
 
Boc2O 1.2 DMAP 1 THF Rt /50°C 
 
Boc2O 1.2 DMAP 2 THF Rt/ 50°C 
 
Boc2O 2 TEA 10% DMF 50°C 
 
Boc2O 2.5 NH2OH.HCl/ NaOH 2 Dioxane/ 
H2O 
Rt / 40°C 
 
Boc2O 2 (CH3)4NOH. 5H2O 1 CH3CN Rt 
 
Boc-ON 1.1 LiHMDS 1 THF Rt / 40°C 
 
Boc-ON 1.1 LiHMDS 2 DMF Rt / 40°C 
 
Boc-ON 1.1 NaH 1 THF Rt / 40°C 
  Boc-ON 1.1 NaH 3 THF 
Rt / 40°C/ 
reflux 
carboxybenzyl 
carbamate  
Cbz-Cl 1.5 NaHCO3 2 Dioxane/ 
H2O 
Rt / 40°C 
  Cbz2O 1.2 TEA 2 Dioxane/ 
H2O 
Rt 
acetyl (CH3CO2)2O 2 Pyridine 2 - 50°C 
       
        As so much time had been devoted to this project without fruition it was decided that this 
avenue of research should be shelved. It would be interesting to see if the conformation of 136 
was the route of the synthetic issues experienced. Unfortunately the x-ray crystallography 
facilities at Keele were unavailable when this avenue was being explored.  
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2.7 In vitro biological testing 
 In order to determine whether the target compounds synthesised during the course of 
the project were PepT1 substrates, in vitro testing was carried out. This was initially carried out in 
Xenopus laevis oocytes by Dr D. Meredith at Oxford Brookes University.   Binding affinity was first 
determined and then transport was confirmed using a trans-stimulation assay. Favourable 
compounds were then put forward for Caco-2 testing so that intestinal permeability could be 
assessed. As part of the collaboration with AstraZeneca, Caco-2 testing was identified as being 
best carried out by me using their facilities. This was due to their in house expertise being able to 
provide training and support in both cell line culture and the most appropriate methodology for 
the Caco-2 studies. This also meant that a validated Caco-2 cell line was available to use for 
occasional studies, without year round maintenance.  Analysis of the samples generated would 
then be performed by LCMS experts in house. This would make analysis of the diverse range of 
compounds tested easier, as they would have the experience to identify suitable methodology. 
They kindly agreed that PepT1 potential substrates synthesised by others in the group would be 
able to be assayed as well as the ones synthesised by me.  
 Unfortunately this research project coincided with a time of restructuring within 
AstraZeneca. As a result expertise was lost from the company, facilities had to be relocated 
(necessitating a delay due to cell line re-validation) and in house projects were prioritised. Out of 
the five Caco-2 studies ran at AstraZeneca only one study yielded full results. The overall apparent 
permeability of the Aurora kinase inhibitor prodrug 108 was determined from the final study, of 
which this was the only prodrug able to be detected.  The other studies failed to yield results due 
to issues arising after the Caco-2 studies had been performed, most notably from issues 
surrounding LCMS analysis. This was due to being unable to find suitable LCMS methodology to 
analyse compounds. Studies that failed to yield results include comparisons of the apparent 
permeability of the parent compound against its thiodipeptide prodrug, and studies to determine 
the PepT1 mediated component of permeability. Overall the experience collaborating with 
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AstraZeneca has been positive with the experts there going above and beyond, despite the 
difficulties, to try and mediate the issues and get useable results.  It is unfortunate that the Caco-2 
studies didn’t work out. The precise experimental details for the in vitro assays can be found in 
section 6.1. The general methodology is given below, in depth evaluation in the use of these 
models to study the interaction of drugs and PepT1 is covered in an excellent review by Xia et 
al.148   
2.7.1 Binding Affinity 
 
 Xenopus laevis oocytes have the capacity to translate exogenous mRNA, in this case 
expressing PepT1.  Simple competitive inhibition assays can therefore be used to quickly 
determine the binding affinity of a potential PepT1 substrate.  Increasing concentrations of 
prodrug were incubated with a set concentration (0.4 μl) of radiolabelled, hydrolysis resistant D-
Phe-L-Gln. As PepT1 transport is an active process only one molecule of substrate can be 
transported at a time. This means that the rate of transport is limited by the concentration of 
PepT1 expression, as a result PepT1 substrates display concentration dependent kinetics 
(Michaelis-Menten Kinetics).149 As the concentration of incubated test compound is increased, the 
concentration of radiolabelled compound transported into cells is reduced due to competitive 
inhibition, allowing binding affinity to be determined.  PepT1 is a low affinity, high capacity 
transporter of substrates. Substrates with an affinity of less than 1 mM are classed as having high 
affinity for PepT1 and those with a binding affinity higher than 5 mM are classed as low affinity. 
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Figure 22 Ooycte inhibition assay. Left: Determination of maximal uptake of radiolabelled 
substrate. Right: Reduced uptake of radiolabelled substrate in the presence of a competitive 
substrate. 
2.7.2 Oocyte transport assay. 
 Although competitive inhibition assays can determine the binding affinity of a potential 
PepT1 substrate, whether the substrate is transported cannot be ascertained.  This is because it is 
possible for a molecule to be recognised and have binding affinity for PepT1, but have 
unfavourable characteristics for transport (an inhibitor). Therefore transport is assessed with a 
trans-stimulation efflux assay (Figure 25).   
 
Figure 23 Oocyte trans-stimulation assay. Left: oocytes injected with radiolabelled PepT1 
substrate. Centre: oocytes incubated with test substrate. Right: trans-stimulated efflux of the 
radiolabel. 
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 PepT1 mRNA expressing Xenopus laevis oocytes are injected with radiolabelled D-Phe-L-
Gln (4.6 nL; 37.0 MBq mL-1) and incubated with the test compound.  Once PepT1 has transported 
a molecule into the cell one of the ways it can reset itself is to efflux another substrate (the 
radiolabel) via trans-stimulation efflux. The intracellular radioactivity of the oocyte is measured 
after the incubation period and then compared to the decrease induced by the PepT1 substrate L-
Gly-L-Gln.150 If intracellular radioactivity of a D-Phe-L-Gln injected oocyte incubated with uptake 
media is taken as a control, then the percentage decrease in intracellular radioactivity seen when 
the oocyte is incubated with L-Gly-L-Gln can be used as a standard.  Therefore, incubated test 
substrates which show an intracellular radioactivity decrease of 0-30% in comparison to Gly-Gln 
can be assessed as poorly transported, 30%-80% assessed as being moderately transported and 
80%+ being excellently transported. Although you cannot get false positive results you can have a 
false negative result, as PepT1 has other pathways to reset.  
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Figure 24 A bar chart showing how transport is assessed using trans-stimulation data. 
2.7.3 Caco-2 assays. 
 Caco-2 is an adenocarcinoma cell line and is widely accepted to be a good model for the 
small intestine and is the most extensively characterised model for examining the permeability of 
drugs.148 The cell line expresses microvilli, tight-junctions, enzymes and transporters which 
resembles the small intestines morphology and functionality and has been shown to correlate 
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well with the in vivo absorption of orally administered drugs in man.151  Prior to Caco-2 testing, 
the test compounds were assessed for stability against the enzymes on the apical cell surface of 
the Caco-2 monolayer. As well as assessing the overall permeability of a compound across a cell 
membrane, significance of the PepT1 mediated component can be identified by incubating the 
substrate with an excess of a known PepT1 substrate.  
 
 
Figure 25 A Caco-2 monolayer. 
2.7.4 Biological results. 
 Binding affinity, trans-stimulation and apparent permeability had already been 
determined in the group for the thiodipeptide ibuprofen117 (79) and propofol (76) (unpublished) 
prodrugs.127 However, these compounds were re-analysed to ensure consistency between the 
Caco-2 data produced at AstraZeneca and Oxford Brookes. The binding affinity and trans-
stimulation data for these prodrugs is also shown in Table 8.117,127 Binding affinity, trans-
stimulation efflux and overall apparent permeability for the Aurora Kinase inhibitor thiodipeptide 
prodrug 108 was generated during the course of this project. Studies to assess the PepT1 
mediated component of substrate transport ran into problems with analysis of the samples 
generated from the studies. This had already been performed by Dr. Meredith’s group for the  
thiodipeptide ibuprofen (79) and propofol (76) prodrugs and so is shown in Table 8 alongside the 
results obtained for prodrug 108. 
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Table 8 In vitro data for prodrugs (76), (79) and (108). 
Compound Ki Trans-stimulation Overall Papp Overall Papp previously found               PepT1 Papp previously found 
76 0.92 ± 0.19 mM 122% 0.40 ± 0.01 x 10-6 cm S-1 0.53 ± 0.05 x 10-6 cm S-1 0.52 ± 0.05 x 10-6 cm S-1 
79 0.26 ± 0.03 mM 109% 3.97 ± 0.27 x 10-6 cm S-1 3.65 ± 0.22 x 10-6 cm S-1 2.10 ± 0.27 x 10-6 cm S-1 
108 0.10 ± 0.02 mM 110% 0.31 ± 0.00 x 10-6 cm S-1 - - 
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The thiodiprptide propofol prodrug (76) was found to have an apparent permeability of 
0.40 ± 0.01 x 10-6 cm S-1 in Caco-2 cells, which is considered a moderate permeability. This data is 
similar to that previously found at Oxford Brookes (0.53 ± 0.05 x 10-6 cm S-1). The binding affinity 
for PepT1 was found to be high (0.92 mM) and trans-stimulation was induced (122%), indicating 
that 76 is a PepT1 substrate.  This is of significance as the parent drug propofol (74) has very low 
solubility and has to be administered intravenously as an oil-in-water emulsion, making this a 
potentially a prodrug of commercial interest.   
 
The thiodipeptide ibuprofen prodrug (79) was found to have an apparent permeability of 
3.97 ± 0.27 x 10-6 cm S-1, which is considered to be a high permeability. This is similar to data 
previously generated at Oxford Brookes (3.65 ± 0.57 x 10-6 cm S-1).  This indicates that targeting 
ibuprofen (77) towards PepT1 through the attachment of a carrier still results in high 
permeability. This is an excellent result as there is in fact some evidence that parent ibuprofen 
(77) is a non-competitive inhibitor of PepT1.152   Binding affinity was found to be excellent  (0.26 
mM) and trans-stimulation was induced (109%). This indicates that this prodrug should be 
investigated further to establish whether gastrointestinal side effects seen with the parent drug 
are reduced. Ibuprofen prodrug 79 was selected for a pharmacokinetic study and taste evaluation 
test in rat (chapter 3). 
 
The Aurora kinase inhibitor prodrug 108 was found to have moderate apparent 
permeability (0.31 ± 0.01 x 10-6 cm S-1). However this was generated from a single data point using 
parent compound detected on the basolateral side of the Caco-2 monolayer in apical to 
basolateral transport.  The two other repeats were found to have an analytical response too low 
to detect.  Very little of prodrug 108 was detected on the basolateral side, indicating that 
hydrolysis of the ester bond has occurred either during or subsequent to the assay.  The parent 
Aurora kinase inhibitor (105) is slightly permeable through a Caco-2 monolayer (0.07 ± 0.01 x 10-6 
cm S-1), meaning that some of the parent prodrug (105) detected on the basolateral side may 
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have crossed the monolayer of cells if the prodrug was hydrolysed prior to transport. However, 
some of prodrug (108) must have been intact when moving from the apical to basolateral side of 
the cells for the apparent permeability to be as high as detected. To be sure of this result is 
reproducible Caco-2 testing should be performed again on this prodrug. Binding affinity was 
found to be high (0.10 mM) and trans-stimulation was induced (110%), indicating 108 is a PepT1 
substrate.   
 
Several prodrugs synthesised by Dr. Pathak were also assayed in Caco-2 cells at 
AstraZeneca. However, problems with analysis after the studies meant that apparent permeability 
could not be determined. For the purposes of assessing PepT1 for prodrug targeting the oocyte 
data generated by Dr. Meredith’s team at Oxford Brookes (unpublished) is shown.    
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Table 9 In vitro data for thiodipeptide prodrugs synthesised by R. Pathak (unpublished). 
Compound Ki Trans-stimulation 
Atenolol prodrug 146 0.44 ± 0.15 mM 70% 
Baclofen prodrug 147 1.87 ± 0.26 mM 25% 
Relenza prodrug 148 0.13 ± 0.02 mM 0% 
Mycophenolate prodrug 149 0.21 ± 0.08 mM 80% 
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 Caco-2 data is needed to fully assess whether prodrugs 146-149 are transported by 
PepT1.  The binding affinities for the thiopeptide atenolol (146) and mycophenolate (149) 
prodrugs are excellent, with both inducing moderately high trans-stimulation efflux. This suggests 
that both 146 and 149 are PepT1 substrates, but PepT1 mediated apparent permeability in Caco-2 
cells will need to determined to confirm this. Although the thiodipeptide relenza prodrug (145) 
has a high binding affinity, lack of trans-stimulation efflux suggests that it is an inhibitor of PepT1. 
The thiodipeptide baclofen prodrug 147 only showed moderate binding affinity and poor trans-
stimulation efflux. This suggests that it is a very poor substrate of PepT1, which would established 
with a PepT1 mediated apparent permeability Caco-2 assay. 
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3.1 Synthesis of carriers  
 Previous work in our group has focused on the use of thiodipeptides as the carriers of 
choice when targeting drugs towards PepT1.  These are favourable as the lack of peptide bond 
means they are resistant to hydrolysis in the gastrointestinal tract (section 2.4). Problems do 
however arise due to the presence of sulphur in the carriers. Synthetically the use of 
hydrogenation, once the carrier has undergone oxygen-sulphur exchange, is not possible due to 
poisoning of the catalyst. This limits the protecting group strategy that can be utilised in the 
synthesis of the desired prodrugs, which is particularly pertinent for acid or base sensitive drugs. 
The presence of sulphur in a drug can also drastically negatively alter taste, which can affect 
compliance especially in children.  In the extreme this is demonstrated by the drug used to treat 
cystinosis, mercaptamine bitartrate, which has a very unpleasant taste. Finally the presence of a 
thiodipeptide in the final prodrug has often experimentally been found within our group to 
produce a non-crystalline product which presents a problem for formulation. 
  Previous work within our group (Dr D. Foley, unpublished)127 showed that N-terminal α,α-
disubstituted dipeptides 150 and 151 (shown with benzyl as a model drug moiety) had potential 
as alternative hydrolysis resistant carriers.   
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These results are consistent with the finding by Lyons et al.91 that there is an elongated 
cavity in the N-terminal end of the ligand binding site in the prokaryotic POT transporter PepTso.
89 
To explore the tolerance of PepT1 for bulk in this area a series of dipeptides were synthesised.  
The use of carbocyclic rings on the N-amino moiety allowed us to investigate this steric region, 
whilst having the added benefit of increasing the overall lipophilicity of resultant prodrugs due to 
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the added hydrocarbon bulk. Traditional prodrug strategies for poorly bioavailable drugs often 
involves increasing lipophilicity which can increase permeability.  
By adding steric bulk to the N-terminal α-carbon, access to the backside of the carbonyl 
group is reduced.  This should prevent hydrolysis of the dipeptide in the gut and prevent the 
access of peptidases to the dipeptide.  To gain the best understanding of how bulk in the N-
terminal region affects PepT1 transport the data for N-terminal α-monomethyl through to α- 
cyclohexane must be assessed. This was achieved by comparing both the free carrier and carrier 
with moiety attachment through the N-terminal side chain. Benzyl was used to represent a small 
drug moiety and ibuprofen the real drug entity as it is a simple molecule to attach to a carrier due 
the presence of one functional group. This necessitated the use of serine as the second amino 
residue. The data for dipeptide 39117 and 152127 attached to both benzyl and ibuprofen had 
already been collected within the group, so dipeptides 153-156 were synthesised (Figure 30).  
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Synthetic work on this project was initiated by 3rd year student Lucy Richards, under my 
supervision, with the project target being cycloleucine-serine-ibuprofen (162) (Scheme 15).  Due 
to the favourable price of cycloleucine (5g, £30), the project was initiated from this starting 
material rather than Boc-cycloleucine (1g, £20).This was to enable the student to gain experience 
in protecting group reactions and to economise the limited student project budget.  
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Scheme 15 Initial synthesis of cycloleucine-Ser-ibuprofen. (i) Boc2O, TEA, NaOH, C2H3N, 0˚C → rt, 
4h (ii) tert-butyl-2,2,2-trichloroacetimidate, DCM/Et2O, 3 days (iii) TBAF in THF, 3h (iv) (158), 
DPPA, DIPEA, DMF, 0˚C, 3 days (v) 10% Pd/C, H2, MeOH, 24h (iv) HBTU, DIPEA, ibuprofen (77), 
DMF, 4 days (v) HCO2H, reflux, 3h. 
Traditional Boc-protection procedures (NaOH, dioxane, H2O and Boc2O) failed to give the 
desired product 158, so a bi-phasic procedure was utilised to give N-Boc-cycloleucine (158) in a 
65% yield. NaOH enabled solvation of the cycloleucine, whilst acetonitrile enabled solvation of 
Boc2O and TEA was used to activate Boc2O. Synthesis of H-Ser(Bn)-
tBu (50) was carried out using 
the established methodology (tert-butyl protection of Fmoc-Ser(Bn)-OH (46) using tert-butyl-
2,2,2-trichloroacetimidate, followed by Fmoc deprotection using TBAF) (Section 2.3). Synthesis of 
Boc-cycloleucine-Ser(Bn)-OtBu (159) was initially carried out  using the coupling conditions utilised 
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in the synthesis of our tert-butyl and Benzyl protected carriers (1.1 eq DPPA, 2 eq TEA in DMF) to 
give an expected yield of 78%. Although this is a good yield, to my knowledge no optimisation of 
this step had been carried out since the establishment of the original methodology. Therefore, to 
gain experience in synthesis optimisation and the different classes of coupling reagents, Lucy was 
asked to screen coupling conditions for this step (Table 10).   
Table 10 Optimisation of the coupling conditions for Boc-cycloleucine-Ser(Bn)-OtBu (159). All 
reactions carried out over 3 days at 0˚C in DMF 
Excess amino 
acid (1.1 eq) 
Coupling 
reagent Eq. Additive Eq. Yield  
Boc-cycloleucine DPPA 1.1 TEA 2 78% 
Boc-cycloleucine DPPA 1.1 DIPEA 1.5 61% 
Boc-cycloleucine DPPA 1.1 DIPEA 2 96% 
Boc-cycloleucine EDC 1.1 HOBt 2 49% 
H-Ser(Bn)OtBu EDC 1.1 HOBt 2 88% 
Boc-cycloleucine HBTU 1.1 DIPEA 2 35% 
 
Benzyl deprotection of Boc-cycloleucine-Ser(Bn)-OtBu (159) was carried out using 10% 
Pd/C in MeOH to give 160. 160 was then coupled to ibuprofen (77) using the previously 
established methodology of HBTU and DIPEA in DMF to give 161 in a 26% yield. Final deprotection 
of 161 was carried out in formic acid, but for some reason failed to give a clean product (162, 
Scheme 16). 
 Although Lucy made good progress with the synthesis of protected cycloleucine-serine-
ibuprofen (161), the target compound was not made.  Therefore, to continue this project the free 
carrier, carrier with benzyl attachment and carrier with ibuprofen attachment were synthesised 
by me using stock 159 from Lucy’s project.  Due to low yield (26%) the coupling conditions used to 
synthesise 161 was optimised. DCC and DMAP in DCM was found to give the desired ibuprofen 
prodrug (161) in 82% yield (Scheme 16).  
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Scheme 16 Synthesis of H-cycloleucine-Ser(Bn)-OH (163), H-cycloleucine-Ser(OH)-OH (155) and 
H-cycloleucine-Ser(ibuprofen)-OH (162). (i) HCO2H, reflux, 3h (ii)10% Pd/C, H2, MeOH, 24h (iii) 
HCO2H, reflux, 3h (iv) DCC, DMAP, ibuprofen (77), DCM, 3 days (v) HCO2H, reflux, 3h. 
 Synthesis of the cyclopropane, cyclobutane and homocycloleucine carriers was carried 
out from their purchased Boc-amino acids (Scheme 17). The first set to be synthesised was the 
cyclopropane carrier derivatives. Difficulties were encountered upon the benzyl deprotection of 
165 to give 167, as 10% Pd/C in MeOH resulted in only starting material being obtained. It was 
only upon the addition of catalytic AcOH to Pd/C in MeOH that successful protection occured to 
give 167. The cyclobutane carrier derivatives and homocycloleucine carrier derivatives were 
synthesised using the same methodology (Scheme 17). 
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Scheme 17 Synthesis the free carrier, carrier with benzyl attachment and carrier with ibuprofen 
attachment for the cyclopropane, cyclobutane and homocycloleucine carriers. (i) N-Boc amino 
acid, DPPA, DIPEA, DMF, 0˚C, 3 days (ii) HCO2H, reflux, 3h (iii) AcOH, Pd/C, MeOH, 24h (iv) 
HCO2H, reflux, 3h (v) DCC, DMAP, ibuprofen, DCM, 3 days (vi) HCO2H, reflux, 3h. 
3.2 In vitro biological testing 
The synthesis of; H-Ala(S)Ser(Bn)-OH (182),117 H-Ala(S)Ser(ibuprofen)-OH (79),117 H-Aib-
Ser(Bn)-OH (150)127 (Dr. F. Foley) and H-Aib-Ser(ibuprofen)-OH (183) (Dr R. Pathak, unpublished) 
had previously been carried out by our group. Previously obtained oocyte data for these 
compounds are included in Table 11 for comparison purposes. Apparent permeability data for the 
ibuprofen attached carriers was attempted to be generated during the course of the project. 
Unfortunately data was not obtained from the Caco-2 studies, although the cycloleucine 
ibuprofen prodrug was found to fragment during stability testing, suggesting that this carrier is 
not hydrolysis resistant. 
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Table 11 Binding affinity and trans-stimulation efflux for dipeptides. 
 
 
 
 
 
 
 
 
             
X= H Oocytes 
Ki - - 0.79 ± 0.41 mM 0.69 ± 0.22 mM 0.66 ± 0.26 mM 0.17 ± 0.05 mM 
trans-
stimulation - - 117% 68% 68% 151% 
  
Compound No. 
  
153 154 155 156 
X= Bn Oocytes 
Ki 0.25 ± 0.05 mM* 0.13 ± 0.03 mM* 0.25 ± 0.12 mM 0.42 ± 0.14 mM 0.26 ± 0.08mM 0.25 ± 0.12 mM 
trans-
stimulation 112% * 0% * 166% 98% 117% 120% 
  
Compound No. 182 151 166 172 163 178 
X= 
ibuprofen 
Oocytes 
Ki 0.26 ± 0.03 mM 0.22 ± 0.04 mM* 0.23 ± 0.05 mM 0.09 ± 0.17 mM 0.16 ± 0.06mM 0.02 ± 0.003 mM 
trans-
stimulation 109% * 82% * 55% 26% 173% 0% 
  
Compound No. 79 183 169 175 162 181 
 
* Previously generated data. 
 
 
 
H
N
O
OH
OR
S
H2N
H
N
O
OH
OR
O
H2N
H
N
O
OH
OR
O
H2N
H
N
O
OH
OR
O
H2N
H
N
O
OH
OR
O
H2N
H
N
O
OH
OR
O
H2N
91 
 
 All dipeptides were shown to have excellent binding affinity for PepT1, this suggests that 
adding bulk to the N-terminal α-carbon does not affect the ability of the compounds to bind to 
PepT1. For each dipeptide there a slight general trend of the binding affinity increasing as the size 
of the ligand attached to the serine alcohol increases H<Bn<ibuprofen. This can be explained by 
the fact the benzyl moiety and ibuprofen are hydrophobic and PepT1 has been shown to have a 
hydrophobic pocket with a strong directional vector in this region (section 1.3.8).  
 Trans-stimulation assays previously carried by out by Dr D. Meredith on H-Aib(S)Ser(Bn)-
OH (150), as part of Dr R. Pathak’s research, failed to show efflux.   Although false negatives 
should not occur in trans-stimulation assays transport has since been demonstrated in Caco-2 
cells. This result is perhaps a result of abnormal oocytes. All dipeptides except cyclobutane-serine-
ibuprofen (175) simulated moderate to excellent efflux in trans-stimulation assays. This is perhaps 
an anomalous result as both the free carrier and benzyl linked carrier stimulated efflux. Higher 
binding affinities were seen for the homocycloleucine carrier than the other carriers when as a 
free carrier or with drug moieties attached.  This is surprising as the homocycloleucine carrier has 
the most N-terminal α-carbon bulk and was expected to give the lowest binding affinity as a 
result.  The lack of trans-stimulation and the high binding affinity seen for homocycloleucine-
serine-ibuprofen (181) suggests that this may be an inhibitor for PepT1. Although the excellent 
trans-stimulation efflux seen for both the free homocycloleucine carrier and benzyl linker carrier 
indicates that these are in fact transported. This could be established though Caco-2 testing.   
 It is unfortunate that Caco-2 data could not be obtained for these molecules. It has been 
established that these molecules are recognised by PepT1, but not if they are able to be 
transported. Although apparent permeability data was not generated subsequent to Caco-2 
testing, stability testing indicated that cycloleucine-serine-ibuprofen (162) was able to be 
hydrolysed. The ibuprofen-linked cyclopropane (169), cyclobutane (175) and homocycloleucine 
(181) carriers all seemed to be hydrolysis resistant. Further Caco-2 assays need to be performed 
on these molecules to assess the apparent permeability of the carriers. If found to be transported 
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well by PepT1, these carriers represent an attractive alternative to the thiodipeptide carriers 
currently used by the group.  
3.3 In vivo biological testing. 
Both the Ala(S)Ser (79) and Aib-Ser (183) ibuprofen prodrugs had previously been shown 
in the group to be substrates of PepT1. They were therefore selected for both an in vivo 
pharmacokinetic study and a taste tolerance study, performed in rat, by Saretuis Ltd. The object 
of the study was to assess whether the addition of the carriers significantly differed the 
pharmacokinetic profile for the prodrugs, when compared to ibuprofen. We were also interested 
in whether the presence of sulfur in prodrug 79 negatively affected its taste. Prodrug 79 was 
synthesised by myself for this study and prodrug 183 was synthesised by Dr. R. Pathak. 
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3.3.1 Pharmacokinetic study 
 For the study Ala(S)Ser-ibuprofen (79) and Aib-Ser-ibuprofen (183) were prepared at 10 
mg/Kg and ibuprofen was prepared at 6 mg/Kg in distilled water. This was administered orally to 
male CD rats (n=3). All compounds were well tolerated and no adverse events were reported.  
Plasma samples were collected 0.25, 0.5, 1, 2, 4, 8 and 24 h after dosing. An equal volume of 
heparinised saline was infused back into the rat to replace the blood volume taken from the 
animal, thus ensuring patency.  
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Table 12 Summary of the mean calculated pharmacokinetic parameters. Each prodrug 
administered was detected both as the prodrug and parent ibuprofen. 
 
 Ibuprofen (77) Ala(S)Ser-ibuprofen (79) Aib-Ser-ibuprofen (183) 
Parameter Units  prodrug Ibuprofen prodrug Ibuprofen 
T1/2 h 2.87 1.67 3.17 2.19 3.27 
Tmax h  0.66 1 1  0.66 1.83 
Cmax ng/mL 5664.13 199.7 207.20 31.40 3140.00 
Tlast h 8 3.33 8 3.33 16 
Clast ng/mL 418.267 79.60 31.70 19.033 428.27 
AUClast h*ng/mL 14045.14 488.53 652.46 70.64 10363.16 
AUCINF_obs h*ng/mL 16111.45 790.34 799.62 125.64 12290.69 
  
 Ibuprofen (77) was found to be detectable in the plasma up to 8 hours after 
administration, with exposure levels consistent across all three rats.  The mean peak serum 
concentration (Cmax) was determined as 5664.13 ± 0.64 μg/mL.  The elimination of ibuprofen (77) 
was very similar for two of the rats, but an anomalous reading at the 8 hour time point in rat 1 
generated a poorer fit. This suggests that the half life of Ibuprofen (77) is closer to 2 hours rather 
than 2.8 hours as generated by the mean.   
 Ala(S)Ser-ibuprofen (79) was detectable in plasma as the prodrug 3.3 hours after 
exposure and as the parent drug, ibuprofen (77), up to 8 hours after administration. Levels of 
compound exposure across the n=3 were consistent, a mean Cmax of 199.7 ± 35.9 ng mL for 
Ala(S)Ser-ibuprofen (79) was detected 1 hour after dosing. A mean Cmax of 207.20 ± 17.1 ng mL 
was detected for ibuprofen (77) 1 hour after dosing.  As exposure levels were found to be low for 
one of the rats elimination curves were fitted for the data on an n=2 basis. Data from the n=2 to 
indicated a mean T1/2 of approximately 1.67 hours for Ala(S)Ser-ibuprofen (79) and 3.17 hours for 
ibuprofen (77).    
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 Aib-Ser-ibuprofen (183) was detectable in plasma as the prodrug or parent ibuprofen (77) 
up to 16 hours after administration. The levels of detection for Aib(S)Ser-ibuprofen (183) across 
the three treated rats were reasonably consistent although levels were very low. Cmax occurred 
0.66 hours after dosing and was determined as 31.40 ± 5.1 ng/mL. Ibuprofen (77) was detected up 
to 16 hours after administration with Cmax determined as 1340 ± 260.5 ng/mL.  Elimination curves 
could only be fitted to two of the three rats and the mean T1/2 was found to be 2.19 hours for 
Aib(S)Ser-ibuprofen (183) and 3.27 hours for ibuprofen (77).  
 Combining the prodrug and parent drug Cmax for Ala(S)Ser-ibuprofen (79) results in a Cmax 
of 406.9 μg/mL which is only 0.07% of the Cmax observed when ibuprofen (77) was administered 
(5664.13 μg/mL). The parent drug, ibuprofen (77), was seen for up to 8 hours after 
administration, but Clast was very low indicating that this prodrug was not well absorbed. In 
contrast, if you combine the prodrug and parent drug Cmax for Aib-Ser-ibuprofen (183) the Cmax 
observed is 3171.4 μg/mL. This is 56% of the Cmax observed when ibuprofen (77) was administered 
(564.136 μg/mL). However, the majority of the combined Cmax observed for Aib-Ser-ibuprofen 
(183) comes from detected ibuprofen (77). This indicates that cleavage of the prodrug occurred 
prior to intestinal permeation or soon after the prodrug was in systemic circulation. The Tmax was 
3 times longer for Aib-Ser-ibuprofen (183) than when ibuprofen (77) was administered and 
elimination was twice as long. This indicates that Aib-Ser-ibuprofen (183) promotes a longer 
exposure duration than ibuprofen (77) and it is better absorbed than Ala(S)Ser-ibuprofen (79).  
This suggests that Aib-Ser-ibuprofen (183) may have therapeutic potential as an ibuprofen 
prodrug.  
 A 24 hour pharmacokinetic study for Ala(S)Ser-ibuprofen (79) had previously been 
performed in the group using a single male CD rat.117 A 10 mg/kg dose of Ala(S)Ser-ibuprofen (79) 
resulted in a detected prodrug Cmax of 930 ± 90 ng/mL with a Tmax of 1.33 hours. This Cmax is much 
higher (4.6 times) than the result obtained here, although the Tmax is roughly the same. This may 
be due to an anomalous rat as n=1 rather than n=3 was used the study. The study was also limited 
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as only the appearance of Ala(S)Ser-ibuprofen (79) in plasma was studied, rather than Ala(S)Ser-
ibuprofen (79)  and ibuprofen (77). This makes it hard to assess overall the transport and 
clearance of ibuprofen (77), both as the prodrug and parent drug. 
3.3.2 Taste assessment.  
To assess whether the presence of sulfur in the Ala(S)Ser carrier (56) negatively affected 
the taste of the resultant prodrug a taste assessment in rats was performed. In addition to 
Ala(S)Ser-ibuprofen (79),  Aib-Ser-ibuprofen (183)  was also assessed as it is not a sulfur 
containing prodrug, and ibuprofen (77). Rats were initially habituated in cages, for two days, 
with a choice of two identical water bottles, one containing ibuprofen (77) solution and one 
containing water.  After this time the bottle which had contained water was replaced with either 
Ala(S)Ser-ibuprofen (79) solution or Aib-Ser-ibuprofen (183) solution. This meant that the rats 
now had a choice between a bottle containing an ibuprofen prodrug solution and a bottle 
containing an ibuprofen solution. This part of the experiment was carried out for three days and 
the water bottles were randomly switched each day to prevent preference.  
 
When Ala(S)Ser-ibuprofen (79) solution was used as the prodrug solution there was a 
marked preference for the ibuprofen (77) solution. There was also a slight increase in the 
volume of ibuprofen (77) solution consumed during the three day test period than the volume 
of consumed during the 2 day acclimatisation period.  When the Aib-Ser-ibuprofen (183) 
solution was used as the prodrug solution again more slightly more ibuprofen (77) was 
consumed over the three day test period than had been consumed in the 2 day acclimatisation 
period. There was also marked preference for the bottle containing ibuprofen (77) solution than 
the bottle containing Aib-Ser-ibuprofen (79) solution during the three day test period.  When 
the volumes of the two prodrug test solutions consumed over the test period are compared, 
very little difference is seen.  This indicates that the rats had no preference between these two 
prodrugs and therefore the presence of the sulfur atom in the carrier attached to the parent 
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drug does not make the taste significantly more unpalatable. However, the taste of both 
prodrug solutions is more unpalatable than ibuprofen solution.   
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4.1 PepT1 in cancer 
 The treatment of many cancers requires a chronic schedule. However, the oral 
bioavailability of many oncology drugs is both poor and highly variable. As well as being poorly 
absorbed, many anticancer drugs are substrate to efflux pumps such as P-gp which are designed 
to remove toxic substances from cells. This makes oral formulation difficult, although 
transmembrane targeting has been used as a tool to overcome this (Chapter 2).  
 Recently PepT1 has been shown to be over-expressed in several epithelial-derived cancer 
cell lines, where oligopeptide uptake is presumably necessary for rapid cell growth. These are; the 
malignant ductal pancreatic cancer cell lines AsPc-1 and Capan-2, human extrahepatic 
cholangiocarcinoma cell line SK-ChA-1,153 human gastric cancer cell line MKN45154 and human 
renal adenocarcinoma cell line VMRC-RCW.155 This raises the possibility of using targeted PepT1 
drug delivery as a tool in cancer therapy, potentially reducing side effects as off target delivery 
would be minimised. Once inside the cell the PepT1 recognised component of the prodrug would 
be cleaved from the oncology drug giving the active drug.  The validity of this approach has been 
demonstrated in the constructed cell line HeLa-hPepT1. Bestatin, an oncology drug known to be 
transported by PepT1, was shown to inhibit HeLa-hPepT1 in vitro. In vivo, HeLa-hPepT1 tumours 
grown in mice were found to be suppressed and bestatin accumulated, following oral 
administration.155  
 Pancreatic cancer is particularly difficult to detect as symptoms often do not present until 
the cancer is relatively advanced. Although it is the 9th most common cancer in the UK, prognosis 
is poor with a 4% survival rate after 5 years.157 Ductal pancreatic adenocarcinoma in particular can 
be resistant to chemotherapy due to the complex microenvironment that surrounds the 
pancreas.158 The discovery that PepT1 is over-expressed in pancreatic cancer cell lines therefore 
enables research into the targeted delivery of cytotoxic drugs. 
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4.2 Ala(S)Ser-ibuprofen 
 The link between tumour growth and inflammation was first made in the 19th century and 
is now accepted as an underlying factor in the development of many cancers. Up to 20% of 
cancers are directly associated with microbial infection, with the causality of many others related 
to chronic infection, obesity, dietary factors and inhaled pollutants.159 It has been shown that as a 
tumour develops it expresses phenotypes similar to inflammatory cells.160 Inflammation has also 
been shown to play a role in both tumourgenesis and aggression of the resultant malignancy.161 In 
fact the risk of developing prostate, colorectal and pancreatic cancers has been shown to increase 
in patients who have suffered chronic infection in those areas.161   There are several excellent 
reviews into the research undertaken into understanding the inflammatory feedback mechanisms 
which can promote tumourgenesis.162-3 This research has improved understanding into the 
molecular causation of cancer and opened up a new avenue of research into the use of anti-
inflammatory drugs in the treatment of cancer.  
 Several studies have also shown the prophylactic benefit of taking nonsteroidal anti-
inflammatory drugs (NSAID) for several cancers including, breast, colorectal, lung and ovarian 
cancers.161  This was first demonstrated in patients with Gardner’s syndrome, which causes 
intestinal polyps. When the patients were treated with the nonsteroidal anti-inflammatory drug 
sulindac, a reduction was seen in adenoma formation.164  NSAID’s are commonly used for the long 
term management of chronic pain conditions like arthritis and the preventive treatment of 
cardiovascular disease, allowing comparisons in the long term use and cancer incidents.  Although 
this demonstrates the potential of NSAID’s on a prophylactic basis, in most cases the side effects 
of long-time usage would outweigh any benefit in the reduction of incidence to the general 
population.  
 
101 
 
  The use of anti-inflammatory drugs to treat established cancers, may however be an 
option. In vitro, proliferation in colorectal cell lines,165 ovarian carcinoma cell lines166 and lung 
cancer cell lines167 has been demonstrated to reduce upon the treatment with a variety of 
NSAID’s.  In vivo, indomethacin has been shown to reduce the growth of both new and 
established spontaneous mammary tumors.168 Diclofenac was shown to decrease pancreatic 
tumour growth.169 Ibuprofen (77) and aspirin (80) have also been shown to reduce growth of 
colon cancer cells.169 This shows the targeted use of nonsteroidal anti-inflammatory drugs may be 
of benefit as part of cancer therapy as toxicity would be minimised.   
4.2.1 In vitro testing 
 A collaboration with Prof. Randy Mrsny at the University of Bath enabled a study into the 
use of PepT1 as a vehicle to deliver anti-inflammatory drugs into cancer cells. As anti-
inflammatory drugs are only able to access the surface of cells efficacy is limited.  By using PepT1 
to deliver a NSAID into the cancerous cells it was hoped efficacy would be improved as the drug 
would be accumulated. Ibuprofen (77) was selected as the NSAID to be studied as its ability to 
reduce cell proliferation had been demonstrated170 and the thiodipeptide prodrug had already 
been synthesised (section 2.5.2).  The study was carried out by PhD student Ana Santos Cravo 
using the human pancreas adenocarcinoma cell line AsPC1, which has been shown to express 
PepT1. The studies were designed as a result of discussions between myself and Ana and any 
conclusions drawn from the studies are my own.  
 An AsPc1 PepT1 knockdown cell line was prepared by Ana for use as a control. Some 
cytostolic and nuclear expression of PepT1 was seen in the knock down cell line via immunoblot 
analysis (Figure 26). However, as this study is only concerned with PepT1 expressed at the cell 
surface this is not relevant.  
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Figure 26 Immunoblot assay showing absence of PepT1 at the cell surface of AsPc1 PepT1 -/- 
cells 
 To assess whether Ala(S)Ser-ibuprofen (79) would have an effect in reducing cell 
proliferation via PepT1 uptake, different concentrations of the prodrug was incubated with cells 
for 24 hours.  Figure 27 shows that the AsPc1 cells expressing PepT1 displayed a statistically 
significant reduction in cell proliferation compared to AsPc1 knockdown cells. To confirm that the 
reduced proliferation seen was due to uptake of Ala(S)Ser-ibuprofen (79) via PepT1, rather than 
another mechanism, a competitive inhibition study was carried out (Figure 28). Different 
concentrations of Ala(S)Ser-ibuprofen (79) were incubated with AsPc1 PepT1 expressing cells in 
RPMI medium and a huge excess of Gly-Sar (50mM) for 24 hours. As Gly-Sar is a PepT1 substrate, 
this effectively blocks Ala(S)Ser-ibuprofen uptake into cells via the PepT1 transporter. Figure 28 
shows that increased cell proliferation is seen in AsPc1 cells which have been supplemented with 
Gly-Sar, when compared to cells which have just been exposed to Ala(S)Ser-ibuprofen (79). This 
suggests PepT1 is involved in the uptake of Ala(S)Ser-ibuprofen (79) in AsPC1 cells.    
 
Figure 27 Rate of proliferation in cells exposed to Ala(S)Ser-ibuprofen (79). Values are expressed 
as mean ± SEM from 3 independent experiments; **p< 0.01; ***p< 0.001. 
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Figure 28 Ala(S)Ser-ibuprofen (79) Competitive inhibition study. Values are expressed as mean ± 
SEM from 3 independent experiments; **p< 0.01; ***p< 0.001. 
 To assess whether Ala(S)Ser-ibuprofen (79) had an effect on cell viability as well as 
proliferation, a MTT assay was carried out. NAD(P)H-dependent cellular oxidoreductase enzymes 
in the cytosol of cells are able to reduce a colourless tetrazolium dye to a coloured  formazan dye.   
Rapidly dividing cells display high cellular metabolism and therefore tetrazolium reduction is 
increased, resulting in a stronger colour.  Cell viability can therefore be assessed as measure of 
colour. Different concentrations of Ala(S)Ser-ibuprofen (79) were incubated with cells for 24 
hours. Figure 29 shows that the cell viability of AsPc1 cells was significantly decreased when 
compared to AsPc1 knockdown cells. This suggests that Ala(S)Ser-ibuprofen (79), once 
transported into cells, has an effect on cell viability either as  the prodrug or the parent drug 
ibuprofen.  
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Figure 29 MTT cell viability assay. Values are expressed as mean ± SEM from 3 independent 
experiments; **p< 0.01; ***p< 0.001. 
 To my knowledge the reduced cell proliferation by an ibuprofen prodrug or ibuprofen in 
AsPc1 cells has not been previously reported, but is in line with the effect that has been described 
in other cancerous cell lines using alternative nonsteroidal anti-inflammatory drugs.165-70 Cyclo-
oxygenase-2 (COX-2) is one of the accepted pharmacological targets of ibuprofen and has been 
shown to be unregulated in several cancers, including pancreatic ductal adenocarcinomas. This is 
as a stress response induced by inflammatory cytokines, growth factors and oncogenes.171 
Disregulation of COX-2 results in increased biosynthesis of prostaglandin E2 (PGE2) which has been 
shown to promote proliferation, angiogenesis, migration and inhibit apoptosis.164 Therefore, one 
of the ways that ibuprofen may reduce proliferation is by inhibiting the  COX-2/PGE2 pathway.   
 To assess whether COX-2 levels in both AsPc1 and AsPc1 PepT1 knockdown cells were 
differentially affected by Ala(S)Ser-ibuprofen (79) than ibuprofen (77), an immunoblot assay was 
carried out subsequent to exposure for 24 hours. Figure 30 shows that COX-2 levels were 
significantly reduced in both cell lines after exposure to either ibuprofen (77) or the ibuprofen 
prodrug (79). However, COX-2 expression is eliminated in the ASPC1 cells expressing PepT1 that 
were exposed to Ala(S)Ser-ibuprofen (79).  This may be explained by the accumulation of 
ibuprofen within the cells, which may have a bigger effect on disrupting the COX-2/PGE2 pathway. 
In ASPC1 PepT1 knockdown cells incubated with Ala(S)Ser-ibuprofen (79), reduction in COX-2 
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expression was seen.  This may be due to the ibuprofen prodrug (79) still being able to have a 
partial action in the prodrug form, alternatively some prodrug degradation could have occurred to 
give the free ibuprofen (77).  
 
Figure 30 Immunoblot assay showing COX-2 levels after AsPc1 and AsPc1 PepT1 -/- cells were 
exposed to Ala(S)Ser-ibuprofen (79). 
4.2.2 Conclusions 
 Ala(S)Ser-ibuprofen (79) was shown to have a more pronounced effect on cell 
proliferation and vitality in AsPc1 cells expressing PepT1 compared to AsPc1 knockdown cells and 
affects COX-2 expression levels . The inhibitory affect of ibuprofen on cancerous cells which highly 
express COX-2 was recently demonstrated by Lichtenberger in colon cancer cells,170 reflecting our 
results.  Cell proliferation increased when uptake of Ala(S)Ser-ibuprofen (79) was blocked by Gly-
Sar. This confirms that PepT1 involvement in the decreased proliferation and vitality in PepT1 
expressing AsPc1 cells. The use of NSAID’s in a prophylactic manor and as part of cancer therapy 
remains controversial due to the side effects reported from long-term use.161 These side effects 
can be potentially mitigated through the use of active targeting. However, there is some 
indication that Ala(S)Ser-ibuprofen (79) may have some action in its prodrug form and this needs 
to be investigated further. Despite this, the reduction in proliferation and vitality of cells seen in 
this study justify the investigation Ala(S)Ser-ibuprofen (79) for efficacy in an in vivo oncology 
model. 
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4.3 Gemcitabine prodrugs 
As part of the collaboration with Prof. Mrsny the thiodipeptide prodrugs of gemcitabine 
(184) was also synthesised and assessed for efficacy in AsPc1 cells.   
O
OHHO
F
N
N
O
NH2
F
184
 
Gemcitabine (184) is a deoxycytidine analogue which has been licensed for the treatment 
of bladder cancer, breast cancer, non-small lung cancer and pancreatic cancer.172 Gemcitabine 
(184) works by replacing one of the cytosine building blocks in DNA replication. As new 
nucleosides in the chain cannot be attached to gemcitabine (184) apoptosis is induced. As with 
other nucleoside analogues, gemcitabine suffers from low oral bioavailability.  This is primarily 
due to extensive first pass metabolism of gemcitabine (184) by cytidine deaminase (CDA) to 
inactive 2,2-difluorodeoxyuridine.172  As a result gemcitabine (184) is administered intravenously. 
There has been extensive research into oral formulations of gemcitabine (184), which would 
provide a more convenient dosing regimen. Currently gemcitabine (184) is injected over 30 
minutes by a hospital professional.173 It is however often used in combination with other orally 
formulated chemotherapy drugs such as capecitabine, making a combination oral formulation 
desirable. 
 There have been several strategies to improve the oral bioavailability of gemcitabine 
(184) both through increased lipophilicity and PepT1 targeting.  The most clinically advanced 
gemcitabine prodrug is LY2334737 (185) developed by Eli Lilly and company, which is set to start 
phase II trials. The 4-amide linked valprolate prodrug blocks deamination of CDA thereby 
improving bioavailability and is hydrolysed slowly by carboxylesterase 2 leading to the sustained 
release of gemcitabine in vivo.174   
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Also in clinical trials is NUC-1031 (186), developed by the Cardiff School of Pharmacy.175 
This has been based on the premise that gemcitabine (184) must be activated by deoxycytidine 
kinase (dCK) to 5’-O-monophosphate-gemcitabine (187).175 Down-regulation of this enzyme would 
therefore limit gemcitabine efficacy. To overcome this, a ProTide approach has been developed 
whereby a 5’-O-monophosphate group is protected by a biolabile group. NUC-1031 (186) has 
been shown to have a greater efficacy both in vitro and in vivo than gemcitabine (184), with an 
improved safety profile.175 
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The oral bioavailability of several nucleoside drugs has been improved through PepT1 
targeting. The most common method being the addition of a valine residue to create the amino 
acid ester prodrug (section 2.1.1). It is therefore unsurprising that this is a strategy that has been 
applied to gemcitabine (184), primarily by the Amidon research group. The most recent research 
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from this lab utilising this approach involves with the in vitro and in vivo testing of L- and D-valine 
(188, 189) and L- and D-phenylalanine (190, 191)  5’- mono acid ester prodrugs of gemcitabine 
(184) for transport via PepT1.176  
Table 13 Caco-2 and AsPc1 data for 5'-amino acid ester prodrugs of gemcitabine (185).176 
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phenylalanyl 
191 
Caco-2 
Papp (x 10
-6 
cm S-1) 1.0 ± 0.2 3.8 ± 0.9 4.5 ± 0.9 4.0 ± 0.1 3.9 ± 0.1 
 
approximate 
uptake 
(μM/ug of 
protein) 10 140 112 170 75 
Uptake 
composition 
(%) 
Prodrug - 82 69 85 90 
Gemcitabine 50 18 31 15 10 
Cytosine 50 0 0 0 0 
AsPc1 approximate 
uptake 
(μM/ug of 
protein) 1 2.8 5.2 1.4 4.4 
Uptake 
composition 
(%) 
Prodrug - 6 12 69 19 
Gemcitabine 90 84 87 11 77 
Cytosine 10 10 1 20 4 
 
Table 13 shows that, as expected, the 5’-L-amino acid ester prodrugs (188, 190) displayed 
greater uptake in Caco-2 cells. This was also seen for mouse single-pass perfusion (not shown). 
Interestingly, overall uptake for AsPc1 was reduced (<6%). This could be attributed to a 
significantly higher amount and/or type of metabolising enzymes present in ASPC1 cells compared 
to Caco-2 cells. Therefore, much more prodrug degradation would occur in ASPC1 cells than in 
Caco-2 cells, limiting PepT1 transport. Interestingly, uptake of the D-amino acid ester prodrugs 
(189, 191) in AsPc-1 cells was much greater than the L-amino acid ester prodrugs (188, 190). This 
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is contrary to what is usually seen in PepT1.  One explanation for this is the higher enzymatic 
stability of D-amino acid ester prodrugs, thereby allowing higher uptake prior to degradation. This 
does suggest that D-enantiomer prodrugs would be favourable for the active targeting of tumours 
which upregulate PepT1. One limitation of this study is that degradation of gemcitabine (184) to 
2,2-difluorodeoxyuridine was not assessed. The validity of this prodrug approach to limit first pass 
metabolism into the inactive metabolite can therefore not be established. It would also be 
interesting to screen the AsPc1 cell line with known PepT1 substrates to assess whether the same 
transport profile is seen. This would confirm that the preference for D-amino acids seen in this 
case is due to prodrug degradation and not due to altered substrate specify. 
The Amidon group has also created a dipeptide monoester of gemcitabime.177 5’-L-
phenylalanyl-L-tyrosyl-gemcitabine (192). This particular dipeptide was chosen as it been has 
experimentally shown to be hydrolysed by lysomal cathepsin D,178 which has been found to be 
unregulated in tumours.   Being a dipeptide, L-phenylalanyl-L-tyrosyl is also a substrate for PepT1, 
thereby acting as a ‘carrier’ for attached drugs. This not only allows transport into cancerous cells, 
but ensures that prodrug activation can occur to give the free drug.  
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This is a similar approach to that used in our group, where cytostolic esterases release the 
attached drug. 5’-L-phenylalanyl-L-tyrosyl-gemcitabine (192) was shown to be taken up by Caco-2 
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cells, but uptake was not inhibited by Gly-Pro, suggesting that a mechanism of uptake other than 
PepT1 is responsible. If this prodrug is assessed against a PepT1 substrate template (section 1.3.8) 
it can be seen that the stereochemistry of the tyrosine residue is not optimum.  Although a 
hydrophobic entity with a strong directional vector at the C-terminus is present, which is 
necessary for transport, it is not in the optimum position and should be in line of the plane (the 
position occupied by gemcitabine (184)). In turn, bulk is best tolerated by PepT1 in the C-terminus 
side chain. Alteration of the C-terminus residue to D-tyrosine would give the required 
stereochemistry and may have resulted in PepT1 transport.  
4.3.1 Gemcitabine prodrug synthesis. 
When creating an oral formulation of gemcitabine (184) several factors must be 
considered; 1) ability of the drug to be absorbed in the gastrointestinal tract, 2) stability of the 
prodrug to both intestinal epithelial cells and esterases in systemic circulation, 3) prevention of 
deamination to inactive 2,2-difluorodeoxyuridine, 4) resistance to enzymes at the cancerous cell 
surface, 5) ability to be transported into cancerous cells. Tackling these factors can be approached 
in different ways, as shown by different research groups. From a thiodipeptide prodrug 
perspective, two different gemcitabine prodrugs were synthesised to encompass the strategies 
utilised by previous groups (193 and 194).  
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 Prodrug 193, 5’-O-Ala(S)Asp-gemcitabine, is in line with the prodrug strategy historically 
used by our group. The Ala(S)Asp carrier (57) is attached to gemcitabine (184) through the 
primary alcohol via an ester linkage. By attaching through the primary alcohol gemcitabine (184) 
is set slightly away from the carrier which has been found historically within our group to improve 
transport. Prodrug 194, 4’-N-Ala(S)Asp-gemcitabine, attempts to solve the problem of the 
deamination of gemcitabine to 2,2-difluorodeoxyuridine. Protection of the amino group of 
gemcitabine has been shown in LY2334737 (185) to block deamination and give a prodrug with 
sustained release. This reduces the dosage needed for clinical efficacy and therefore reduces 
potential toxicity.  
  The synthesis of the 5’-monoester prodrug of gemcitabine (193) was initially carried out 
using the methodology published by the Amidon research group.176 In their hands the use of Boc 
protected dipeptide, DCC (1.1eq), DMAP (0.1eq) and gemcitabine (184) in DMF gave the 3’-
monoester, 5’-monoester and 3’-5’diester of gemcitabine after 24 hours. However, in my hands 
both the one pot method and pre-charging method gave tert-butyl protected 4’-N-Ala(S)Asp-
gemcitabine (195) as the only product in a 72% yield (scheme 18). Tert-butyl deprotection was 
carried out using neat formic acid to give 194 in a near quantitative yield (97%).  
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Scheme 18 Synthesis of 4'-N-Ala(S)Asp-gemcitabine (194). (i) (57), DCC, DMAP, DMF, 24h (ii) 
HCO2H, reflux, 3h. 
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 Synthesis of the desired ester prodrugs of gemcitabine proved problematic with 
carbodiimide coupling reagents giving 195 as the only product. The utilisation of HATU and DIPEA 
in DMF also resulted in the formation of 195 (52%). However, the protected 5’-ester (196) and 3’-
5’-diester (197) prodrugs were also synthesised, both in a 3% yield (scheme 19).   Unexpectedly 
the 3’-monoester was not seen in the reaction mixture. Optimisation of this step was not carried 
out as enough material had been generated (after deprotection) to satisfy the quantities needed 
for characterisation and biological testing.  
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Scheme 19 Synthesis of 5'-O-Ala(S)Asp-gemcitabine (193) and 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-
gemcitabine (198). (i) (57), HATU, DIPEA, DMF (ii) HCO2H, reflux, 3h. 
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 The efficacy of previously created gemcitabine prodrugs176 has been potentially affected 
by degradation at the surface of pancreatic cancer cells, thereby limiting transport. The addition 
of two carriers to gemcitabine in 198 may prevent PepT1 in the gut from transporting the 
molecule. However, it should give added resistance to enzymes at the cell surface of tumours as 
cleavage of one of the carriers would give a prodrug still potentially transportable by PepT1. 
Biological testing of 198, was therefore carried out alongside 193 and 194.       
4.3.2 In vitro testing 
 Biological testing of 193, 194 and 198 in AsPc1 and AsPc1 knockdown cells was one again 
carried out by Ana Santos Cravo at the University of Bath. Once again these studies were designed 
as a result of discussions between myself and Ana and any conclusions drawn are my own. The 
action of gemcitabine is through incorporation into the genome, blocking DNA synthesis. 
Therefore, the three gemcitabine prodrugs were initially assessed for cell viability response.  
 
Figure 31 MTT cell viability assay. AsPc1 and AsPc1 knockdown cells were incubated with 
different concentrations of 4’-N-Ala(S)Asp-gemcitabine (194) for 24 hours. Values are expressed 
as mean ± SEM from 3 independent experiments; **p< 0.05; ***p< 0.001. 
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Figure 32 MTT cell viability assay. AsPc1 and AsPc1 knockdown cells were incubated with 
different concentrations of 5'-O-Ala(S)Asp-gemcitabine (193) for 24 hours. Values are expressed 
as mean ± SEM from 3 independent experiments; **p< 0.05; ***p< 0.001. 
 
Figure 33 MTT cell viability assay.  AsPc1 and AsPc1 knockdown cells were incubated with 
different concentrations of 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine (198) for 24 hours. 
Values are expressed as mean ± SEM from 3 independent experiments; **p< 0.05; ***p<0.05; 
***p< 0.001. 
 Figure 31 shows a small decrease in cell viability in AsPc1 PepT1 expressing cells when 
compared AsPc1 knockdown cells. This suggests that PepT1 is transporting 4’-N-Ala(S)Asp-
gemcitabine (194) in to the cell and some activation of the prodrug is occurring, most likely by 
carboxylesterases in the cytoplasm. Figure 32 shows no difference between the cell viability of 
AsPc1 PepT1 expressing cells and AsPc1 knockdown cells.  This suggests that 5'-O-Ala(S)Asp-
gemcitabine (193) is not transported by PepT1, or more likely that degradation of the prodrug is 
occurring prior to transport as occurred in the 5'-amino acid ester prodrugs of gemcitabine 
created by the Amidon group.171 Figure 33 shows that 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine 
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(198) was the most effective at decreasing AsPc1 cell viability in both AsPc1 PepT1 expressing cells 
and AsPc1 knockdown cells. Cell viability is significantly reduced in AsPc1 expressing cells 
compared knockdown cells, suggesting that PepT1 plays a part in the reduction of cell viability. 
This is surprising as we theorised that 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine (198) would be 
the least likely to be transported, due to the presence of the two carrier motifs.  
 Cell proliferation in AsPc1 and AsPc1 knockdown cells after exposure to 3'-O-Ala(S)Asp-5'-
O-Ala(S)Asp-gemcitabine (198) was then assessed. Figure 34 shows that in AsPc1 PepT1 
expressing cells there is a statistically significant reduction in cell proliferation when compared to 
AsPc1 knockdown cells.  This suggests that the selective growth inhibition of AcPc1 expressing 
cells is due to 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine (198) transport by PepT1. 
 
Figure 34 Rate of proliferation in cells exposed to different concentrations of 3'-O-Ala(S)Asp-5'-
O-Ala(S)Asp-gemcitabine (198) after 48 hours. Values are expressed as mean ± SEM from 3 
independent experiments; ***p< 0.001. 
 To evaluate the role of PepT1 in the uptake of 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine 
(198) a competitive inhibition study was carried out. Different concentrations of 3'-O-Ala(S)Asp-5'-
O-Ala(S)Asp-gemcitabine (198) were incubated with AsPc1 PepT1 expressing cells in RPMI 
medium and a huge excess of Gly-Sar (50 mM) for 48 hours. As can be seen in Figure 35 some 
increase in cell viability is seen when PepT1 uptake is blocked by Gly-Sar, suggesting that PepT1 is 
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involved in the uptake of 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine (198). However, a decrease 
in cell viability is also seen with increasing concentration when PepT1 transport is blocked, 
suggesting that the uptake of 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine (198) also occurs via an 
alternative mechanism. 
 
Figure 35 Competitive inhibition study of 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine (198). 
Values are expressed as mean ± SEM from 3 independent experiments; **p< 0.01. 
 The cytotoxic potential of 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine (198) was compared 
to its parent drug gemcitabine.  Figure 36 shows that 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine 
(198) displayed significantly lower cell vitality than its parent compound gemcitabine (184).   
 
Figure 36 MTT cell viability assay. AsPc1 cells were incubated with different concentrations of 
3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine (198) or gemcitabine (184) for 48h. Data presented 
as mean of 3 independent experiments ± SEM; *p < 0.05; ** p < 0.01; *** <0.01; *** < 0.001. 
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 The binding affinity and trans-stimulation efflux for the gemcitabine prodrugs was also 
assessed in oocytes. 4’-N-Ala(S)Asp-gemcitabine (194) was shown to have a binding affinity of 
1.37 mM meaning that is moderately binds to PepT1, however trans-stimulation efflux was poorly 
induced with only a 35% reduction of intracellular radiation when compared to the control 
dipeptide Gly-Gln which is known to be transported by PepT1.  3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-
gemcitabine (198) and 5'-O-Ala(S)Asp-gemcitabine (193) in contrast were found to have very high 
binding affinities.  The binding affinity for 5'-O-Ala(S)Asp-gemcitabine (193) was found to be 0.07 
mM, however trans-stimulation efflux in oocytes was not induced. The binding affinity for 3'-O-
Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine (198) was found to be 0.04 mM and with only 0.07% trans-
stimulation efflux induced when compared to Gly-Gln. This suggests that suggests that both 193 
and 198 are able to be recognised, but not transported by PepT1.  
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4.3.3 Conclusions  
 5'-O-Ala(S)Asp-gemcitabine (193) was not found to decrease cell viability in AsPc1 cells 
when compared to AsPc1 knock down cells. This suggests that it is not transported by PepT1 and 
is supported by the lack of trans-stimulation efflux induced in oocytes. Alternatively degradation 
of the prodrug by AsPc1 cell surface enzymes could be occurring prior to transport, as was seen by 
the Amidon group.175  This could be assessed both though a Caco-2 study and an AsPc1 cell 
surface enzyme stability assessment.  
 4’-N-Ala(S)Asp-gemcitabine (194) shows a small reduction in cell viability in AsPc1 cells 
expressing PepT1 compared to AsPc1 knockdown cells, but efficacy is limited by the rate of 
activation. Activation is expected to occur by carboxylesterase 2, which has been shown to 
activate LY2334737 in vivo.174 However, only certain cell lines have been shown to express 
carboxylesterase 2 at high levels, such as the ovarian cancer cell line SKOV3.  It would therefore 
be interesting to test 4’-N-Ala(S)Asp-gemcitabine within this cell line to see if activation does 
occur.   If so then 4’-N-Ala(S)Asp-gemcitabine may be a candidate for a prodrug of gemcitabine 
which is resistant to deamination and like LY2334737 gives sustained release of gemcitabine. 
Although only a moderate binding affinity and poor trans-stimulation efflux was seen in oocytes, 
full Caco-2 testing would assess whether the same poor permeability is seen in this cell line.  
 3'-O-Ala(S)Asp-5'-O-Ala(S)Asp-gemcitabine (198) decreases cell viability and proliferation 
in AsPc1 cells expressing PepT1 compared to AsPc1 knockdown cells and is more cytotoxic than 
gemcitabine. Transport into AsPc1 cells has been shown to occur via a separate mechanism as 
well as by PepT1. This is supported by the poor trans-stimulation efflux induced in oocytes, 
indicating that is perhaps only once the prodrug is hydrolysed to a single carrier attachment that 
PepT1 transport can occur. If 5'-O-Ala(S)Asp-gemcitabine (193) is not found to be transported 
across a Caco-2 monolayer of cells it would indicate that perhaps 3'-O-Ala(S)Asp-gemcitabine 
(199) is a PepT1 substrate.  3'-O-Ala(S)Asp-gemcitabine (199) could be synthesised by N-Boc 
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protecting the cytosine amine and tert-butyl protecting the primary alcohol on gemcitabine (184) 
prior to coupling.  
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 The targeted use of oncology drugs via up-regulated nutrient pathways shows promise as 
a novel cancer therapy tool.  Currently there have been abnormal function of PepT1 reported, 
highlighting this protein as target for rational drug design and delivery. However, the secondary 
toxicity of PepT1 targeted anti-cancer drugs in organs where the protein is normally rather than 
pathologically expressed must be considered.      
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 The highly hydrophobic drug propofol (74), which was re-examined in this research, 
showed a marked improvement in solubility when attached to our carriers. New methodology 
was developed for the synthesis of the propofol prodrug (76), as the previous methodology127 
failed to couple propofol (74) to the carrier (40) and the purification procedure failed to  cleanly 
isolate the prodrug. The resultant prodrug 76 has been found to have an excellent binding affinity 
for PepT1 and be transported well though Caco-2 cells. 
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Ki= 0.92±0.19 mM
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 Attachment of our thiodipeptide carrier (40) to the Aurora kinase inhibitor (71), supplied 
by AstraZeneca, also resulted in a marked improvement in solubility compared to the parent drug. 
The solubility of 105 was improved from 0.35 mg/mL to approximately 6 mg/mL when our 
Ala(S)Asp carrier (40) was attached to create prodrug 108.  
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 Although 108 was found to have a high affinity for the PepT1 transporter (0.10 ± 0.02 
mM), apparent permeability in Caco-2 cells was moderate 0.31 ± 0.00 x 10-6 cm S-1. This is 
however slightly higher than the apparent permeability of the parent drug 105 indicating the 
PepT1 plays a small role in the permeation of 108 across Caco-2 cells. The use of a glycol spacer 
between our carrier and the attached drug had previously been shown by our group to improve 
the water solubility of the resultant nabumetone prodrug.116 The use of a glycol spacer may also 
improve the transport of the resultant prodrug.  By setting the drug slightly away from the mouth 
of the binding pocket in PepT1, only the carrier motif of the prodrug is likely to be recognised. As 
a result the PepT1 transport mechanism may already be in motion before the attached drug is 
detected.  The use of glycol spacers to improve the apparent permeability of 108 was therefore 
investigated. Unfortunately one the acetic acid glycol linkers had been coupled to 105, the benzyl 
ether protecting the other end of the linker could not be removed (Figure 37).  
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Figure 37 Acetic acid glycol linkers attached to (105) 
 Failure to remove the benzyl protecting group with palladium hydrogenation only 
highlights the difficulty of working with sulfur containing chemicals.   It was initially thought that 
in the thiazole ring would be sufficiently conjugated to prevent poisoning of the catalyst. 
However, this was not found to be the case. The presence of ether and ester bonds in the 
molecule also prevented benzyl deprotection with boron trichloride or trimethylsilyl iodide and 
mild esterification methods also gave multiple products. Use of an alternative protecting group 
which can withstand coupling conditions and be selectively deprotected in the presence of a 
methyl ether would allow the desired linker prodrugs to be synthesised.   
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 The presence of a thioamide in our carriers prevents hydrolysis of the prodrug by 
peptidases in the gastrointestinal tract.  Tert-butyl type protection of our carrier is traditionally 
used, as after coupling of our carrier to a drug, they can be cleaved cleanly in one step in the 
presence of a sulfur atom. When this final step was performed by Dr R. Pathak with the protected 
thiodipeptide prodrug of doxorubicin (60), it was found that the doxorubicin was unstable to acid 
conditions.   
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 In an attempt to broaden the classes of drugs that can be targeted to PepT1 to include 
acid sensitive drugs, alternatively protected thiodipeptide carriers were created.  The serine or 
aspartate component of the dipeptide must be differentially protected to allow selective 
deprotection of both the amine and R2 group during synthesis of the carrier. Finding protecting 
groups which would allow this, withstand coupling conditions and are cleaved with one step after 
coupling of the carrier to a selected drug in the presence of sulfur proved a challenge. Benzyl type 
protection was ultimately chosen as although they must be deprotected in the relatively harsh 
conditions of dissolving metal reduction in the presence of sulfur, if this atom is not present 
hydrogenation can be used.  The use of alternative carriers, which do not contain a sulfur atom, 
was also explored in this research project.  
 Alternative routes to synthesis the tert-butyl protected carriers were explored.  Mono-
protection of the aspartate and serine amino acids to give H-X(OBn)-OtBu eliminated the need for 
one of the steps in the synthesis of the carriers. This increased the overall yield to ~69% in 5 days, 
compared to the established methodology of ~50% in 9 days. However, the prohibitive cost of the 
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new starting material compared to that in the established methodology meant this method of 
synthesis was not pursued.  The established method for the synthesis of the tert-butyl protected 
carriers was however improved through the elimination of halogenated solvents during 
purification procedures. Halogenated solvents have a much larger environmental impact than 
non-halogenated solvents and were avoided during the course of this research where possible.  
 The presence of a thiodipeptide in carriers has often been found to result in non-
crystalline prodrugs being synthesised, which can present a problem for formulation. We were 
also worried about the presence of the sulfur atom negatively affecting the taste of any prodrugs 
taken forward in development.  R1 α,α-disubstituted dipeptides 150 and 151 (shown with benzyl 
as a model drug moiety) had previously been explored for use as alternative carriers (Dr D. Foley, 
unpublished).127 Both displayed excellent binding affinities for PepT1 and had been found to be 
transported across a Caco-2 cell line much better than their thiodipeptide counterparts. 
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 Newstead et al.89 had recently shown that there is an elongated cavity ( 16 x 7 x 11 Å) in 
the N-terminal end of the ligand binding site in the prokaryotic POT transporter PepTso. This is 
where R1 would be positioned when the carrier is ‘docked’ in the substrate binding pocket of 
PepT1. Therefore in an attempt to find a second alternative PepT1 carrier, as well as explore the 
tolerance of PepT1 for bulk in this area, a series of dipeptides were synthesised (153-156).   
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 The use of cyclic groups on the N-terminal α-carbon allowed the presence of bulk in this 
region to be assessed, whilst preventing hydrolysis by peptidases as access to the backside of the 
carbonyl group is reduced.  The addition of hydrocarbon bulk to the dipeptides also has the added 
benefit of increasing overall lipophilicity. This is of benefit as traditional prodrug strategies for 
poorly bioavailable drugs often include increasing lipophilicity as permeability will be increased.  
 All carriers (with no moiety attached in the R2 position, or with benzyl or ibuprofen 
attached) were found to have excellent binding affinity in oocytes. Trans-stimulation data was 
also favourable with only homocycloleucine-serine-ibuprofen (181) failing to induce efflux. This 
may be an anomalous result as both the free dipeptide and benzyl attached dipeptide were 
transported, or it may be an inhibitor of PepT1. During stability testing of the ibuprofen linked 
carriers, only the cycloleucine carrier (155) was found to fragment, suggesting this carrier is not 
hydrolysis resistant. The results obtained for the cyclopropane (153), cyclobutane (154) and 
cyclohexane (156) carriers indicates that in addition to the Aib carrier, these may be promising 
alternative carriers. Full Caco-2 testing will need to be undertaken to confirm this. 
 Caco-2 permeability was attempted to be generated for the ibuprofen linked carriers 
during the course of this research. Unfortunately analysis of the samples generated from the 
Caco-2 study could not be carried out. This has been a theme across this research and is primarily 
attributed to unfortunate timing of this project with a time of restructuring at AstraZeneca. In 
many ways the collaboration with AstraZeneca has been excellent with free access to facilities and 
expertise being provided, as well as the kind supply of the equipment, chemicals and cells needed 
for Caco-2 testing. In addition new chemical entities developed by AstraZeneca were kindly 
donated for use in this project and support was freely offered when synthetic problems were 
encountered. Everyone involved at AstraZeneca, both past and present, went out of their way to 
try and mediate the problems encountered during the course of this project.  
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 Synthesis of an aspirin (80) prodrug hit a barrier when the coupling of aspirin (80) to 91 
resulted in 98 rather than 92. Alternative coupling methods were investigated, but each time 
transesterification occurred.   
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This is surprising as the synthetic conditions utilised were based on conditions employed by the 
group at Trinity College130 to make the aspirin prodrug ISAS (87). 
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 In an attempt to overcome this salicylic acid was used as an alternative to aspirin. Using 
pre-charged coupling conditions 99 was achieved in good yields (86%).  Due to this work being 
undertaken at the very end of this research project the acetylation of 99 was not investigated as 
deacetylation could possibility occur when 100 was coupled to 89 or 95 was coupled to our 
carrier. 
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 In an attempt to make a carrier coupled prodrug that would be useful for the in vitro 
testing of a model aspirin like prodrug, our protected carrier (57) was coupled directly to 100. 
Unfortunately 102 could not be isolated from the reaction mixture, with carrier attached to both 
alcohols on salicylic-isosorbide (100) the only compound separated from the reaction mixture. 
This project was abandoned due to the prioritisation of other work and the difficulties previously 
encountered in the group by Dr. Foley127 in making a thiodipeptide aspirin prodrug. If successful 
conditions are found to couple aspirin to isosorbide-benzyl or to acetylate salicylic-isosorbide-
benzyl then hopefully no further problems should be encountered in the synthetic route.   
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 The Ala(S)Ser-ibuprofen prodrug 79 had previously been created in our group117 and had 
been shown to have both favourable binding affinity and Caco-2 permeability. The apparent 
permeability for this prodrug was also assessed in the course of this research and was found to 
closely resemble reported data. 
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Papp= 3.97 ± 0.27 x 10
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An in vivo pharmacokinetic test of 79 had been previously carried out. Plasma detection of a 
10 mg/kg dose in rat gave a Cmax of 930 ± 90 ng/mL with a Tmax of 1.33 hours.
117 It was therefore 
decided to perform full pharmacokinetic analysis 79 in rat, detecting both the presence of 
prodrug and parent in plasma. Synthesis of 79 was therefore undertaken using the reported 
coupling conditions.117 Problems with the tert-butyl final deprotection step using TFA necessitated 
a switch to formic acid. This was used as the standard deprotection conditions for the rest of this 
project. As Aib carriers had previously been shown to be promising sulfur free hydrolysis resistant 
alternatives to our thiodipeptides, the Aib-seine prodrug of ibuprofen (183) was also tested. This 
was synthesised by Dr R. Pathak who also synthesised the prodrug for the taste assessment study.  
In contrast to the previous in vivo result found for Ala(S)Ser-ibuprofen (79), in this study it 
was not found to be well absorbed in rat.  The Cmax value obtained was approximately similar for 
both 79 and parent ibuprofen (77) (~200 ng/mL, after 1 hour), which is much less than the Cmax 
when an equivalent dose of ibuprofen was given (5664 ng/mL, after 1 hour). Ibuprofen (77) was 
able to be detected in plasma 8 hours after dosing of 79, which is how long parent ibuprofen (77) 
was detected after an equivalent dose was given.  Aib-Ser-ibuprofen (183) was found to have a 
longer exposure profile than ibuprofen (77), with a Tlast of 16 hours compared to 8 hours for 
ibuprofen (77).  The Cmax for Aib-Ser-ibuprofen (183) was very low (32 ng/ mL, after 1 hour) 
indicating that either prodrug breakdown was occurring prior to transport or very quickly once in 
systemic circulation.  The Ala(S)Ser-ibuprofen prodrug 79 was also synthesised to assess whether 
rats preferred ibuprofen prodrugs with and without a sulfur atom. It was found that rats did not 
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care for either the Ala(S)Ser-ibuprofen (79) or Aib-Ser-ibuprofen (183) prodrugs and instead 
preferentially consumed parent ibuprofen.  
 The discovery that PepT1 is over-expressed in pancreatic adenocarcinoma cell lines, AsPc-
1 and Capan-2,4153 has also led to research being undertaken into PepT1 targeted anti-cancer 
therapy. Pancreatic cancer often has a poor prognosis, with only a 5% survival rate 5 years after 
diagnosis,157 this highlights the need for treatment options in this area. The use of PepT1 targeting 
could potentially reduce the side effects experienced during cancer therapy, as off target delivery 
would be minimised. Cell proliferation in several cancerous cell lines165-7 had been shown to 
reduce upon the treatment of a variety of nonsteroidal anti-inflammatory drugs. As these drugs 
can only access the surface of these cells efficacy is limited. We were therefore intrigued to see if 
our PepT1 targeted ibuprofen prodrug 79 would have an increased efficacy over parent ibuprofen 
(77) due to its ability to be transported into cells.  
 Testing was carried out by Prof R. Mrsny’s group at the University of Bath in AsPc1 cells. 
As a control AsPc1 knockdown cells which did not express PepT1 were used. The meant the PepT1 
component of any results seen could be assessed.  Ala(S)Ser-ibuprofen (79) was shown to have a 
more pronounced effect on cell proliferation and vitality in AsPc1 cells expressing PepT1 than 
AsPc1 knockdown cells. In both cell lines Ala(S)Ser-ibuprofen (79) also showed a more 
pronounced effect on cell proliferation and vitality than ibuprofen (77). To my knowledge this is 
the first time that reduced cell proliferation by an ibuprofen prodrug or ibuprofen (77) in AsPc1 
cells has been reported.  One of the ways that ibuprofen (79) may reduce proliferation is by 
inhibiting the COX-2/PGE2 pathway, which if disregulated has been shown to result in cell 
proliferation, angiogenesis, migration and inhibit apoptosis.164 COX-2 is an accepted 
pharmacological target of ibuprofen (77). Its expression in AsPC1 (PepT1) cells was assessed after 
treatment with either ibuprofen prodrug (79)  or ibuprofen (77). Although levels of COX-2 was 
reduced by ibuprofen (77), it was eliminated by Ala(S)Ser-ibuprofen (79).  This suggests that the 
prodrug 79 was accumulating in cells therefore having a greater effect on COX-2 expression. 
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Through the active targeting of ibuprofen (77) the side effects normally reported with long term 
ibuprofen (77) use may be mitigated.161 This opens up the possibility of use as part of cancer 
therapy and in a prophylactic manor. The efficacy of Ala(S)Ser-ibuprofen (79) or indeed Aib-Ser-
ibuprofen (183) in an in vivo oncology model should therefore be assessed.  
Gemcitabine (184) is a nucleoside drug licensed for the treatment of bladder cancer, 
breast cancer, non-small lung cancer and pancreatic cancer.172 As with other nucleoside 
analogues, gemcitabine (184) suffers from low oral bioavailability due to extensive first pass 
metabolism to an inactive metabolite.   As part of the collaboration with Prof. Mrsny it was 
decided to synthesise thiodipeptide prodrugs of gemcitabine (184) to assess for efficacy in AsPc1 
cells.  It was hoped that as was seen for the ibuprofen prodrug 79, the active targeting of 
gemcitabine (184) towards PepT1 would result in accumulation of gemcitabine (184) within cells. 
This would hopefully result in increased efficacy. The oral bioavailability of several nucleoside 
drugs have been improved through PepT1 targeting (section 2.1.1) so we were hopeful that a 
prodrug that was both recognised and transported by PepT1 could be created.    
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Out of the three prodrugs synthesised only 198 was shown to reduce viability and 
proliferation in AsPc1 cells. However, a Gly-Sar blocking study still showed a reduction in cells 
vitality indicating that this prodrug is entering cells both by PepT1 and via an alternative route.  
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Poor trans-stimulation data in oocytes indicated that the prodrug was not being transported into 
cell intact. However, the significantly lower cell vitality in AsPc1 cells seen for 198 compared to 
gemcitabine (184) indicating that accumulation of 198 in cells was occurring.  Most likely 
degradation of 198 by enzymes on the surface of AsPc 1 cells was resulting in gemcitabine (184) 
linked to a single carrier being transported into cells. If 5'-O-Ala(S)Asp-gemcitabine (193) is not 
found to be transported across a Caco-2 monolayer of cells it would indicate that perhaps 3'-O-
Ala(S)Asp-gemcitabine (199) is the gemcitabine prodrug responsible for the reduced cell vitality 
seen.  
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Although PepT1 can be used as a tool to improve oral bioavailability, the use of PepT1 as a 
tool for targeted cancer therapy is where PepT1 research should be focused. Although PepT1 
targeting has been shown to improve the oral bioavailability of drugs, both through the use of our 
thiodipeptide and amino acid attachment, drug choice is perhaps limited to the existing 
physiochemical properties of the parent drug. Although solubility of propofol was improved 
through attachment our carrier, this has not always been the case with other drugs.  The 
previously created thiodipeptide prodrug of poorly soluble dehydrocholic acid (Dr. R. Pettecrew, 
unpublished), was both recognised and transported by PepT1 but solubility was not significantly 
improved. This has again been demonstrated during this project with the synthesis of Aurora 
Kinase inhibitor 105. Although solubility was increased 200 fold when compared to the parent 
drug, only a 50 μM solution in buffer could be created for Caco-2 testing.  The issue of ‘brick dust’ 
compounds was also highlighted by the failure of the planned α1β5 Integrin inhibitor prodrug.  
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These are compounds in pharmaceutical development that may have found to have good target 
efficacy, but are shelved due to less than optimum solubility properties.  
If however, poor oral bioavailability is a result of active efflux, PepT1 targeting is an 
attractive option.  Quinidine which is actively effluxed by P-gp was found to no longer be a 
substrate when turned into the PepT1 substrate L-valine-quinidine.106 As most oncology drugs are 
also P-gp substrates, bypassing this mechanism is an important step in improving oral 
bioavailability.   There is also the third class of drugs which may benefit from PepT1 targeting.  
Drugs such as ibuprofen (77) and aspirin (80) cause gastrointestinal side effects but there are 
benefits to patients in their long term use. Although difficulties have been encountered both in 
the project and by a previous group member in making a PepT1 targeted aspirin prodrug, the 
thiodipeptide and Aib-serine prodrugs of ibuprofen have been synthesised (79, 80).   More work is 
needed to assess the stability of these ibuprofen prodrugs in vivo although favourable binding 
affinity and transport in Caco-2 has been demonstrated. Assessment would also need to be 
undertaken to ensure that these drugs are not active in their prodrug form.      
 The targeted use of oncology drugs via up-regulated nutrient pathways shows promise as 
a novel cancer therapy tool.  However, this is certainly not without its challenges. Cell surface 
enzymes on cancer cells are more likely to hydrolyse PepT1 targeted prodrugs before they reach 
the PepT1 transporter than is found in the small intestines.  This necessitates the use of a more 
robust method to link the drug to a PepT1 recognised motif. Unless pathways are present in the 
cell to active the resulting prodrug, this attachment must be approached with the view of keeping 
the resultant prodrug active.  Although this would allow for accumulation of drug within cells and 
therefore higher efficacy, off target delivery would not necessarily be minimised.   There has also 
been mutations in PepT1 reported for several cancers.179 The substrate specificity of PepT1 which 
has been upregulated in cancer cells has yet to be assessed.  It may be found that a slightly 
different transport profile is seen requiring a different carrier.  
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6.1 General methods 
6.1.1 Oocyte binding affinity 
 Six solutions of test substrate between 0 and 5 mM were prepared from serial dilution of 
a 10 mM test compound in pH 5.5 uptake media stock solution.   An n=5 was performed for each 
concentration of test solution by adding a 50 μL aliquot of test solution to  50 μL of radiolabelled 
[3H]-D-Phe-L-Gln  (0.4 μM, 37.0 MBq mL-1) in a 96 well plate.  An n=5 was also performed for a 
blank control using pH 5.5 uptake media stock solution. A Xenopus laevis oocytes expressing 
rabbit PepT1 was added to each well and incubated for one hour. After one hour the oocytes 
were removed from the test solution and washed with five 1 mL portions of ice-cold uptake 
media, transferred to individual scintillation vials, lysed and tested. Binding affinity (Ki) was 
obtained from a plot of fractional uptake versus substrate concentration, using standard 
Michaelis-Menten kinetics. Carried out by Dr. Meredith or Anish Senan at Oxford Brookes 
University. 
6.1.2 Oocyte trans-stimulation assay 
 A 10 mM solution in pH 5.5 uptake media was made for each test compound and a 100 μl 
aliquot was added to a 96 well plate to give an n=5 for each test compound. An n=5 was also 
performed for a blank control using pH 5.5 uptake media stock solution and a 10mM solution of L-
Gly-L-Gln in pH 5.5 uptake media. A rabbit PepT1 Xenopus laevis oocyte injected with 4.6 nM of 
[3H]-D-Phe-L-Gln (37.0 MBq mL-1), which had been pre incubated for 15 minutes with pH 5.5 
uptake media, was added to each well and incubated for 90 minutes. After 90 minutes the 
oocytes were removed from the test solution and washed with five 1 mL portions of ice-cold 
uptake media, transferred to individual scintillation vials, lysed and tested. Trans-stimulation 
efflux was measured as a reduction in radioactivity of the test solution incubated oocyte 
compared to the control. This is then compared to the decrease in radiation induced by the PepT1 
substrate L-Gly-L-Gln. Carried out by Dr. Meredith or Anish Senan at Oxford Brookes University. 
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6.1.3 Caco-2 assay 
 Caco-2 cells (supplied at passage number 17) were purchased from American Type 
Culture Collection and were used for transport studies at passage 28-35, the count of which was 
continued from the received passage. For the transport studies the Caco-2 cells were grown on 
BD FalconTM 24-multiwell insert systems with polyethylene terephthalate membranes (1 mm 
pore size, 0.3 cm2 surface area) with  BD FalconTM 24-multiwell companion plates in a cell culture 
medium consisting of Dulbecco’s Modified Eagle’s Medium supplemented with 20% (w/v) foetal 
bovine serum and 1% (v/v) non-essential amino acids until confluent (16-18 days, trans-epithelial 
electrical resistance (TEER) > 1000 Ω cm-2). 
 650 μM solutions of each test compound (except Aurora kinase inhibitor 108 which was 
made to 50 μM due to solubility issues)  were made in pH 5.5 (Hanks Balanced salt solution, (v/v) 
0.1% bovine serum albumin, MES 25 mM ) and 7.4 buffer solution (Hanks Balanced salt solution, 
(v/v) 0.1% bovine serum albumin, HEPES 25 mM). 1% DMSO was added to all stock solutions to 
maintain consistency with the test compounds which did not dissolve well in buffer. Stability of 
the test compounds was assessed by incubating them for 30 minutes in pH 5.5 buffer solution 
which had been aspirated from the apical surface of Caco-2 cells.  
 All solutions were heated to 37°C prior to use on cells. The cells incubated in buffer 
solution at 37°C for 25 minutes prior to use in the study (apical pH 5.5, basolateral pH 7.4) and 
then aspirated. For apical to basolateral transport 200 μL of pH 5.5 test compound solution was 
aliquoted on the apical side of the monolayer (n=3) and 600 μL of pH 7.4 buffer aliquoted on the 
basolateral side.  For basolateral to apical transport 200 μL of pH 5.5 buffer solution was aliquoted 
on the apical side of the monolayer and 600 μL of  pH 7.4 test compound solution buffer 
aliquoted on the basolateral side (n=3). The plates were incubated for 60 minutes (37°C, 50 cycles 
min-1), before 50 μl of solution was removed from both the apical and basolateral compartments, 
placed in separate LCMS vials, frozen (-20°C) and sent for LCMS analysis.  As an integrity marker 
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for the cells 14C Mannitol (100 KBq/mL) was prepared in pH 5.5 buffer (apical to basolateral plate) 
and pH 7.4 (basolateral to apical plate) and assayed on each plate (n=3). After incubation 50 μl of 
solution was removed, vortex mixed with UltimaGold scintillation fluid (2 mL) and counted using a 
Tricarb 2300LTR counter using a dual dpm protocol. Mannitol is transported through cells via the 
paracellular route so Papp values exceeding 1 x 10
6 cm s-1, would indicate that the tight junctions 
were not properly formed.  
 For PepT1 transport component studies only apical to basolateral transport was 
measured and 2000 μM Gly-Sar was added to each pH 5.5 test solution. Studies were performed 
under the guidance and assistance of Kate Harris at AstraZeneca in Charnwood and Alderley Park.  
LCMS analysis was performed by either Sarah Kelly at Alderley Park or Constanze Hilgendorf at 
AstraZeneca Mölndal.   
6.1.4 AcPc1 assay 
AsPc1 WT and AsPc1 PepT1-/- cells were plated in 96 well plates at a cell density of 500 
cells per well.  50 mM in DMSO stock solutions of the ibuprofen and gemcitabine prodrugs were 
serially diluted to; 500 µM, 200 µM, 100 µM, 50 µM, 20 µM, 10 µM, 5 µM and 1 µM in buffer. 
After incubation, cell viability was assessed using the MTS reagent. To assess the PepT1 mediated 
component of transport the cell culture media was supplemented with 50 mM Gly-Sar.  These 
assays were carried out by Ana Maria Cravo at the University of Bath. 
6.1.5 Pharmacokinetic study in rat 
Ibuprofen (77) was prepared in distilled water at 1.2 mg/mL which gave a dose of 6 mg/kg 
with a dose volume of 5 mL/kg. The ibuprofen prodrugs were prepared in distilled water at 2 
mg/mL which gave a dose of 10 mg/kg (equivalent ibuprofen does of 6 mg/kg) with a dose volume 
of 5 mL/kg.   
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Nine male CD (Sprague Dawley equivalents) rats (251-281 g at the time of dosing, Charles 
River, UK) were housed singly following jugular vein cannulation, maintained under a 12 hour 
light/dark cycle and allowed free access to food and water.  An n=3 was performed for each test 
compound  and blood samples (~ 230 μL) were collected 0.25, 0.5, 1, 2, 4, 8 and 24 h after dosing, 
with an equal volume of heparinised saline was then infused back into the rat thus ensuring 
patency. 
Blood samples were added to an Eppendorf 1.5 mL tube containing 5 L heparin (25,000 
IU in 5 mL), shaken and centrifuged (Biofuge Pico, Kendro Lab Products) at 10,000 rpm for 3 
minutes. 80 μL of plasma was extracted an added to  10 μL of water and 810 μL acetonitrile. The 
sample was then centrifuged at 13,000 rpm for 5 minutes at 4°C and 500 μL of the supernatant 
was extracted and added to 500 μL water.  This sample was then diluted 20 fold by mixing a 50 μL 
aliquot with 950 μL of water.  Samples were than analysed by LC-MS/MS on a 50 x 2.0 mm C18 
Gemini 5 μM column. Carried out by Saretius Ltd at the University of Reading. 
6.1.7 Synthetic materials 
 All solvents used were commercial grade. Dichloromethane was distilled over calcium 
hydride and tetrahydrofuran was distilled over sodium metal and benzophenone to make 
anhydrous. Anhydrous dimethyl sulfoxide and anhydrous dimethylforamide were purchased from 
Sigma Aldrich and used without further treatment.  All chemicals purchased from suppliers were 
used without further purification (Sigma Aldrich, Flurochem, Tokyo Chemicals Limited, AGTC 
Bioproducts, Acros Organics). Aurora Kinase Inhibitor N-(3-fluorophenyl)-2-(2-(7-(3-(4-
(hydroxymethyl)piperidin-1-yl)propoxy)-6-methoxyquinazolin-4-ylamino)thiazol-5-yl)acetamide 
and α1β5 Integrin inhibitor (S)-2-(2-chloro-6-fluorobenzamido)-3-(4-(2-(5,6,7,8-tetrahydro-1,8-
naphthyridin-2-yl)ethoxy)phenyl)propanoic acid was kindly supplied by AstraZeneca and  after 
structure confirmation were used without further purification. Flash column chromatography was 
carried out on silica gel 60 (40-63 µm mesh). 
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6.1.8 Characterisation 
 Analytical TLC was performed on Macherey-Nagel aluminium sheet silica gel 60 UV254 
plates. Spots were visualised with a UV lamp, potassium permanganate stain or vanillin stain. 
Retention factors (Rf) are quoted to the nearest 0.01. 
1H and 13C NMR spectra were recorded on a 
Brucker Advance DPX 300 spectrometer at 300 MHz and 75 MHz respectively. Splitting patterns 
are recorded as follows: chemical shift, multiplicity, integration and atom. Multiplicity is described 
as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin), multiplet (m), broad (br), or any 
combination thereof. AB refers to secondary splitting effects where the chemical shift between 
protons is large.  Coupling constants (J) are stated in Hz to the nearest 0.01 Hz.  Infrared spectra 
were recorded on a Thermo Nicolet Nexus FT-IR spectrometer. Optical rotations were measured 
using a Rudolph Research Analytical Autopol l automatic polarimeter with sodium D light (λ = 589 
nm). [α]D
T values are recorded in unites of 10-1 deg cm2 g-1 and concentrations are stated in g per 
mL of solvent.  Mass spectra were recorded on a Thermofisher LTQ Orbitrap XL spectrometer 
using nano-electrospray. Melting points were determined on a Stuart SMP30 Digital Advance 
machine and are uncorrected.   
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6.2 Synthesis of Benzyl type protected carriers (section 2.4) 
(S)-benzyl-2-fluorenylmethyloxycarbonyl-3-tert-butoxypropanoate (63). 
 
H
N
O
O
O
O
O
 
 N-(9-Fluroenylmethoxycarbonyl)-O-(tert-butyl)-L-serine (61) (15.150 g; 39.51 mM) and 
sodium bicarbonate (6.638 g; 79.02 mM) was dissolved in 20 mL of anhydrous DMF under a 
nitrogen atmosphere.  Benzyl bromide (18.77 mL; 158.04 mM) was added dropwise and the 
reaction stirred for 72 hours at room temperature. The solvent was removed in vacuo to yield a 
clear oil. The oil was dissolved in 20 mL EtOAc and washed with three 20 mL portions of water 
followed by 20 mL of brine, dried over anhydrous MgSO4 and filtered. 200 mL of cyclohexane was 
added and the reaction left to stand overnight to yield a white solid, which was collected by 
filtration. The white solid was recrystallised from 200 mL cyclohexane to yield 12.788 g of 63 as a 
white solid (27.00 mM, 68%).  
 Rf: 0.61 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, chloroform-d)  ppm  1.13 (s, 9H, CH3 
tert-butyl), 3.63 (ABdd, J=9.04 Hz, 1H, CH2 serine), 3.88 (ABdd, J=8.67 Hz, 1H, CH2 serine), 4.28 (t, 
J=7.20 Hz, 1H, CH Fmoc), 4.32-4.48 (m, 2H, CH2 Fmoc), 4.57 (t, 1H, J=8.95, 2.86 Hz, CH serine), 
5.24 (qAB, J=1.00 Hz, 2H, CH2-benzyl), 5.73 (d, J=9.04 Hz, 1H, NH), 7.29-7.46 (m, 9H, CH benzyl, CH 
Fmoc), 7.64 (d, J=7.16 HZ, 2H, CH Fmoc), 7.79 (d, J=7.16Hz, 2H, CH Fmoc). 13C NMR (75 MHz, 
chloroform-d)  ppm 27.27, 47.12, 54.70, 62.13, 67.12, 67.21, 73.47, 119.99, 125.18, 125.23, 
127.09, 127.71, 128.25, 128.36, 128.55, 135.51, 141.28, 143.79, 144.00, 156.16, 170.60. υmax (thin 
film, cm-1): 3430, 3035-2874, 1723, 1499, 1333, 1102, 1088, 739. [α]D
25 (CHCl3; c = 0.103): - 3.88. 
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MS: C29H31NO5, m/z (ES
+) 474.23 [M+H]+. HRMS: Calculated C14H22NO3 474.2275, found 474.2266. 
MP: 84˚C 
(S)-benzyl-2-amino-3-tert-butoxypropanoate (65). 
 
H2N
O
O
O
 
 63 (4.052 g; 8.56 mM) was dissolved in 20 mL of anhydrous THF under a nitrogen 
atmosphere.  The reaction was cooled to 0°C and a 1.0 M solution of TBAF in THF (9.41 mL) was 
added dropwise.  The reaction was stirred at 0°C for 30 minutes, and allowed to proceed a further 
2-3 hours at room temperature, monitored by TLC. The solvent was removed in vacuo to yield a 
sticky pink residue which was taken up into 20 mL of water.  The pH of the solution was adjusted 
to pH 2 using 2 M HCl, and 20 mL of EtOAc added.  The aqueous layer was separated and 
extracted with a further two 10 mL portions of EtOAc. The aqueous phase was adjusted to pH 8-9 
using 2 M NaOH, and extracted with one 20 mL and two 10 mL portions of EtOAc.  The EtOAc 
portions from the basic aqueous extraction were combined, dried over anhydrous MgSO4 and 
filtered. The solvent was reduced in vacuo to give 1.493g of 65 as a brown oil (5.94mM, 69%). 
Rf: 0.43 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, chloroform-d)  ppm 1.13 (s, 9H, CH3 tert-butyl), 
3.56-3.63 (m, 2H, CH2 serine), 3.64-3.71 (m, 1H, CH serine), 5.23 (qAB, J=1 Hz, 2H, CH2 benzyl), 
7.30-7.45 (m, 5H, CH benzyl). 13C NMR (75 MHz, chloroform-d)  ppm 27.36, 55.24, 63.72, 66.64, 
73.08, 128.21, 128.54, 135.82, 174.22. υmax (thin film, cm
-1): 3384, 3033-2875, 1737, 1363, 1137, 
1081, 880, 735, 697. [α]D
25 (CHCl3; c = 0.138): - 17.39. MS: C14H21NO3, m/z (ES
+) 252.16 [M+H]+. 
HRMS: Calculated C14H22NO3 252.1600, found 252.1594. 
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(S)-benzyl-2-((S)-2-benzyloxycarbonylpropanamino)-3-tert-butoxypropanoate (67).  
H
N
O
O
O
O
N
H
O
O
 
 65 (2.027 g; 8.07 mM) and N-(carboxybenzyl)-L-alanine (1.980 g; 8.87 mM) was dissolved 
in 10 mL of anhydrous DMF under nitrogen and cooled to 0°C. TEA (2.25 mL; 16.13 mM) was 
added dropwise and the reaction stirred for 10 minutes. DPPA (1.91 mL; 8.87 mM) was added 
dropwise and the reaction stirred for 18 hours at 0°C. The solvent was removed in vacuo to give a 
pale brown oil.  The oil was dissolved in 30 mL EtOAc and washed with two 15 mL portions of 
NH4Cl, two 15 mL portions of Na2CO3 and one 15 mL portion of brine. The organic layer was dried 
over anhydrous MgSO4 to yield 2.528 g of 67 as a pale brown oil which solidified upon 
refrigeration to an off white sticky solid (5.54 mM, 69%).  
 Rf: 0.35 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHZ, chloroform-d)  ppm  1.08 (s, 9H, CH3 
tert-butyl), 1.40 (d, J=7.16 Hz, 3H, CH3 alanine), 3.54 (ABdd, J=8.85, 3.01 Hz, 1H, CH2 serine), 3.84 
(ABdd, J=9.04, 2.64 Hz, 1H, CH2 serine), 4.30 (quin, J=7.44 Hz, 1H, CH alanine), 4.74 (dt, J=8.48, 
2.83 Hz, 1H, CH serine), 5.04 - 5.28 (m, 4H, CH2 benzyl), 5.43 (d, J=6.78 Hz, 1H, NH alanine), 6.64 
(d, J=8.48 Hz, 1H, NH serine), 7.32 - 7.37 (m, 10H, CH aromatic). 13C NMR (75 MHZ, chloroform-d) 
 ppm 19.06, 27.23, 50.43, 52.83, 61.74, 66.96, 67.17, 73.42, 73.50, 128.07, 128.18, 128.27, 
128.39, 128.55, 135.40, 136.20, 136.25, 155.72, 170.10, 172.80. υmax (thin film, cm
-1): 3357, 3281, 
2975, 1735, 1654, 1507, 1355, 1243, 1044, 744, 696. [α]D
25 (CHCl3; c = 0.117): - 4.51. MS: 
C25H32N2O6, m/z (ES
+) 457.23 [M+H]+. HRMS: Calculated C25H33N2O6 457.2339, found 457.2346. 
MP: 69.7˚C 
143 
 
 (S)-benzyl-2-((S)-2-benzyloxycarbonylpropanethioamino)-3-tert-butoxypropanoate (69).  
H
N
O
O
O
S
N
H
O
O
 
 67 (2.528 g; 5.54 mM) and Lawesson’s reagent (1.148 g; 2.84 mM) was dissolved in 30 mL 
anhydrous toluene. The reaction was refluxed under nitrogen at 115oC for 4 hours. The solution 
was allowed to return to room temperature, the solvent removed in vacuo and the residue 
dissolved onto silica. Purification was obtained by flash chromatography (DCM followed by 9:1 Pet 
ether: EtOAc) to give 2.016 g of 69 as a yellow oil (4.27 mM, 77%). 
 Rf: 0.29 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHZ, chloroform-d) ppm  1.14 (s, 9H, CH3 
tert-butyl), 1.43 (d, J=7.14 Hz, 3H, CH3 alanine), 3.92 (m, J=5.46, 2.83 Hz, 2H, CH2 serine),  4.79 (m, 
1H, CH alanine), 4.91 (m, 1H, CH serine),  5.08 - 5.32 (m, 4H, CH2 benzyl), 5.48 (d, J=6.15 Hz, 1H, 
NH alanine),  7.18 - 7.44 (m, 10H, CH aromatic), 8.49 (d, J=7.91 Hz, 1H, NH serine). 13C NMR (75 
MHZ, chloroform-d)  ppm 20.47, 27.95, 56.24, 58.24, 64.92, 68.12, 68.57, 73.52, 128.21, 128.34, 
128.69, 128.91, 136.27, 136.41, 155.14, 171.82, 204.27. υmax (thin film, cm
-1): 3293, 2976, 1404, 
1506, 1192, 1045, 743, 695. [α]D
25 (CHCl3; c = 0.0324): - 0.31. MS: C25H32N2O5S, m/z (ES
+) 473.21 
[M+H+]. HRMS: Calculated C25H33N2O5S 473.2110, found 473.2107. 
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(S)- benzyl-2-((S)-2-benzyloxycarbonylpropanethioamido)-3-hydroxypropanoate (71).  
H
N
OH
O
O
S
N
H
O
O
 
 69 (483 mg; 1.02 mM) was dissolved in 30 mL of 33% TFA in DCM under a nitrogen 
atmosphere. After 1 hour a further 20 mL portion of 33% TFA in DCM was added to give  a final 
ratio of ~1 mL 33% TFA in DCM per 10 mg of starting material. The reaction was allowed to 
proceed for 5 hours before the solvent was removed in vacuo and the residue dissolved in 50 mL 
water, filtered through glass wool and extracted with 20 mL Et2O.  The aqueous layer was 
lyophilised to give 391 mg of 71 as a yellow oil (0.94 mM; 92%). 
 Rf: 0.21 (EtOAc:Pet ether 6:4). 
1H NMR (300 MHZ, chloroform-d)  ppm  1.41 (d, J=7.14 Hz, 
3H, CH3 alanine), 3.91 ABdd, J=8.94, 3.11 Hz, 1H, CH2 serine), 4.23 (ABdd, J=9.02, 2.67 Hz, 1H, CH2 
serine), 4.79 (m, 1H, CH alanine), 4.87 (m, 1H, CH serine),  5.11 - 5.32 (m, 4H, CH2 benzyl), 5.51 (d, 
J=6.15 Hz, 1H, NH alanine),  7.15 - 7.44 (m, 10H, CH aromatic), 8.42 (d, J=7.94 Hz, 1H, NH serine). 
13C NMR (75 MHZ, chloroform-d)  ppm 21.36, 56.14, 58.36, 64.83, 67.93, 68.84, 128.21, 128.30, 
128.42, 136.31, 136.52, 155.32, 172.18, 203.96. υmax (thin film, cm
-1): 3335, 2977, 2932, 1683, 
1367, 1248, 1154, 1053. [α]D
25 (CHCl3; c = 0.0094): + 12.23. MS: C21H24N2O5S, m/z (ES
+) 417.15 
[M+H]+. HRMS: Calculated C21H25N2O5S 417.1484, found 417.1487. 
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 (S)-1-benzyl-4-tert-butyl-2-fluorenylmethyloxycarbonylsuccinate (64). 
H
N
O
O
O
O
O
O
 
 N-(9-Fluroenylmethoxycarbonyl)-O-(tert-butyl)-L-aspartic acid (62) (15.005 g; 36.47 mM) 
and sodium bicarbonate (6.131 g; 72.91 mM) was dissolved in 30 mL anhydrous DMF under a 
nitrogen atmosphere.  Benzyl bromide (17.33 mL; 145.87 mM) was added dropwise and the 
reaction stirred for 72 hours at room temperature. The solvent was removed in vacuo to yield a 
clear oil. The oil was dissolved in 50mL EtOAc washed three times with 50mL water and once with 
20mL brine, dried over anhydrous MgSO4 and filtered. 200mL of petroleum ether was added and 
the reaction stirred for 30 minutes to yield a white precipitate which was collected by filtration. 
100mL of 10% EtOAc in petroleum ether was added to the filtrate, stirred and the white 
precipitate collected via filtration. 15.254 g of 64 was collected as a white solid (30.41 mM, 83%). 
 Rf: 0.47 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, chloroform-d)  ppm  1.44 (s, 9H, CH3 
tert-butyl), 2.81, (ABdd, J=4.10 Hz, 1H, CH2 aspartate), 3.02 (ABdd, J=4.50 Hz, 1H, CH2 aspartate), 
4.26 (t, J=7.20 Hz, 1H, CH Fmoc), 4.30-4.49 (m, 2H, CH2 Fmoc), 4.64-4.71 (m, 1H, CH aspartate), 
5.23 (qAB, J=12.06 Hz, 2H, CH2-benzyl), 5.87 (d, J=8.67 Hz, 1H, NH), 7.29-7.47 (m, 9H, CH benzyl, 
CH Fmoc), 7.62 (d, J=7.54 Hz, 2H, CH Fmoc), 7.79 (d, J=7.54Hz, 2H, CH Fmoc). 13C NMR (75 MHz, 
chloroform-d)  ppm 28.01, 37.75, 47.07, 50.61, 67.31, 67.51, 81.94, 120.01, 125.17, 125.22, 
127.10, 127.74, 128.29, 128.46, 128.62 ,135.24, 141.29, 143.70, 143.92, 156.02, 170.04, 170.86 
(C=O). υmax (thin film, cm
-1): 3416, 3186-2857, 1735, 1723, 1493, 1341, 1180, 1026, 739, 728. [α]D
25 
(CHCl3; c = 0.105): + 15.23. MS: C30H31NO6, m/z (ES
+) 502.22 [M+H]+. HRMS: Calculated C30H32NO6 
502.2224, found 502.2213. MP: 126˚C. 
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(S)- 1-benzyl-4-tert-butyl-2-aminosuccinate (66). 
 
H2N
O
O
O
O
 
 64 (4.202 g; 8.38 mM) was dissolved in 20 mL of anhydrous THF under a nitrogen 
atmosphere and cooled to 0°C. A 1.0 M solution of TBAF in THF (9.22 mL, 0.92 mM) was added 
dropwise. The solution stirred at 0°C for 30 minutes and allowed to proceed a further 2-3 hours at 
room temperature, monitored by TLC. The solvent was removed in vacuo to yield a sticky pink 
residue which was taken up into 20 mL of water.  The pH of the solution was adjusted to pH 2 
using 2 M HCl, and 20 mL of EtOAc was added.  The aqueous layer was separated and extracted 
with a further two 10 mL portions of EtOAc. The aqueous phase was adjusted to pH 8-9 using 2 M 
NaOH, and extracted with one 20 mL and two 10 mL portions of EtOAc.  The EtOAc portions from 
the basic aqueous extraction were combined, dried over anhydrous MgSO4 and then filtered. The 
solvent was reduced in vacuo, to give 1.926 g of 66 as a clear oil (6.87 mM, 82%). 
 Rf: 0.43 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, chloroform-d)  ppm 1.42 (s, 9H, CH3 
tert-butyl), 2.67-2.73 (m, 2H, CH2 aspartate), 3.72-3.81 (m, 1H, CH aspartate), 5.06-5.30 (m, 2H, 
CH2-benzyl), 7.30-7.45 (m, 5H, CH benzyl). 13C NMR (75 MHz, chloroform-d)  ppm 28.29, 39.87, 
47.07, 64.84, 66.97, 81.29, 128.29, 128.60, 141.43, 170.34, 174.33. υmax (thin film, cm
-1): 3106-
2852, 1722, 1671, 1456, 1392, 1148, 852, 735, 697. [α]D
25 (CHCl3; c = 0.110): - 4.55. MS: C15H21NO4, 
m/z (ES+) 280.15 [M+H]+. HRMS: Calculated C15H22NO4 280.1543, found 280.1542. 
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(S)- 1-benzyl-4-tert-butyl-2-((S)-2-tert-benzyloxycarbonylpropanamindo)succinate (68).  
H
N
O
O
O
OO
N
H
O
O
 
 66 (2.498 g; 8.94 mM) and N-(carboxybenzyl)-L-alanine (2.200 g; 9.84 mM) was dissolved 
in 10 mL of anhydrous DMF under nitrogen and cooled to 0°C. TEA (2.50 mL; 17.90 mM) was 
added dropwise and the reaction stirred for 10 minutes. 1.1eq DPPA (2.12 mL; 9.84 mM) was 
added dropwise and the reaction stirred for 18 hours at 0°C. The solvent was removed in vacuo to 
yield a pale brown oil.  The oil was dissolved in 30 mL EtOAc and washed with two 15 mL portions 
of NH4Cl, two 15 mL portions of Na2CO3 and one 15 mL portion of brine. The organic layer was 
dried over anhydrous MgSO4 to yield 3.437 g of 68 as a pale brown oil which solidified upon 
refrigeration to an orange sticky solid (7.07mM, 79%).  
 Rf: 0.37 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHZ, chloroform-d)  ppm 1.36 (s, 3H, CH3 
alanine), 1.40 (s, 9H, CH3 tert-butyl),  2.75 (ABm, J=4.33 Hz, 1H, CH2 aspartate), 2.96 (ABm, J=4.52 
Hz, 1H, CH2 aspartate), 4.32 (m, J=6.59 Hz, 1H, CH alanine), 4.86 (dq, J=8.38, 4.36 Hz, 1H, CH 
aspartate), 5.07 - 5.27 (m, 4H, CH2 benzyl), 5.65 (d, J=7.54 Hz, 1H, NH alanine), 7.08 - 7.16 (m, 1H, 
NH aspartate), 7.34 (s, 10H, CH aromatic). 13C NMR (75 MHZ, chloroform-d)  ppm 18.74, 18.87, 
27.93, 27.96, 37.18, 37.18, 48.71, 48.80, 50.45, 66.91, 67.00, 67.47, 81.84, 81.93, 128.09, 128.16, 
128.19, 128.26, 128.30, 128.46, 128.53, 128.60, 135.16, 136.20, 136.28, 155.83, 155.91, 169.85, 
170.10, 170.52, 170.57, 172.25, 172.33. υmax (thin film, cm
-1): 3673, 3361, 3293, 2980, 1701, 1646, 
1360, 1217, 1056, 695. [α]D
25 (CHCl3; c = 0.092): +8.66. MS: C26H32N2O7, m/z (ES
+) 485.23 [M+H+]. 
HRMS: Calculated C26H33N2O7 485.2288, found 485.2293. MP: 94.9˚C  
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(S)- 1-benzyl-4-tert-butyl-2-((S)-2-tert-benzyloxycarbonylpropanethioamindo)succinate (70).  
H
N
O
O
O
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O
 
 68 (3.437 g; 7.07 mM) and Lawesson’s reagent (1.465 g; 3.63 mM) was dissolved in 30 mL 
anhydrous toluene. The reaction was refluxed at 115oC for 4 hours, under nitrogen.   The solution 
was allowed to return to room temperature, the solvent removed in vacuo and the residue 
dissolved onto silica. Purification was achieved by flash chromatography (DCM followed by 8:2 Pet 
ether: EtOAc) to give 2.914 g of 70 as a yellow oil (5.82 mM; 82%).  
 Rf: 0.32 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHZ, chloroform-d)  ppm  1.34 - 1.40 (m, 
9H, CH3 tert-butyl), 1.44 (d, J=6.78 Hz, 3H, CH3 alanine), 3.00 (m, J=4.43 Hz, 2H, CH2 aspartate), 
4.56 (quin, J=6.88 Hz, 1H, CH alanine), 5.03 - 5.29 (m, 4H, CH2 benzyl), 5.35 - 5.48 (m, 1H, CH 
aspartate), 5.69 (d, J=6.22 Hz, 1H, NH alanine), 7.34 (s, 10H, CH aromatic), 8.65 (d, J=7.72 Hz, 1H, 
NH aspartate). 13C NMR (75 MHZ, chloroform-d)  ppm 22.25, 27.96, 35.51, 35.80, 53.86, 56.80, 
67.02, 67.12, 67.72, 82.12, 82.26, 128.09, 128.17, 128.37, 128.54, 128.57, 128.64, 134.96, 136.21, 
155.45, 169.60, 169.70, 169.87, 170.04, 204.59, 205.34. υmax (thin film, cm
-1): 3279, 2977, 1704, 
1498, 1148, 1047, 735, 695, 583. [α]D
25 (CHCl3; c = 0.098): + 31.48. MS: C26H32N2O6S, m/z (ES
+) 
501.21 [M+H]+. HRMS: Calculated C26H33N2O6S 501.2059, found 501.2062. 
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(S)- 4-benzyloxy-3-((S)-2-tert-benzyloxycarbonylpropanethioamido)-4-oxobutanoic acid (72).  
H
N
O
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 70 (500 mg; 1.00 mM) was dissolved in 30 mL of 33% TFA in DCM under a nitrogen 
atmosphere. After 1 hour a further 20 mL portion of 33% TFA in DCM was added to give  a final 
ratio of ~1 mL 33% TFA in DCM per 10 mg of starting material. The reaction was allowed to 
proceed for 5 hours before the solvent was removed in vacuo and the residue dissolved in 50 mL 
water, filtered through glass wool and extracted with 20 mL Et2O.  The aqueous layer was 
lyophilised to give 413 mg of 72 as a pale yellow oil (0.93 mM; 93%). 
 Rf: 0.42 (DCM:MeOH 19:1).
1H NMR (300 MHZ, chloroform-d)  ppm 1.32 (d, J=6.59 Hz, 3H, 
CH3 alanine), 2.98 - 3.22 (ABdq, 2H, CH2 aspartate), 4.81 - 5.21 (m, 5H, CH2 benzyl, CH alanine), 
5.47 (br. s., 1H, CH aspartate), 5.88 (d, J=8.48 Hz, 1H, NH alanine), 7.21 - 7.36 (m, 10H, CH 
aromatic), 9.07 (d, J=7.72 Hz, 2H, NH aspartate).13C NMR (75 MHZ, chloroform-d)  ppm 22.28, 
35.47, 35.82, 53.89, 56.74, 67.03, 67.52, 128.19, 128.43, 128.56, 128.69, 135.21, 136.81, 155.41, 
169.82, 170.60, 205.42. υmax (thin film, cm
-1): 3306, 2978, 2930, 1715, 1506, 1393, 1367, 1246, 
1153, 910. [α]D
25 (CHCl3; c = 0.0102): + 67.93. MS: C22H24N2O6S, m/z (ES
+) 445.14 [M+H+]. HRMS: 
Calculated C22H25N2O6S 445.1433, found 445.1428. 
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(S)- 2-((S)-2-aminopropanethioamido)succinic acid (73).  
 
H
N
OH
O
O
OS
H2N
 
 72 (1.023g, 2.04 mM) was dissolved in 10 ml anhydrous THF and cooled to -78˚C. 
Approximately 10 ml of liquid ammonia was added, the mixture stirred for 10 minutes and then 
sodium metal (188 mg, 8.17 mM) added in small portions to form a dark blue solution. The 
reaction was stirred under nitrogen for 3 hours, before being quenched with NH4Cl(s) and warmed 
to room temperature. The solvent was removed in vacuo, the residue taken up in 20ml of EtOAc 
and washed with two 10ml portions of water. The aqueous phase was acidified to pH 2 with 2M 
HCl and extracted with two 20ml portions of EtOAc and one 20ml portion of CH3Cl. The organic 
phases were combined, dried with MgSO4, filtered, and the solvent reduced in vacuo to give 520 
mg of 73 as a clear oil (1.88 mM, 92%).  
 Rf: 0.32 (1:9:90 NH4OH:MeOH:DCM) 
1H NMR (300 MHZ, methanol-d4)  ppm 1.36-1.43 (m, 
9.5H, CH3 tert-butyl, CH3 alanine*), 1.51 (d, J=6.81 Hz, 2.5H, CH3 alanine), 2.98-3.03 (m, 2H, CH2 
aspartate), 4.39 (quin, J=6.94 Hz, 1H, CH alanine), 5.54 (t, J=5.83 Hz, 1H, CH aspartate). * minor 
rotamer. 13C NMR (75 MHZ, methanol-d4)  ppm 19.80, 27.96, 34.92, 54.21, 55.98, 82.18, 170.83, 
171.92, 202.74.  MS: C11H20N2O4S m/z (ES+) 277.12 [M+H]
+. HRMS: Calculated C11H21N2O4S 
277.1222, found 277.1228. 

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6.3 Synthesis of PepT1 targeted prodrugs using commercially available drugs (section 2.5). 
6.3.1 Propofol prodrug (section 2.5.1). 
(S)-1-tert-butyl-4-(2,6-diisopropylphenyl)-2-((S)-2-tert-butoxycarbonylpropanethioamido) 
succinate (75). 
H
N
O
O
S
N
H
O
O
O
O
 
  57 (222 mg; 0.59 mM), EDC.HCl (124 mg; 0.65 mM), DMAP (72 mg; 0.59 mM) and 2,6-
diisopropylphenol (74) (104 μl; 0.56 mM) were stirred in 3 mL anhydrous DMF for one hour at 0 
°C. The solution was warmed to room temperature and stirred for 72 hours. The solvent was 
removed in vacuo and the residue purified by flash column chromatography (petroleum ether to 
9:1 Pet ether:EtOAc) to give 188mg of 75 as a yellow oil (0.35 mM; 62%). 
 Rf: 0.73 (EtOAc:Pet ether 1:9). 
1H NMR (300 MHz, chloroform-d)  ppm 1.03 - 1.16 (m, 
12H, CH(CH3)2), 1.34 (s, 3H, CH3 alanine), 1.35 - 1.44 (m, 18H, CH3 Boc, CH3 tert-butyl), 2.65 - 2.87 
(m, 2H, CH(CH3)2), 3.32 (m, 1H, CH2 aspartate), 3.43 - 3.64 (m, 1H, CH2 aspartate), 4.32 - 4.48 (m, 
1H, CH alanine), 4.99 - 5.11 (m, 1H, NH alanine),  5.15 - 5.29 (m, 1H, CH aspartate), 6.95 - 7.22 (m, 
3H, CH aromatic), 8.44 - 8.53 (m, 0.1H, NH aspartate*), 8.61 (d, J=7.16 Hz, 0.9H, NH aspartate) * 
minor rotamer. 13C NMR (75 MHz, chloroform-d)  ppm 22.14, 23.86, 27.62, 27.82, 28.26, 33.90, 
53.88, 56.39, 80.40, 83.55, 124.04, 126.83, 140.05, 145.20, 154.75, 168.16, 170.29, 204.91. υmax 
(thin film, cm-1): 3323, 2959-2856, 1689, 1504, 1439, 1150, 746. MS: C28H44N2O6S m/z (ES+) 537.30 
[M+H]+. HRMS: Calculated C28H45N2O6S 537.2998, found 537.2996. 
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This compared to data previously recorded by Price (unpublished) in the group. 
 1H NMR (500 MHz, chloroform-d)  ppm 1.18 (d, 12H), 1.50-1.41 (m, 21H), 2.95-2.70 (m, 
2H), 3.44-3.35 (m, 1H), 3.66-3.55 (m, 1H), 4.49 (t, J = 6.5, 1H), 5.13 (s, 1H), 5.28 (s, 1H), 7.15 (d, J = 
7.5, 2H), 7.22 (t, J = 7.5, 1H), 8.56 (br. s., 0.2 H)*, 8.69 (d, J = 7.0, 0.8H). 13C NMR (100 MHz, 
chloroform-d) ppm 22.1, 22.8-24.4, 27.8, 28.2, 34.2, 53.7, 53.9, 83.4, 124.0, 126.8, 140.0, 145.2, 
155.1, 168.1, 170.3, 204.9. * minor rotamer. υmax (thin film, cm
-1): 3323, 2980, 2934, 1728, 1514, 
1396, 1370, 1335, 1248, 1158, 1053, 912, 846, 734. [α]D
31 (CHCl3; c = 3.00): +60.20. 
 
(S)-2-((S)-2aminopropanethioamido)-4-(2,6-diisopropylphenoxy)-4-oxobutanoic acid (76).  
H
N
OH
O
S
H2N
O
O
 
 75 (103 mg; 0.19 mM) was dissolved in 5 mL 97% formic acid and the solution refluxed at 
100 °C for three hours. The reaction was cooled to room temperature and the formic acid 
removed in vacuo. The residue was taken up in 5 mL distilled water, filtered through a pipette 
plugged with glass wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 
70 mg of 76 as a white solid in formate salt form (0.16 mM; 87%). 
 1H NMR (300 MHZ, methanol-d4)  ppm  1.04 - 1.12 (d, J=6.78 Hz, 12H, CH(CH3)2), 1.37 - 
1.43 (m, 1.4H, CH3 alanine*), 1.50 (d, J=6.78 Hz, 1.6H, CH3 alanine), 2.83 - 2.93 (m, 1H, CH(CH3)2), 
3.27 (d, J=5.65 Hz, 2H, CH2 aspartate),  4.23 (m, J=6.78 Hz, 1H, CH alanine), 5.41 (dt, J=9.42, 5.56 
Hz, 0.2H, CH aspartate*), 5.48 (t, J=5.65 Hz, 0.8H, CH aspartate), 7.02 - 7.18 (m, 3H, CH aromatic), 
7.90 (br. s., 1H, NH aspartate). * minor rotamer. 13C NMR (75 MHZ, methanol-d4)  ppm 20.80, 
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23.23, 28.18, 28.56, 31.71, 35.59, 37.04, 55.53, 56.15, 125.00, 127.88, 141.71, 146.69, 170.99, 
171.84, 202.17. υmax (thin film, cm
-1): 3379, 2967, 2522, 1660, 1453, 1385, 1364, 1140. MS: 
C19H28N2O4S m/z (ES+) 381.1 [M+H]
+. HRMS: Calculated C19H29N2O4S 381.1843, found 381.1846. 
This compared to data previously recorded by Price (unpublished) in the group, so no further 
characterisation was carried out. 
 1H NMR (500 MHz, methanol-d4) ppm 1.17 (s, 6H), 1.18 (s, 6H),  1.49 (d, J = 6.5, Ala-CH3, 
3H), 2.85-3.05 (m, 2H), 3.22-3.55 (m, 2H), 4.27 (q, J = 7.0, 1H Ala-α-CH), 5.53 (br. s., 1H), 7.15-7.23 
(m, 3H). 13 NMR (100 MHz, methanol-d4) ppm 20.9, 23.5, 24.2, 28.3, 28.7, 35.7, 55.2, 55.7, 
125.1, 127.9, 141.8, 146.8, 171.1, 171.9, 202.3. MS: C19H28N2O4S m/z (ES
+) 381.1 [M+H+]. HRMS: 
Calculated C19H29N2O4S: 381.1843, found: 381.1836. * minor rotamer.  
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6.3.2. Ibuprofen prodrug (section 2.5.2). 
(S)-2-((S)-2-tert-butoxycarbonylpropanethioamido)-3-((R)-2-(4-isobutylphenyl)propionyloxy)-
propanoic acid tert-butyl ester (78). 
H
N
O
O
O
S
N
H
O
O
O
  
Published data: Foley et al. 117 
 Ibuprofen (77) (848 mg; 4.11 mM) and HBTU (1.870 g; 4.93 mM) were dissolved in 10 mL 
anhydrous DMF under a nitrogen atmosphere. DIPEA (1.22 mL; 6.99 mM) was added dropwise 
and the solution stirred at room temperature for 30 minutes. 56 (1.146 g; 3.29 mM) was dissolved 
in 5 mL anhydrous DMF was added and the solution stirred at room temperature for three days. 
The solvent was removed in vacuo and the residue purified by flash column chromatography (a 
gradient of 2:8 to 7:3 EtOAc:Pet ether) to give 1.307 g of 78 as a yellow oil (2.44 mM; 74%). 
 Rf: 0.57 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHZ, chloroform-d)  ppm  0.86 - 0.92 (m, 
6H, CH(CH3)2), 1.26 (d, J=6.97 Hz, 3H, CH3 alanine) 1.35 (s, 3H, Ibu-CH3),  1.45-1.51 (m, 18H, CH3 
Boc, CH3 tert-butyl),  1.76 - 1.91 (m, 1H, CH(CH3)2), 2.44 (d, J=7.16 Hz, 2H, Ibu-CH2), 3.57 - 3.80 (m, 
1H, Ibu-CH), 4.41 (m, 2H, CH alanine, CH2 serine), 4.64 (ABdd, J=2.60, 11.49, 1H, CH2 serine), 4.95 
(br. s., 0.2H, NH alanine*), 5.07 - 5.25 (m, 0.8H, NH alanine), 6.95 - 7.31 (m, 4H, CH aromatic), 8.26 
- 8.38 (d, J=6.41 Hz, 0.7H, NH serine), 8.41 - 8.56 (d, J=6.59 Hz, 0.3H, NH serine*). * minor 
rotamer. 13C NMR (75 MHZ, chloroform-d)  ppm 18.16, 18.45, 27.76, 27.87, 28.28, 30.19, 44.79, 
44.97, 45.04, 57.11, 57.23, 62.87, 83.49, 127.29, 129.40, 129.50, 137.07, 137.27, 140.76, 140.83, 
167.30, 174.08, 180.49, 205.22, 205.44. υmax (thin film, cm
-1): 3307, 2977, 2931, 1715, 1614, 1505, 
1394, 1368, 1248, 1157, 778. MS: C28H44N2O6S m/z (ES+) 537.30 [M+H]
+. HRMS: Calculated 
C28H45N2O6S 537.2998, found 537.3003. 
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 (S)-2-((S)-2-aminopropanethioamido)-3-((R)-2-(4-isobutylphenyl)propionyloxy)-propanoic acid 
(79). 
H
N
O
OH
O
S
H2N
O
 
Published data: Foley et al. 117 
 78 (532 mg; 0.99 mM) was dissolved in 15 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction mixture was cooled to room temperature and the formic acid removed 
in vacuo. The residue was taken up in 15 mL distilled water, filtered through a pipette plugged 
with glass wool and extracted with 7 mL Et2O. The aqueous layer was lyophilised to give 414 mg of 
79 as a yellow resin in formate salt form (0.97 mM; 98%). 
 1H NMR (300 MHZ, methanol-d4) ppm 0.86 - 0.95 (m, 6H, CH(CH3)2), 1.45 (dd, J=7.16, 
1.70 Hz, 5H, CH3-ibuprofen, CH3 alanine), 1.54 (d, J=6.59 Hz, 1H, CH3-alanine*), 1.79 - 1.92 (m, 1H, 
CH(CH3)2), 2.46 (d, J=6.97 Hz, 2H, CH2-ibuprofen), 3.62 - 3.81 (m, 1H, CH-ibuprofen), 4.15 (q, 
J=6.91 Hz, 1H, CH-alanine),  4.56 (m, J=4.71 Hz, 2H, CH2-serine), 5.09 (dd, J=4.62, 3.30 Hz, 1H, CH 
serine), 7.08 - 7.14 (m, 2H, CH aromatic), 7.16 - 7.27 (m, 2H, CH aromatic). * minor rotamer 13C 
NMR (75 MHz, methanol-d4) ppm 19.11, 20.40, 22.72, 31.49, 56.20, 60.71, 65.12, 128.23, 
130.28, 130.37, 139.83, 142.3, 176.18, 200.58. υmax (thin film, cm
-1): 3152, 2953, 1732, 1614, 1507, 
1455, 1381, 1165, 779. MS: C19H28N2O4S m/z (ES
+) 381.1 [M+H]+. HRMS: Calculated C19H29N2O4S 
381.1848, found 381.1845. 
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6.3.3 Aspirin prodrug (section 2.5.3). 
(3S,3aR,6R,6aR)-6-(benzyloxy)-hexahydrofuro[3,2-b]furan-3-ol (91). 
O
O
HO H
H O
1
2
34
5
6
 
Published data:  Huynh et al.130 
 Isosorbide (90) (20.00g, 136.88 mM), lithium hydride (1.088 g, 136.88 mM), and lithium 
chloride (5.800 g, 136.88 mM) were dissolved in 65 mL anhydrous DMSO and stirred at 90˚C for 
20 min under a nitrogen atmosphere. Benzyl chloride (15.75 mL, 136.88 mM) was added dropwise 
and the reaction stirred for 18 h. The pH of the solution was adjusted to pH 2 with 2 M HCl  and 
extracted with three 50 mL portions of EtOAc. The organic phases were combined and dried over 
anhydrous MgSO4 and filtered. The solvent was evaporated in vacuo and the residual oil was 
purified by flash column chromatography (1:1; 3:7; 1.5:8.5 EtOAc:Pet ether) to give 18.767 g of 91 
as a tan solid (79.43 mM; 58%). 
 Rf: 0.13 (EtOAc:Pet ether 6:4). 
1H NMR (300 MHZ, dimethyl sulfoxide-d6)  ppm  3.42 (t, 
J=8.19 Hz, 1H, CH2(ax)-isosorbide 3), 3.68 - 3.82 (m, 3H, CH2(eq)-isosorbide 3, CH2-isosorbide 6), 4.01 
- 4.11 (m, 2H, CH-isosorbide 1, CH-isosorbide 4), 4.28 (d, J=4.14 Hz, 1H, CH-isosorbide 5), 4.44 - 
4.52 (ABd, 1H, CH2-benzyl), 4.60 - 4.68 (m, 2H, CH2-benzyl, CH-isosorbide 2),  5.18 (s, 1H, OH), 7.25 
- 7.41 (m, 5H, CH-benzyl). 13C NMR (75 MHZ, chloroform-d)  ppm 72.17, 74.41, 77.73, 78.31, 
81.97, 82.53, 90.60, 129.90, 130.13, 130.43, 140.40. [α]D
25 (CHCl3; c = 0.0133): + 91.80. υmax (thin 
film, cm-1): 3416, 2960-2873, 1368, 1063, 979, 833, 739. MS: C13H16O4 m/z (ES
+) 237.11 [M+H]+. 
HRMS: Calculated C13H17O4 237.1127, found: 237.1125. MP: 93.9˚C 
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(3S,3aR,6R,6aR)-6-(benzyloxy)-hexahydrofuro[3,2-b]furan-3-yl acetate (98). 
O
O
O H
H O
O
1
2
34
5
6
 
 Aspirin (80) (2.000 g, 11.10 mM), DCC (2.520 g, 12.21 mM) and DMAP (0.136 g, 1.10 mM) 
were dissolved in 20 mL anhydrous DCM under a nitrogen atmosphere at 0˚C and left to stir for 1 
hour.  91 (2.617 g, 11.10 mM) in 10 mL anhydrous DCM was added and reaction mixture stirred at 
room temperature for 18 hours. The solution was filtered and the DCM removed in vacuo. The 
resultant oil was purified by flash column chromatography (a gradient of 1:1 to 2:4; EtOAc:Pet 
ether) to give 2.914 g of 98 as an orange oil (10.48 mM, 94%). 
 Rf: 0.28 (EtOAc:Pet ether 6:4). 
1H NMR (300 MHZ, chloroform-d)  ppm  2.06 (s, 3H, CH3-
acetyl), 3.64 (dd, J=8.67, 7.72 Hz, 1H, CH2(ax)-isosorbide 3), 3.87 (dd, J=8.85, 6.59 Hz, 1H, CH2(eq)-
isosorbide 3), 3.97 - 4.15 (m, 3H, CH2-isosorbide 6, CH-isosorbide 4), 4.49 (d, J=4.33 Hz, 1H, CH-
isosorbide 5), 4.56 (ABd, J=11.87 Hz, 1H, CH2-benzyl), 4.68 (t, J=4.52 Hz, 1H, CH-isosorbide 2), 4.76 
(ABd, J=11.68 Hz, 1H, CH2-benzyl),  5.16 (d, J=3.77 Hz, 1H, CH-isosorbide 1), 7.28 - 7.40 (m, 5H, CH 
benzyl). 13C NMR (75 MHZ, chloroform-d)  ppm 20.94, 70.35, 72.47, 73.75, 76.76, 77.18, 77.61, 
78.58, 79.06, 80.57, 85.87, 127.95, 128.49, 137.65, 170.01. υmax (thin film, cm
-1): 2874, 1743, 1369, 
1237, 1102, 1056, 740. [α]D
25 (CHCl3; c = 0.0354): + 101.98. MS: C15H18O5 m/z (ES
+) 279.12 [M+H]+. 
HRMS: Calculated C15H19O5 279.1233, found: 279.1234.  
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(3S,3aR,6R,6aR)-6-(benzyloxy)-hexahydrofuro[3,2-b]furan-3-yl 2-hydroxybenzoate (99). 
O
O
O H
H O
O
HO
1
2
34
5
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7
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 Salicylic acid (88) (2.925 g, 21.18 mM), DCC (4.806 g, 23.29 mM) and DMAP (2.587 g, 
21.18 mM) were dissolved in 20 mL anhydrous DCM under a nitrogen atmosphere at 0˚C and left 
to stir for 30 minutes. 91 (5.00 g, 21.18 mM in 10 mL anhydrous DCM was added and reaction 
mixture stirred at room temperature for 18 hours. The solution was filtered and the filtrate 
washed with one 30 mL portion of 1 M HCl, one 30 mL portion of saturated aqueous Na2HCO3 and 
three 30 mL portions of water. The organic layer was dried over anhydrous MgSO4 and the solvent 
removed in vacuo. The resultant colourless oil was purified by flash column chromatography (a 
gradient of 3:7 to 7:3 Pet ether: EtOAc) to give 6.538 g of 99 as a cream solid (18.26 mM, 86%). 
 Rf: 0.70 (EtOAc:Pet ether 6:4). 
1H NMR (300 MHZ, chloroform-d)  ppm  3.68 - 3.78 (m, 
1H, CH2(ax)-isosorbide 3), 3.93 (dd, J=8.85, 6.59 Hz, 1H, CH2(eq)-isosorbide 3), 4.07 - 4.29 (m, 3H, 
CH2-isosorbide 6, CH-isosorbide 4), 4.60 (d, J=11.87 Hz, 1H, ABd, 1H, CH2-benzyl), 4.66 (d, J=4.33 
Hz, 1H, CH-isosorbide 5), 4.76 - 4.83 (m, 2H, CH2-benzyl, CH-isosorbide 2), 5.44 (d, J=3.77 Hz, 1H, 
CH-isosorbide 1), 6.89 (ddd, J=8.10, 7.16, 1.13 Hz, 1H, CH-salicylic 8), 6.96 - 7.02 (m, 1H, CH-
salicylic 10), 7.28 - 7.41 (m, 5H, CH-benzyl), 7.48 (ddd, J=8.48, 7.16, 1.88 Hz, 1H, CH-salicylic 9), 
7.79 - 7.85 (m, J=1.70, 0.38 Hz, 1H, CH-salicylic 7). 13C NMR (75 MHZ, chloroform-d)  ppm 70.54, 
72.59, 73.51, 76.63, 79.02, 79.45, 80.70, 85.91, 111.84, 117.75, 119.26, 127.99, 128.04, 128.56, 
129.94, 136.22, 137.58, 161.87, 169.25. υmax (thin film, cm
-1): 3212, 2962-2877, 1674, 1483, 1141, 
1077, 1017, 747, 696, 529. [α]D
25 (CHCl3; c = 0.0074): + 95.68. MS: C20H20O6 m/z (ES
+) 357.13 
[M+H]+. HRMS: Calculated C20H21O6 357.1338, found: 357.1341. MP: 59.7˚C 
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(3S,3aR,6R,6aR)-6-hydroxy-hexahydrofuro[3,2-b]furan-3-yl 2-hydroxybenzoate (100). 
O
O
O H
H OH
O
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2
34
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 99 (3.046 g, 8.51 mM) was dissolved in 10 mL 1:1 MeOH:EtOAc. 10% Pd/C (300 mg) was 
added and the suspension stirred under a hydrogen atmosphere at room temperature for 24 
hours. The reaction mixture was filtered through a Celite® bed and the organic solvent removed in 
vacuo. 2.245 g of 100 was obtained as a clear oil (8.43 mM, 99%). 
 Rf: 0.65 (EtOAc:Pet ether 6:4). 
1H NMR (300 MHZ, chloroform-d)  ppm  3.65 (dd, J=9.51, 
5.93 Hz, 1H, CH2(ax)-isosorbide 3), 3.96 (dd, J=9.42, 6.03 Hz, 1H, CH2(eq)-isosorbide 3), 4.11 - 4.27 
(m, 2H, CH2-isosorbide 6), 4.38 (q, J=5.71 Hz, 1H, CH-isosorbide 4), 4.66 (d, J=4.52 Hz, 1H, CH-
isosorbide 5), 4.71 - 4.78 (m, 1H, CH-isosorbide 2), 5.51 (d, J=3.58 Hz, 1H, CH-isosorbide 1), 6.86 - 
6.95 (m, 1H, CH-salicylic 8), 6.97 - 7.05 (m, 1H, CH-salicylic 10), 7.50 (ddd, J=8.52, 7.11, 1.70 Hz, 
1H, CH-salicylic 9), 7.83 (dd, J=8.01, 1.79 Hz, 1H, CH-salicylic 7). 13C NMR (75 MHZ, chloroform-d)  
ppm 72.33, 73.37, 73.63, 79.19, 82.12, 85.57, 111.72, 117.78, 119.31, 129.91, 136.32, 161.88, 
169.16. υmax (thin film, cm
-1): 3484, 2977-2858, 1189, 1488, 1304, 1077, 1007, 748, 529. [α]D
25 
(CHCl3; c = 0.0286): + 53.49. MS: C13H14O6 m/z (ES
+) 267.09 [M+H]+. HRMS: Calculated C13H15O6 
267.0869, found: 267.0874. MP: 93.9˚C 
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6.4 Synthesis of polyethylene glycol based linkers (section 2.6.1). 
2-benzyloxyacetic acid (110). 
HO
O
O
  
Published data:  Yamashita et al.180 
 Sodium metal (3.040 g; 132.28 mM) was added in small portions to 22 ml benzyl alcohol 
(109) at 0˚C. The reaction was allowed to warm to room temperature before being heated to 
100˚C. When no sodium metal was visible the reaction was cooled to room temperature and 
chloroacetic acid (5 g; 52.91 mM) in benzyl alcohol (5.5 mL) was added dropwise. The solution 
was refluxed at 210˚C for 2 hours. Once cooled 30 mL water was added and washed with five 20 
mL portions of Et2O. The pH of the aqueous layer was adjusted to pH 2 with 2M HCl solution and 
extracted with five 20 mL portions of Et2O. The organic layers were combined and washed with 
three 20 mL portions of water, one 20 mL portion of brine, dried over anhydrous MgSO4 and 
filtered. The solvent was reduced in vacuo. The resultant clear oil was purified with flash column 
chromatography (a gradient of 19:1 to 7:3 Pet ether: EtOAc) to give 8.096g of 110 as a pale yellow 
oil (48.72 mM, 92%). 
 Rf: 0.43 (EtOAc:Pet ether 6:4). 
1H NMR (300 MHZ, chloroform-d)  ppm  3.91 - 4.35 (m, 
2H, CH2COOH),  4.45 - 4.78 (m, 2H, CH2 benzyl), 7.09 - 7.54 (m, 5H, CH benzyl), 8.60 (br. s., 1H, 
COOH). 13C NMR (75 MHZ, chloroform-d)  ppm 60.86, 67.41, 130.01135.34, 136.71, 170.52, 
175.19. υmax (thin film, cm
-1): 3030, 1732, 1208, 1120, 632, 534, 498. [α]D
25 (CHCl3; c = 0.0965): 
0.00. MS: C9H10O3 m/z (ES
+) 167.07 [M+H]+. HRMS: Calculated C9H11O3 167.0707, found: 167.0706.  
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2-(2-(benzyloxy)ethoxy)ethanol (112). 
HO
O
O
 
Published data by the group:  Foley et al.116 
 60% NaH in mineral oil (1.327 g; 33.19 mM) was suspended in 50 mL anhydrous THF 
under a nitrogen atmosphere. Diethylene glycol (111) (3.00 mL; 31.61 mM) was added dropwise 
and the reaction stirred at room temperature for 1 hour. Benzyl bromide (3.76 mL, 31.61 mM) 
was added dropwise and the white suspension stirred for 48 hours at room temperature.   100 mL 
DCM and 50 mL 10% (w/v) K2CO3 was added. The organic layer was separated and washed with 
one 50 mL portion of water, dried over anhydrous MgSO4 and filtered. The solvent was reduced in 
vacuo to give a brown oil which was purified by flash column chromatography (a gradient of 4:1 to 
0:1 Pet ether:EtOAc) to give 3.614 g of 112 as a yellow oil (18.42 mM; 58%). 
 Rf: 0.40 (EtOAc:Pet ether 6:4). 
1H NMR (300 MHZ, chloroform-d)  ppm 2.92 (br. s., 1H, 
OH), 3.24 - 4.08 (m, 8H, CH2 glycol), 4.42 - 4.72 (m, 2H, CH2 benzyl), 7.03 - 7.57 (m, 5H, CH benzyl). 
13C NMR (75 MHZ, chloroform-d)  ppm 61.63, 69.41, 70.32, 72.58, 73.25, 73.27, 73.30, 127.78, 
127.86, 128.44. υmax (thin film, cm
-1): 3346, 2866, 1661, 1494, 1367, 1315, 1066, 630. [α]D
25 (CHCl3; 
c = 0.0817): 0.00. MS: C11H16O3 m/z (ES
+) 197.12 [M+H]+. HRMS: Calculated C11H17O3 197.1172, 
found: 197.1171.         
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2-(2-(benzyloxy)ethoxy)acetic acid (113). 
HO
O
O
O
 
 112 (534 mg;  2.72 mM) was dissolved in 15 mL acetone at 0˚C. Chromic trioxide (0.463 
mg; 4.63 mM) in 4.6 mL 0.25 M H2SO4 was added dropwise and the reaction stirred at room 
temperature for 24 hours, during which the reaction turned dark green. 2-propanol (10 mL) was 
added and the reaction stirred vigorously for 10 minutes. The solution was extracted with five 10 
mL portions of EtOAc, which were combined and washed with two 10 mL portions of water.  The 
organic layer was extracted with five 10 mL portions of saturated NaHCO3, which were combined 
and the pH adjusted to pH 2 with 5 M HCl. The acidified solution was washed with five 10 mL 
portions of EtOAc, which were combined, dried over anhydrous MgSO4 and filtered. The solvent 
was removed in vacuo to give 416 mg of 113 as a colourless oil (1.98 mM, 73%)  
 Rf: 0.22 (EtOAc:Pet ether 6:4). 
1H NMR (300 MHZ, chloroform-d)  ppm 3.52 - 3.84 (m, 6H, 
CH2 glycol), 4.08 - 4.30 (m, 2H, CH2COOH), 4.45 - 4.65 (m, 2H, CH2 benzyl), 7.27 - 7.49 (m, 5H, CH 
benzyl). 13C NMR (75 MHZ, chloroform-d)  ppm 68.63, 69.20, 70.32, 70.66, 71.17, 73.31, 127.77, 
127.89, 124.44, 137.90, 173.50. υmax (thin film, cm
-1): 3500, 2869, 1731, 1453, 1353, 1208, 1088. 
[α]D
25 (CHCl3; c = 0.0107): 0.00. MS: C11H14O3 m/z (ES
+) 211.10 [M+H]+. HRMS: Calculated C11H15O5 
211.0970, found: 211.0974.               
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2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethanol (115). 
HO
O
O
O
 
Published data by the group:  Foley et al.116 
 Ag2O (11.708 g; 50.52 mM) was suspended in 50 mL anhydrous THF under a nitrogen 
atmosphere in a flask made light impenetrable. Triethylene glycol (114) (4.5 mL; 33.68 mM) was 
added dropwise and the reaction stirred at room temperature for 1 hour. Benzyl bromide (4.01 
mL, 33.68 mM) was added dropwise and the suspension stirred for 72 hours at room 
temperature. The reaction mixture was filtered through a Celite® bed and the organic solvent 
removed in vacuo to give a brown oil. The oil was purified by flash column chromatography (a 
gradient of 4:1 to 0:1 Pet ether:EtOAc) to give of 5.648 g of 115 as a colourless oil (23.50 mM, 
70%).  
 Rf: 0.25 (EtOAc:Pet ether 6:4). 
1H NMR (300 MHZ, chloroform-d)  ppm 3.22 (s, 1H, OH), 
3.52 - 3.78 (m, 12H, CH2 glycol),  4.56 (s, 2H, CH2 benzyl), 7.22 - 7.39 (m, 5H, CH benzyl). 
13C NMR 
(75 MHZ, chloroform-d)  ppm 61.2, 63.99, 68.90, 69.21, 69.30, 70.24, 70.58, 72.60, 73.24, 
127.82, 128.39, 138.00. υmax (thin film, cm
-1): 3419, 2866, 1748, 1455, 1351, 1205, 1136. [α]D
25 
(CHCl3; c = 0.0614): 0.00. MS: C13H20O4 m/z (ES
+) 241.14 [M+H]+. HRMS: Calculated C11H17O3 
241.1440, found: 241.1392.    
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2-(2-(2-(benzyloxy)ethoxy)ethoxy)acetic acid (116). 
HO
O
O
O
O
 
 115 (1.014 g;  4.22 mM) was dissolved in 25 mL acetone at 0˚C. Chromic trioxide (0.717 
mg; 7.17 mM) in 7.2 mL 0.25 M H2SO4 was added dropwise and the reaction stirred at room 
temperature for 24 hours, during which the reaction turned dark green. 2-propanol (15 mL) was 
added and the reaction stirred vigorously for 10 minutes. The solution was extracted with five 20 
mL portions of EtOAc, which were combined and washed with two 20 mL portions of water.  The 
EtOAc was extracted with five 20 mL portions of saturated NaHCO3, which were combined and 
the pH adjusted to pH 2 with 5 M HCl. The acidified solution was washed with five 20 mL portions 
of EtOAc, which were combined, dried over anhydrous MgSO4 and filtered. The solvent was 
removed in vacuo to give 764 mg of 116 as a colourless oil (3.00 mM, 71%).  
 Rf: 0.49 (EtOAc:Pet ether 6:4). 
1H NMR (300 MHZ, chloroform-d)  ppm 3.56 - 3.80 (m, 8H, 
CH2 glycol), 4.08 - 4.24 (m, 2H, CH2COOH),  4.51 - 4.60 (m, 2H, CH2 benzyl), 7.28 - 7.38 (m, 5H, CH 
benzyl).  13C NMR (75 MHZ, chloroform-d)  ppm 68.57, 69.17, 70.31, 70.60, 71.05, 73.29, 127.77, 
127.90, 128.44. υmax (thin film, cm
-1): 3419, 2866, 1748, 1455, 1351, 1205, 1136. [α]D
25 (CHCl3; c = 
0.0112): 0.00. MS: C13H18O5 m/z (ES
+) 255.12 [M+H]+. HRMS: Calculated C13H19O5 255.1232, found: 
255.1237.               
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6.5 Synthesis of Aurora Kinase inhibitor prodrug (section 2.6.1) 
 (S)-1-tert-butyl-4-(1-(3-(4-(5-(2-(3-fluorophenylamino)-2-oxoethyl)thiazol-2-ylamino)-6-
methoxy-4a,8a-dihydroquinazolin-7-yloxy)propyl)piperidin-4-yl)methyl-2-((S)-2-(tert-
butoxycarbonylpropanethioamido)succinate (107). 
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 57 (142 mg; 0.38 mM), EDC.HCl (79 mg; 0.41 mM), DMAP (46 mg; 0.38 mM) and HOBt 
(102 mg; 0.76 mM) were stirred in 5 mL anhydrous DMF for one hour at 0 °C under a nitrogen 
atmosphere. 105 (200 mg; 0.34 mM) dissolved in 2 mL anhydrous DMF was added dropwise. The 
solution was warmed to room temperature and stirred for 72 hours. The solvent was removed in 
vacuo and the residue purified by flash column chromatography (1:9:90 NH4OH:MeOH:DCM) to 
give 103 mg of 107 as an orange resin (0.11 mM; 32%). 
 Rf: 0.57 (NH4OH:MeOH:DCM 1:9:90). 
1H NMR (300 MHZ, methanol-d4)  1.20 - 1.31 (m, 
1H, piperidine-CH 2), 1.39 (d, J=6.97 Hz, 3H, CH3 alanine), 1.44 (s, 9H, CH3 Boc), 1.47 (s, 9H, CH3 
tert-butyl), 1.59 - 1.75 (m, 3H, piperidine-CH(ax) 3), 2.02 (d, J=10.74 Hz, 2H, piperidine-CH(eq) 3), 
2.29 - 2.37 (m, 2H, CH2 6), 3.01 (t, J=5.56 Hz, 3H, CH2 aspartate, piperidine-CH(ax) 4), 3.06 - 3.10 (m, 
1H, piperidine-CH(ax) 4), 3.33 (dt, J=3.34, 1.62 Hz, 2H, piperidine-CH2 5), 3.68 (d, J=12.81 Hz, 2H, 
piperidine-CH(eq) 4), 3.93 (br. s., 2H, thiazole-CH2 13), 3.95 (s, 3H, O-CH3 10), 4.07 (d, J=5.09 Hz, 2H, 
piperidine-CH2 1), 4.17 (t, J=5.56 Hz, 2H, O-CH2 7), 4.45, (q, J=7.16 Hz, 1H, CH alanine), 5.30 (q, 
J=6.47 Hz, 1H, CH aspartate), 6.80 - 6.89 (m, 1H, fluroaniline 16), 6.98 (s, 1H, thiazole 12), 7.30 - 
7.35 (m, 2H, fluroaniline 17, quinazoline 11), 7.36 (s, 1H, fluroaniline 14), 7.60 (s, 1H, fluroaniline 
15), 7.62 - 7.66 (m, 1H, quinazoline 8), 8.53 (s, 1H, quinazoline 9). 13C NMR (75 MHZ, chloroform-
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d)  ppm 22.06, 25.01, 27.22, 28.21, 28.78, 34.27, 35.88, 36.04, 53.53, 55.91, 56.93, 57.86, 67.72, 
80.66, 83.81, 102.90, 107.39, 107.91, 180.26, 111.55, 111.83, 116.46, 131.32, 131.44, 141.58, 
141.72, 150.90, 155.22, 162.66, 165.89, 170.01, 170.79, 171.59, 196.23, 208.14. υmax (thin film, 
cm-1): 3306, 2977-2874, 1722, 1645, 1504, 1365, 1247, 1156, 1070, 884, 750. [α]D
25 (CHCl3; c = 
0.0082): + 11.70. MS: C36H59FN8O9S2 m/z (ES
+) 939.39 [M+H]+. HRMS: Calculated C36H60FN8O9S2 
939.3903, found: 939.3919. MP:  56.2˚C 
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(S)-2-((S)-2-aminopropanethioamido)-4-((1-(3-(4-(5-(2-(3-fluorophenylamino)-2-
oxoethyl)thiazol-2-ylamino)-6-methoxy-4a,8a-dihydroquinazolin-7-yloxy)propyl)piperidin-4-
yl)methoxy)-4-oxobutanoic acid (108). 
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 107 (52 mg, 0.06 mM) was dissolved 5 mL 97% formic acid and refluxed at 100°C for three 
hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. The 
residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass wool 
and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 44 mg of 108 as an 
orange resin in formate salt form (0.05 mM; 96%). 
 1H NMR (300 MHZ, methanol-d4)  ppm 1.24 - 1.36 (m, 1H, piperidine-CH 2), 1.51 (d, 
J=6.78 Hz, 1H, CH3 alanine*), 1.57 (d, J=6.59 Hz, 2H, CH3 alanine), 1.61 - 1.77 (m, 2H, piperidine-
CH(ax) 3), 2.00 - 2.13 (m, 2H, piperidine-CH(eq) 3), 2.41 (br. s., 2H, CH2 6), 3.06 (m, 2H, CH2 
aspartate), 3.37 - 3.46 (m, 2H, piperidine-CH(eq) 4),  3.77 (d, J=12.81 Hz, 2H, piperidine-CH(ax) 4), 
3.98 (s, 2H, thiazole-CH2 13), 4.04 (s, 3H, O-CH3 10), 4.06 - 4.13 (m, 2H, piperidine-CH2 1), 4.25 - 
4.33 (m, 1H, CH alanine), 4.33 - 4.41 (m, 2H, O-CH2 7), 5.43 (t, J=5.75 Hz, 1H, CH aspartate), 6.87 
(t, J=8.57 Hz, 1H, fluroaniline 16), 7.18 - 7.38 (m, 3H, thiazole 12, quinazoline 11, fluroaniline 17), 
7.50 (s, 1 H, fluroaniline 14), 7.60 (d, J=11.87 Hz, 1H, fluroaniline 15), 7.90 - 7.96 (m, 1H, 
quinazoline 8), 8.81 - 8.85 (m, 1H, quinazoline 9) υmax (thin film, cm
-1): 3401, 1669, 1442, 1182, 
1124, 801, 724. MS: C36H43FN8O7S2 m/z (ES
+) 783.28 [M+H]+. HRMS: Calculated C36H44FN8O7S2 
783.2758, found: 783.2757. 
13C NMR was attempted in methanol-d4, water-d2 and dimethyl sulfoxide-d6 but could not be 
obtained due to solubility issues. 
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 (1-(3-(4-(5-(2-(3-fluorophenylamino)-2-oxoethyl)thiazol-2-ylamino)-6-methoxy-4a,8a-
dihydroquinazolin-7-yloxy)propyl)piperidin-4-yl)methyl 2-(benzyloxy)acetate (117). 
 
 110 (28 mg; 0.17 mM), HATU (65 mg; 0.17 mM) and DIPEA (27 μL; 0.15 mM) were stirred 
in 3 mL anhydrous DMF for one hour at 0 °C under a nitrogen atmosphere. 105 (90 mg; 0.15 mM) 
dissolved in 2 mL anhydrous DMF was added dropwise. The solution was warmed to room 
temperature and stirred for 72 hours. The solvent was removed in vacuo and the residue purified 
by flash column chromatography (1:9:90 NH4OH:MeOH:DCM) to give 27 mg of 117 as an orange 
resin (0.04 mM; 24%). 
 Rf: 0.17 (NH4OH:MeOH:DCM 1:9:90). 
1H NMR (300 MHZ, methanol-d4)  ppm 0.92-0.98 
(m, 1H, piperidine-CH 2), 1.42 (m, 2H, piperidine-CH(ax) 3), 1.73 - 1.83 (m, 2H, piperidine-CH(eq) 3), 
2.07 - 2.15 (m, 2H, CH2 6), 2.16 - 2.28 (m, 2H, piperidine-CH2 4H(ax)), 2.69 - 2.77 (m, 2H, piperidine-
CH2 5), 3.09 - 3.17 (m, 1H, piperidine-CH2 4(eq)), 3.21 (q, J=7.41 Hz, 1H, piperidine-CH2(eq) 4), 3.71 
(dt, J=13.33, 6.62 Hz, 2H, CH2 18), 3.90 (d, J=0.75 Hz, 2H, thiazole-CH2 13), 3.99 (s, 3H, O-CH3 10), 
4.06 (d, J=5.84 Hz, 2H, piperidine-CH2 1), 4.16 (m, 2H, O-CH2 7), 4.61 (s, 2H, CH2 benzyl), 6.80 - 
6.88 (m, 1H, fluroaniline 16), 7.10 (s, 1H, thiazole 12), 7.27 - 7.38 (m, 8H, CH benzyl, fluroaniline 
14, fluroaniline 17, quinazoline 11), 7.56 (m, 1H, fluroaniline 15), 7.73 (s, 1H, quinazoline 8), 8.57 
(s, 1H, quinazoline 9). 13C NMR (75 MHZ, chloroform-d)  ppm 13.30, 18.04, 26.74, 28.91, 35.85, 
43.71, 48.73, 49.30, 49.87, 54.12, 55.68, 56.44, 56.86, 68.00, 68.31, 69.58, 74.30, 106.13, 106.84, 
111.24, 117.01, 129.03, 129.18, 129.46, 139.23, 139.84, 149.63, 155.84, 160.82, 166.25, 170.66, 
170.92, 174.88, 197.51, 207.36. υmax (thin film, cm
-1): 3070, 2904, 1678, 1613, 1520, 1454, 1397, 
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1265, 1209, 1139, 849, 657. MS: C38H41FN6O6S m/z (ES
+) 729.29 [M+H]+. HRMS: Calculated 
C38H42FN6O6S 729.2871, found: 729.2872. MP: 62.4˚C   
 
(1-(3-(4-(5-(2-(3-fluorophenylamino)-2-oxoethyl)thiazol-2-ylamino)-6-methoxy-4a,8a-
dihydroquinazolin-7-yloxy)propyl)piperidin-4-yl)methyl 2-(2-benzyloxy)ethoxy)acetate (118). 
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 113 (40 mg; 0.19 mM), HATU (72 mg; 0.19 mM) and DIPEA (30 μL; 0.17 mM) were stirred 
in 3 mL anhydrous DMF for one hour at 0 °C under a nitrogen atmosphere. 105 (100 mg; 0.17 
mM) dissolved in 2 mL anhydrous DMF was added dropwise. The solution was warmed to room 
temperature and stirred for 72 hours. The solvent was removed in vacuo and the residue purified 
by flash column chromatography (1:9:90 NH4OH:MeOH:DCM) to give 36 mg of 118 as a sticky 
orange resin (0.05 mM; 27%). 
 Rf: 0.22 (NH4OH:MeOH:DCM 1:9:90). 
1H NMR (300 MHZ, chloroform-d)  ppm 0.98-1.09 
(m, 2H, piperidine-CH 2), 1.14 - 1.34 (m, 2H, piperidine-CH(ax) 3), 1.61 (d, J=10.74 Hz, 2H, 
piperidine-CH(eq) 3), 1.80 - 1.93 (m, 2H, piperidine-CH(ax) 4), 1.95 - 2.09 (m, 2H, CH2 6), 2.44 (t, 
J=7.16 Hz, 2H, piperidine-CH2 5), 2.79 - 2.91 (m, 2H, piperidine-CH(eq) 4), 3.53 - 3.72 (m, 4H, CH2 
19), 3.79 (s, 2H, thiazole-CH2 13), 3.84 (br. s., 3H, O-CH3 10),  3.93 (d, J=6.03 Hz, 1H, piperidine-CH2 
1), 4.06 - 4.17 (m, 4H, O-CH3 10, CH2 18), 4.48 (s, 2H, CH2 benzyl), 6.43 (d, J=5.46 Hz, 1H, 
quinazoline 11), 6.70 (br. s., 1H, fluroaniline 16),  7.06 - 7.34 (m, 8H, thiazole 12, CH benzyl, 
fluroaniline 14, fluroaniline 17), 7.44 (d, J=9.80 Hz, 1H, fluroaniline 15), 8.17 (br. s., 1H, 
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quinazoline 8), 8.60 - 8.96 (m, 1H, quinazoline 9).13C NMR (75 MHZ, chloroform-d)  ppm 24.96, 
25.57, 26.44, 28.88, 33.69, 35.29, 35.68, 39.07, 49.17, 53.27, 55.16, 56.28, 67.69, 68.59, 69.09, 
69.37, 70.67, 70.93, 73.25, 106.71, 107.26, 107.60, 108.56, 110.93, 111.22, 115.22, 127.63, 
128.38, 129.92, 130.04, 138.17, 139.60, 149.36, 149.94, 154.33, 164.51, 167.97, 170.61. υmax (thin 
film, cm-1): 2926, 2850, 1601, 1540, 1272, 1193, 1104, 892, 739, 697. MS: C40H45FN6O7S m/z (ES
+) 
773.31 [M+H]+. HRMS: Calculated C40H46FN6O7S 733.3133, found: 733.3138. 
 
(1-(3-(4-(5-(2-(3-fluorophenylamino)-2-oxoethyl)thiazol-2-ylamino)-6-methoxy-4a,8a-di 
hydroquinazolin-7-yloxy)propyl)piperidin-4-yl)methyl-2-(2-(2 benzyloxy)ethoxy)ethoxy)acetate 
(119).  
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 116 (53 mg; 0.21 mM), HATU (79 mg; 0.21 mM) and DIPEA (33 μL; 0.19 mM) were stirred 
in 3 mL anhydrous DMF for one hour at 0 °C under a nitrogen atmosphere. 105 (110 mg; 0.19 
mM) dissolved in 2 mL anhydrous DMF was added dropwise. The solution was warmed to room 
temperature and stirred for 72 hours. The solvent was removed in vacuo and the residue purified 
by flash column chromatography (1:9:90 NH4OH:MeOH:DCM) to give 44 mg of 119 as a sticky 
orange resin (0.05 mM; 28%). 
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 Rf: 0.28 (NH4OH:MeOH:DCM 1:9:90). 
1H NMR (300 MHZ, chloroform-d)  ppm  0.81 - 0.91 
(m, 1H, piperidine-CH 2), 1.26 (m, 2H, piperidine-CH(ax) 3), 1.33 (d, J=9.80 Hz, 2H, piperidine-CH(eq) 
3), 1.65 - 1.74 (m, 2H, piperidine-CH(ax) 4), 1.92 - 2.13 (m, 3H, CH2 6, piperidine-CH(eq) 4), 2.55 (t, 
J=6.97 Hz, 2H, piperidine-CH2 5), 2.96 (d, J=10.93 Hz, 1H, piperidine-CH(eq) 4), 3.59 - 3.80 (m, 8H, 
CH2 19),  3.86 (br. s., 2H, thiazole-CH2 13),  4.00 (d, J=5.65 Hz, 3H, O-CH3 10), 4.07 - 4.20 (m, 4H, 
piperidine-CH2 1, CH2 18), 4.55 (s, 2H, CH2 benzyl), 6.77 (m, 1H, fluroaniline 16), 7.06 - 7.38 (m, 9H, 
fluroaniline 14, fluroaniline 17, thiazole 12, quinazoline 11, CH benzyl), 7.51 (d, J=9.98 Hz, 1H, 
fluroaniline 15), 7.92 – 8.11 (m, 1H, quinazoline 8), 8.57 - 8.82 (m, 1H, quinazoline 9). 13C NMR (75 
MHZ, chloroform-d)  ppm 14.20, 21.09, 26.20, 28.59, 35.10, 50.65, 53.16, 53.48, 55.11, 56.18, 
60.46, 67.53, 68.54, 68.93, 69.35, 70.63, 70.90, 73.25, 107.27, 107.62, 111.04, 115.27, 127.65, 
127.78, 128.38, 129.97, 130.09, 138.10, 149.88, 161.24, 164.48, 168.02, 170.61, 171.29. υmax (thin 
film, cm-1): 2924, 2850, 1646, 1541, 1272, 1194, 1086, 892, 697. MS: C42H49FN6O8S m/z (ES
+) 
817.34 [M+H]+. HRMS: Calculated C42H49FN6O8S 817.3395, found: 817.3403. 
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6.6 Synthesis of alternative carriers section (3.1). 
6.6.1. Serine component (section 2.3 and 3.1). 
(S)- 9-Fluorenylmethoxycarbonyl-O-benzyl-L-aspartic acid-tert-butyl ester (48). 
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 N-9-Fluorenylmethoxycarbonyl-O-tert-butyl-L-aspartic acid (46) (4.998 g; 11.97 mM) was 
dissolved in 10 ml anhydrous DCM under a nitrogen atmosphere at room temperature. Tert-butyl-
2,2,2-trichloroacidimidate (4.29 mL; 23.95 mM) was added dropwise, followed by 5ml Et2O. The 
reaction mixture was stirred for 72 days at room temperature, before being cooled to -20˚C and 
left unstirring for 30 minutes. The reaction was filtered to remove the white precipitate and the 
solvent reduced in vacuo to give a brown foam.  Purification was attained by flash column 
chromatography (1:4 Pet ether: EtOAC) to give 5.574 g of 48 as a white solid (11.77 mM; 98%). 
 Rf: 0.62 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHZ, chloroform-d)  ppm  1.49 (s, 9H, CH3 
tert-butyl), 3.73 (ABdd, J=8.70, 3.60 Hz, 1H, CH2-serine), 3.92 (dd, J=9.32, 2.92 Hz, 1H, CH2-serine), 
4.26 (t, J=7.54 Hz, 1H, CH-Fmoc), 4.35 - 4.48 (m, 2H, CH2-Fmoc, CH-serine), 4.49 - 4.66 (AB, 2H, 
CH2-benzyl), 5.75 (d, J=8.67 Hz, 1H, NH), 7.26 - 7.48 (m, 9H, CH aromatic) 7.65 (d, J=6.59 Hz, 2H, 
CH-Fmoc aromatic), 7.79 (d, J=7.35 Hz, 2H, CH-Fmoc aromatic). 13C NMR (75 MHZ, chloroform-d)  
ppm 28.02, 47.13, 50.89, 54.87, 67.17, 70.24, 73.41, 119.99, 125.24, 127.10, 127.73, 127.87, 
128.46. 
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This compared to data previously recorded by Foley et al. in the group, so no further 
characterisation was carried out. 116,117 
 Rf: 0.48 (CHCl3). 
1H NMR (300 MHZ, chloroform-d)  ppm  1.49 (s, 9H), 3.90 (ABdd, J = 9.4 
& 2.6, 2H), 4.25 (t, J = 7.2, 1H), 4.53-4.38 (m, 3H), 4.57 (ABd, J = 12.1, 2H), 5.72 (d, J = 6.8, 1H), 
7.45-7.26 (m, 9H), 7.68-7.62 (m, 2H), 7.81-7.76 (m, 2H). 13C NMR (75 MHZ, chloroform-d)  ppm 
28.4. 47.5, 55.31, 67.5, 70.6, 73.8, 82.7, 120.3, 125.6, 127.5-127.8, 138.0, 141.7-144.4, 156.4, 
169.7. υmax (thin film, cm
-1): 3340, 3053, 2974, 1726, 1515, 1247, 1153. [α]D
25 (CHCl3; c = 0.54): + 
7.0. MS: C29H31NO5 m/z (ES
+) 496.2 [M+Na]+. HRMS: Calculated for C29H31NNaO5 496.2100, found 
496.2115. 
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(S)-benzyl-2-amino-3-tert-butoxypropanoate (50). 
H2N
O
O
O
 
Previously published data by the group: Foley et al.116,117 
Method 1 (section 2.3 and section 3.1). 
 48 (2.513 g; 5.31 mM) was dissolved in 10 mL of anhydrous THF under a nitrogen 
atmosphere.  The reaction was cooled to 0°C and a 1.0 M solution of TBAF in THF (5.84 mL) was 
added dropwise.  The reaction was stirred at 0°C for 30 minutes, and allowed to proceed a further 
2-3 hours at room temperature, monitored by TLC. The solvent was removed in vacuo to yield a 
sticky pink residue which was taken up into 20 mL of water.  The pH of the solution was adjusted 
to pH 2 using 2 M HCl, and 20 mL of EtOAc added.  The aqueous layer was separated and 
extracted with a further two 10mL portions of EtOAc. The aqueous phase was adjusted to pH 8-9 
using 2 M NaOH, and extracted with one 20 mL and two 10 mL portions of EtOAc.  The EtOAc 
portions from the basic aqueous extraction were combined, dried over anhydrous MgSO4 and 
filtered. The solvent was reduced in vacuo, to give 1.043 g of 50 as a clear oil (4.15 mM; 78%). 
Method 2 (section 2.3) 
 O-benzyl-L-aspartic acid (100 mg; 0.45 mM) was dissolved in 1.8ml of tert-butyl acetate 
under a nitrogen atmosphere. Perchloric acid (30 μL; 0.49 mM) was added dropwise, the reaction 
heated to 50˚C and stirred for 2 days.  The solution was diluted with 20 mL water and the pH of 
the solution adjusted to pH 8-9 using 2 M NaOH, and extracted with one 20 mL and two 10 mL 
portions of EtOAc.  The EtOAc were combined, dried over anhydrous MgSO4 and then filtered. The 
solvent was reduced in vacuo, to give 111 mg of 50 as a clear oil (0.44 mM; 99%). 
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Rf 0.43 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, methanol-d4) ppm 1.46 (s, 9H, CH3 tert-butyl), 
3.50 (dd, J=4.52, 3.96 Hz, 1H, CH serine), 3.61 - 3.80 (m, 2H, CH2 serine), 4.54 (m, J=9.98 Hz, 2H, 
CH2-benzyl), 7.15 - 7.44 (m, 5H, CH aromatic).
 13C NMR (75 MHz, methanol-d4)  28.29, 55.99, 
73.11, 74.33, 82.52, 128.76, 128.89, 129.38, 139.37, 173.92.  
This compared to data previously recorded by Foley et al. in the group, so no further 
characterisation was carried out.116,117 
Rf: 0.35 (95:5 CHCl3:CH3OH). 
1H NMR (400 MHz, chloroform-d) ppm 1.47 (s, 9H), 3.68-3.48 (m, 
1H), 3.79-3.68 (m, 2H), 4.55 (AB, J =12.6, 2H), 7.40-7.28 (m, 5H). 13C NMR (100 MHz, chloroform-
d) ppm 28.4, 55.8, 72.8, 73.7, 81.7. 128.0, 128.1, 128.8, 138.4, 173.4. [α]D
25 (CHCl3; c = 1.08): − 
5.9. υmax (thin film, cm
-1): 3382, 2988, 2924, 2864, 1729, 1601, 1377, 1242, 1164. MS: C14H21NO3 
m/z (ES+) 251.2 [M+H]+.HRMS: Calculated for C14H22NO3 252.1599, found 252.1590. 
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6.6.2. Cycloleucine-serine carrier (section 3.1). 
1-(tert-butoxycarbonyl)cyclopentanecarboxylic acid (158). 
OH
O
N
H
O
O
 
 Cycloleucine (157) (2.000 g; 15.48 mM) was dissolved in 20ml acetonitrile at 0˚C. TEA 
(10.79 mL; 77.41 mM) was added dropwise, followed by 1 M NaOH (15.48 mL; 15.48 mM) and the 
reaction stirred for 10 minutes. After the addition of di-tert-butyl dicarbonate (5.069 g; 23.22 
mM), the reaction was brought to room temperature and stirred vigorously for 4 hours, during 
which time a white precipitate formed. The solvent was removed in vacuo to give a white solid 
which was dissolved in 100 mL EtOAc:water (1:1).  The organic phase was separated and washed 
with three 20 mL portions of water. The aqueous phases were combined and the pH adjusted to 
pH 2 with 2 M HCl. The acidified aqueous phase was extracted with three 20 mL portions of 
EtOAC, which were combined and washed with one 20 mL portion of water and one 10 mL 
portion of brine. The organic phase was dried over anhydrous MgSO4, filtered and reduced in 
vacuo to give 2.311 g of 158 as a white solid (1.00 mM, 65%). 
 Rf: 0.425 (EtOAc:MeOH 9:1). 
1H NMR (300 MHZ, chloroform-d)  ppm 1.44 (s, 9H, CH3 
Boc), 1.76 (dt, J = 7.35, 3.49 Hz, 4H (CH2)2 cycloleucine), 1.90 - 2.01 (m, 2H, CH-CH2-CH2-CH 
cycloleucine), 2.09 - 2.23 (m, 2H, CH-CH2-CH2-CH cycloleucine).
13C NMR (75 MHz, methanol-d4) 
25.4, 28.8, 38.15, 66.9, 80.1, 157.6, 178.6. υmax (thin film, cm
-1): 3244, 2971, 2502, 1698, 1643, 
1403, 1260, 1156, 942, 776, 669. [α]D
25 (CHCl3; c = 0.0157): + 10.19 MS: C11H19NO4, m/z (ES
+) 
228.12 [M-H]+. HRMS: Calculated for C11H19NO4 229.1314, found 228.1236. MP 137˚C (Lit: 129-
135-Sigma Aldrich). 
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(S)-tert-butyl 3-(benzyloxy)-2-(1-(tert-butoxycarbonyl)cyclopentanecarboxamido)propanoate 
(159). 
H
N
O
O
O
O
N
H
O
O
 
 158 (254 mg; 1.11 mM) and 50 (253 mg; 1.01 mM) were dissolved in 5 mL anhydrous DMF 
under nitrogen atmosphere at 0˚C. DIPEA (351 μL; 2.01 mM) was added dropwise and the 
reaction stirred for 10 minutes prior to the dropwise addition of DPPA (239 μL; 1.11 mM). The 
solution was stirred at 0˚C for 72 hours after which the solvent was removed in vacuo. The residue 
was dissolved in 20 mL EtOAc and washed with two 10 mL portions of NH4Cl, two 10 Na2CO3 and 
one 20 mL portion of brine. The organic layer was dried over anhydrous MgSO4, filtered and the 
solvent removed in vacuo to give 451 mg of 159 as a white solid (0.97 mM; 96%). 
 Rf: 0.50 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, methanol-d4) ppm 1.42 (s, 9H, CH3 
Boc), 1.45 (s, 9H, CH3 tert-butyl) 1.68 - 1.78 (m, 4H, (CH2)2 cycloleucine), 1.83 - 1.98 (m, 2H, CH-
CH2-CH2 CH-cycloleucine), 2.09 - 2.27 (m, 2H, CH-CH2-CH2-CH cycloleucine), 3.67 (ABdd, J=9.42, 
3.01 Hz, 1H, CH2 serine), 3.82 (ABdd, J=9.42, 3.58 Hz, 1H, CH2 serine),  4.45 - 4.59 (m, 3H, CH 
serine, CH2-benzyl), 7.17 - 7.42 (m, 5H, CH benzyl), 7.50 - 7.63 (m, 1 H, NH serine).
 13C NMR (75 
MHz, methanol -d4) 25.35, 25.41, 28.34, 28.86, 37.35, 38.05, 54.83, 67.87, 71.05, 74.35,  80.66, 
83.22, 121.32, 124.51, 128.87, 129.44, 130.31, 139.15, 157.06, 170.58, 177.02. υmax (thin film, cm
-
1): 3310, 2977-2867, 1681, 1520, 1389, 1250, 1152, 1099, 732. [α]D
25 (CHCl3; c = 0.0128): + 16.22. 
MS: C25H38N2O6, m/z (ES
+) 463.28 [M+H] +. HRMS: Calculated C25H39N2O6 463.2730, found 
463.2795. MP: 72.3˚C 
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(S)-2-(1-aminocyclopentanecarboxamido)-3-(benzyloxy)propanoic acid (163). 
H
N
O
OH
O
O
H2N
 
 159 (50 mg, 0.11 mM) was dissolved 5 mL 97% formic acid and refluxed at 100°C for three 
hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. The 
residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass wool 
and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 35 mg of 163 as a white 
solid in formate salt form (0.10 mM; 96%). 
 1H NMR (300 MHz, methanol -d4) ppm 1.68 - 1.86 (m, 2H, CH-CH2-CH2-CH cycloleucine), 
1.95 (m, 4H, (CH2)2 cycloleucine), 2.07 - 2.48 (m, 2H, CH-CH2-CH2-CH  cycloleucine), 3.68 - 3.94 (m, 
2H, CH2 serine), 3.99 - 4.13 (m, 1H, CH serine), 4.43 - 4.68 (m, 2H, CH2-benzyl), 7.25 - 7.44 (m, 5H, 
CH benzyl). 13C NMR (75 MHz, methanol-d4) ppm 25.77, 25.87, 26.51, 37.26, 37.65, 37.82, 38.10, 
55.78, 67.54, 71.55, 74.05, 128.73, 128.95, 129.13, 129.38, 129.55, 139.54, 165.37, 172.73. υmax 
(thin film, cm-1): 2955, 2870, 1654, 1584, 1385, 1100, 737. MS: C16H22N2O4, m/z (ES
+) 306.16 [M+H] 
+. HRMS: Calculated C16H23NO4 307.1658, found 307.1652.  
 
  
179 
 
(S)-tert-butyl 2-(1-(tert-butoxycarbonyl)cyclopentanecarboxamido)-3-hydroxypropanoate (160). 
H
N
OH
O
O
O
N
H
O
O
 
 159 (998 mg, 2.16 mM) was dissolved in 5 mL MeOH. 10% Pd/C (100 mg) was added and 
the suspension stirred under a hydrogen atmosphere at room temperature for 24 hours. The 
reaction mixture was filtered through a Celite® bed and the organic solvent removed in vacuo. 796 
mg of 160 was obtained as a white solid (2.13 mM, 99%). 
 Rf: 0.32 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, methanol-d4) ppm 1.45 (s, 9H, CH3 
Boc), 1.49 (s, 9H, CH3 tert-butyl), 1.75 (dt, J=7.21, 3.46 Hz, 4H, (CH2)2 cycloleucine), 1.84 - 1.97 (m, 
2H, CH-CH2-CH2-CH cycloleucine), 2.10 - 2.33 (m, 2H, CH-CH2-CH2-CH cycloleucine), 3.84 (ABq, 
J=3.77 Hz, 2H, CH2-benzyl), 4.28 - 4.38 (m, 1H, CH serine), 7.59 (d, J=7.16 Hz, 1H, NH serine). 
13C 
NMR (75 MHz, methanol-d4) ppm 25.36, 28.29, 28.76, 37.55, 37.91, 56.87, 62.99, 67.97, 80.80, 
83.14, 160.30, 170.93, 177.12. υmax (thin film, cm
-1): 3306, 2976. 1682, 1514, 1367, 1158, 734. 
[α]D
25 (CHCl3; c = 0.0143): +11.23. MS: C18H32N2O6, m/z (ES
+) 373.23 [M+H]+. HRMS: Calculated for 
C18H33N2O6 373.2339, found 373.2330. MP: 117.4˚C 
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(S)-2-(1-aminocyclopentanecarboxamido)-3-hydroxypropanoic acid (155). 
H
N
OH
OH
O
O
H2N
 
 160 (52 mg, 0.14 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 29 mg of 155 as a 
white solid in formate salt form (0.14 mM; 97%). 
 1H NMR (300 MHz, methanol -d4) ppm 1.67 - 1.88 (m, 2H, CH-CH2-CH2-CH cycloleucine), 
1.95 (m, 4H, (CH2)2 cycloleucine), 2.07 - 2.49 (m, 2H, CH-CH2-CH2-CH  cycloleucine), 3.69 - 3.95 (m, 
2H, CH2 serine), 4.54 (m, 1H, CH serine). 
13C NMR (75 MHz, methanol-d4) ppm 25.78, 25.92, 
26.50, 37.22, 37.65, 37.83, 38.10, 55.92, 68.32, 74.16, 165.21, 172.84. υmax (thin film, cm
-1): 3239, 
2943, 1396, 742, 621, 517. MS: C9H16N2O4, m/z (ES
+) 217.19 [M+H]+. HRMS: Calculated C9H16N2O4 
217.1188, found 217.1186. 
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(S)-2-(1-(tert-butoxycarbonylcyclopentanecarboxamido)-3-((R)-2-(4 
isobutylphenyl)propanoyloxy) propanoic acid tert-butyl ester (161). 
H
N
O
O
O
O
N
H
O
O
O
 
 Ibuprofen (77) (150 mg, 0.71 mM), DCC (165 mg, 0.80 mM) and DMAP (88 mg, 0.71 mM) 
were dissolved in 5 mL anhydrous DCM under a nitrogen atmosphere at 0˚C and left to stir for 30 
minutes. 160 (284 mg, 0.76 mM) in 2 mL anhydrous DCM was added and reaction mixture stirred 
at room temperature for 72 hours. The solution was filtered and the solvent removed in vacuo. 
The resultant white solid was purified by flash column chromatography (a gradient of 2:8 to 7:3 
EtOAc: pet ether) to give 328 mg of 161 as a colourless oil (0.58 mM, 82%). 
 Rf: 0.68 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, methanol-d4)  ppm 0.92 (d, J=6.59 Hz, 
6H, Ibu-CH(CH3)2), 1.42 (s, 9H, CH3 tert-butyl), 1.45 (s, 9H, CH3 Boc), 1.47 (s, 3H, Ibu-CH3), 1.68 - 
1.78 (m, 4H, (CH2)2-cycloleucine), 1.80 - 1.92 (td, J=13.42, 6.50 Hz, 1H, Ibu-CH(CH3)2), 1.96 - 2.08 
(m, 2H, CH-CH2-CH2-CH cycloleucine), 2.13 - 2.28 (m, 2H, CH-CH2-CH2-CH cycloleucine), 2.47 (d, 
J=7.16 Hz, 2H, Ibu-CH2CH), 3.73 (q, J=7.10 Hz, 1H, Ibu-CHCH3), 4.40 (m, J=3.77 Hz, 2H, CH2 serine), 
4.47 - 4.53 (m, 1H, CH serine), 7.10 - 7.23 (m, 4H, Ibu-CH aromatic), 7.54 (br. s., 1H, NH serine). 
13C 
NMR (75 MHz, methanol-d4) ppm 19.14, 22.79, 25.30, 25.32, 28.18, 28.79, 31.52, 37.24, 46.08, 
46.23, 54.21, 64.82, 67.84, 80.74, 83.71, 128.35, 130.52, 139.04, 169.74, 175.78. υmax (thin film, 
cm-1): 2956, 2471, 1738, 1367, 1153, 759, 497. MS: C31H48N2O7, m/z (ES
+) 561.35 [M+H]+. HRMS: 
Calculated C31H49N2O7 561.3534, found 561.3531. 
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(S)-2-(1-aminocyclopentanecarboxamido)-3-((R)-2-(4-isobutylphenyl)propanoyloxy)propanoic 
acid (162). 
H
N
O
OH
O
O
H2N
O
 
 161 (214 mg, 0.38 mM) was dissolved 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 168 mg of 162 as a 
white solid in formate salt form (0.37 mM; 98%). 
 1H NMR (300 MHz, methanol-d4) ppm 0.91 (d, J=6.59 Hz, 6H, Ibu-CH(CH3)2), 1.44 (d, 
J=7.16 Hz, 3H, Ibu-CH3), 1.68 - 2.00 (m, 7H, CH2 cycloleucine, Ibu-CH(CH3)2), 2.18 - 2.34 (m, 2H, CH2 
cycloleucine), 2.46 (d, J=7.16 Hz, 2H, Ibu-CH2CH), 3.74 (q, J=6.97 Hz, 1H, Ibu-CHCH3), 4.35 - 4.59 
(m, 3H, CH2 serine, CH serine), 7.01 - 7.28 (m, 4H, Ibu-CH aromatic). 
13C NMR (75 MHz, methanol-
d4) ppm 18.87, 22.77, 25.81, 25.92, 31.51, 37.21, 38.08, 46.03, 46.08, 55.21, 65.57, 67.29, 
128.38, 130.44, 139.22, 176.37. υmax (thin film, cm
-1): 2954-2868, 1738, 161, 1488, 1393, 1328, 
1151, 1066, 545. MS: C22H35N2O5, m/z (ES
+) 403.22 [M+H]+. HRMS: Calculated C22H34N2O5 
403.2238, found 403.2230. 
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6.6.3. Cyclopropane-serine carrier (section 3.1). 
(S)-tert-butyl 3-(benzyloxy)-2-(1-(tert-butoxycarbonyl)cyclopropanecarboxamido)propanoate 
(165) 
H
N
O
O
O
O
N
H
O
O
 
 1-(tert-butoxycarbonyl)cyclopropanecarboxylic acid (164) (501 mg; 2.49 mM) and 50 (569 
mg; 2.26 mM) were dissolved in 5 mL anhydrous DMF under nitrogen  atmosphere at 0˚C. DIPEA 
(788 μL; 4.53 mM) was added dropwise and the reaction stirred for 10 minutes prior to the 
dropwise addition of DPPA (537 μL; 2.49 mM). The solution was stirred at 0˚C for 72 hours after 
which the solvent was removed in vacuo. The residue was dissolved in 20 mL EtOAc and washed 
with two 10 mL portions of NH4Cl, two 10 mL potrions of Na2CO3 and one 20 mL portion of brine. 
The organic layer was dried over anhydrous MgSO4, filtered and the solvent removed in vacuo to 
give 871 mg of 165 as a white solid (2.00 mM; 89%). 
 Rf: 0.40 (EtOAc:Pet ether 4:6).
1H NMR (300 MHz, methanol-d4) ppm 1.02 - 1.09 (m, 2H, 
CH –CH cyclopropane), 1.44 (s, 9H, CH3 Boc), 1.46 (s, 11H, CH3 tert-butyl, CH –CH cyclopropane), 
3.70 (ABdd, J=9.42, 3.20 Hz, 1H, CH2 serine), 3.90 (ABdd, J=9.42, 3.39 Hz, 1H, CH2 serine), 4.45 - 
4.61 (m, 3H, CH2-benzyl, CH serine), 7.25 - 7.39 (m, 5H, CH benzyl), 7.61 (d, J=7.72 Hz, 1H, NH 
serine). 13C NMR (75 MHz, methanol-d4)  ppm 17.80, 28.29, 28.70, 36.09, 55.07, 70.96, 74.35, 
81.11, 83.36, 128.83, 129.44, 139.16, 158.09, 170.41, 174.72. υmax (thin film, cm
-1): 2977-2841, 
2446, 1721, 1648, 1443, 1390, 1365, 1256, 1160, 1111, 746. [α]D
25 (CHCl3; c = 0.0122): + 5.63. MS: 
C23H34N2O6, m/z (ES
+) 435.25 [M+H]+. HRMS: Calculated C23H35N2O6 435.2495, found 435.2493. 
MP:  73.2˚C 
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(S)-2-(1-aminocyclopropanecarboxamido)-3-(benzyloxy)propanoic acid (166).  
H
N
O
OH
O
O
H2N
 
 165 (92 mg, 0.21 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 67 mg of 166 as a 
yellow resin in formate salt form (0.21 mM; 97%). 
 1H NMR (300 MHZ, chloroform-d)  ppm 0.98 - 1.12 (m, 2H, CH-CH cyclopropane), 1.39 - 
1.58 (m, 2H, CH-CH cyclopropane), 3.69 - 3.98 (m, 2H, CH2 serine),  4.49 - 4.66 (m, 3H, CH2 serine, 
CH serine), 7.20 - 7.42 (m, 5H, CH benzyl). 13C NMR (75 MHZ, chloroform-d)  ppm 17.30, 34.62, 
71.15, 74.19, 126.67, 129.13, 139.28, 165.13, 173. υmax (thin film, cm
-1): 3293-2868,1654, 1508, 
1392, 1199, 1098, 735, 696. MS: C14H18N2O4, m/z (ES
+) 279.13 [M+H+]. HRMS: Calculated 
C14H19N2O4 279.1345, found 279.1345 
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(S)-tert-butyl 2-(1-(tert-butoxycarbonyl)cyclopropanecarboxamido)-3-hydroxypropanoate (167). 
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 165 (600 mg, 1.38 mM) was dissolved in 5 mL MeOH. 10% Pd/C (100 mg) was added and 
the suspension stirred under a hydrogen atmosphere at room temperature for 24 hours. The 
reaction mixture was filtered through a Celite® bed and the organic solvent removed in vacuo. 466 
mg of 167 was obtained as a  yellow solid (1.35 mM, 98%). 
 Rf: 0.05 (EtOAc:pet ether 4:6). 
1H NMR (300 MHz, methanol-d4)  ppm 1.06 (d, J=3.20 Hz, 
2H, CH –CH cyclopropane), 1.45 (d, J=3.58 Hz, 2H, CH –CH cyclopropane), 1.49 (s, 9H, CH3 Boc), 
1.50 (s, 9H, CH3 tert-butyl), 3.78 - 3.95 (ABq, 2H, CH2 serine), 4.34 (br. s., 1H, CH serine), 7.63 (d, 
J=6.03 Hz, 1H, NH serine). 13C NMR (75 MHz, methanol-d4) ppm 17.29, 18.13, 28.31, 28.71, 
36.11, 57.03, 62.90, 81.29, 83.34, 158.33, 170.73, 174.71. υmax (thin film, cm
-1): 3313, 2973, 1679, 
1515, 1366, 1280, 1157, 847. [α]D
25 (CHCl3; c = 0.0194): + 25.73. MS: C16H28N2O6, m/z (ES
+) 345.120 
[M+H]+. HRMS: Calculated C16H29N2O6 345.2026, found 345.2029. MP:  112.6˚C 
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(S)-2-(1-aminocyclopropanecarboxamido)-3-hydroxypropanoic acid (153). 
H
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 167 (66 mg, 0.19 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 42 mg of 153 as a 
yellow resin in formate salt form (0.18 mM; 93%). 
 1H NMR (300 MHz, methanol-d4)  ppm 1.10 (m, J=3.58 Hz, 2H, CH-CH cyclopropane), 1.20 
(m, J=3.58 Hz, 1H, CH cyclopropane), 1.44 - 1.58 (m, 2H, CH –CH cyclopropane), 3.75 - 4.07 (m, 2H, 
CH2 serine), 4.41 - 4.55 (m, 1H, CH serine), 8.16 (s, 1H, NH serine). 
13C NMR (75 MHz, methanol-d4) 
 ppm 17.51, 17.69, 34.6, 55.31, 62.91, 165.47, 173.53. υmax (thin film, cm
-1): 2953, 2874, 1648, 
1518, 1383, 1208, 1046. MS: C7H12N2O4, m/z (ES
+) 189.09 [M+H]+. HRMS: Calculated C7H13N2O4 
189.0875, found 189.0872. 
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(S)-2-(1-(tert-butoxycarbonylcyclopropanecarboxamido)-3-((R)-2-(4-
isobutylphenyl)propanoyloxy)propanoic acid tert-butyl ester (168). 
H
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O
 
 Ibuprofen (77) (228 mg, 1.10 mM), DCC (251 mg, 1.22 mM) and DMAP (135 mg, 1.10 mM) 
were dissolved in 5 mL anhydrous DCM under a nitrogen atmosphere at 0˚C and left to stir for 30 
minutes. 167 (400 mg, 1.16 mM) in 2 mL anhydrous DCM was added and reaction mixture stirred 
at room temperature for 72 hours. The solution was filtered and the solvent removed in vacuo. 
The resultant white solid was purified by flash column chromatography (a gradient of 2:8 to 7:3 
EtOAc: pet ether) to give 457 mg of 168 as a colourless oil (0.86 mM, 76%). 
 Rf: 0.58 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, methanol-d4) ppm 0.92 (d, J=6.6, 6H, 
Ibu-CH(CH3)2), 1.05 (m, 2H, CH –CH cyclopropane), 1.33 (s, 2H, CH –CH cyclopropane), 1.41 (s, 9H, 
CH3 Boc), 1.43 - 1.51 (m, 12H, CH3 tert-butyl, Ibu-CH3), 1.86 (dt, J=13.54, 6.88 Hz, 1H, Ibu-
CH(CH3)2),  2.47 (d, J=7.16 Hz, 2H, Ibu-CH2CH), 3.73 (m, 1H, Ibu-CHCH3), 4.47 (m, 3H, CH2 serine, 
CH serine), 7.09 - 7.23 (m, 4H, Ibu-CH aromatic). 
13C NMR (75 MHz, methanol-d4)  ppm 17.89, 
19.33, 22.78, 28.17, 28.72, 31.51, 36.77, 46.07, 46.34, 54.16, 64.86, 81.18, 83.85, 128.38, 130.49, 
138.99, 141.82,169.35, 175.83. υmax (thin film, cm
-1): 2974, 1737.1650, 1447, 1392, 1160, 631, 
497. MS: C29H44N2O7, m/z (ES
+) 533.32 [M+H]+. HRMS: Calculated C29H45N2O7 533.3227, found 
533.3230 
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(S)-2-(1-aminocyclopropanecarboxamido)-3-((R)-2-(4-isobutylphenyl)propanoyloxy)propanoic 
acid (169). 
H
N
O
OH
O
O
H2N
O
 
 168 (72 mg, 0.14 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 55 mg of 169 as a 
white solid in formate salt form (0.13 mM; 97%). 
 1H NMR (300 MHz, methanol-d4)  ppm 0.91 (d, J=6.4, 6H, Ibu-CH(CH3)2), 1.04-1.36 (m, 
4H, CH2 cyclopropane), 1.46 (d, 3H, J=4.1, Ibu-CH3), 1.85 (m, 1H, Ibu-CH(CH3)2),  2.46 (d, J=7 Hz, 2H, 
Ibu-CH2CH), 3.78 (m, 1H, Ibu-CHCH3), 4.30-4.60 (m, 3H, CH2 serine, CH serine), 6.98 - 7.32 (m, 4H, 
Ibu-CHar), 8.11 (br. s, 1H, NH serine). 
13C NMR (75 MHz, methanol-d4)  ppm 17.71, 18.73, 22.72, 
31.50, 35.66, 46.03, 46.06, 54.06, 65.32, 128.32, 129.03, 139.06, 141.78, 175.30. υmax (thin film, 
cm-1): 2955, 1682, 1532, 1395, 1150, 1069, 525. MS: C20H28N2O5, m/z (ES
+) 377.21 [M+H]+. HRMS: 
Calculated C20H29N2O5 377.2077, found 377.2081. 
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6.6.4. Cyclobutane carrier (section 3.1). 
(S)-tert-butyl 3-(benzyloxy)-2-(1-(tert-butoxycarbonyl)cyclobutanecarboxamido)propanoate 
(171). 
H
N
O
O
O
O
N
H
O
O
 
 1-(tert-butoxycarbonyl)cyclobutanecarboxylic acid (170) (532 mg; 2.47 mM) and 50 (565 
mg; 2.25 mM) were dissolved in 5 mL anhydrous DMF under nitrogen  atmosphere at 0˚C. DIPEA 
(783 μL; 4.49 mM) was added dropwise and the reaction stirred for 10 minutes prior to the 
dropwise addition of DPPA (533 μL; 2.47 mM). The solution was stirred at 0˚C for 72 hours after 
which the solvent was removed in vacuo. The residue was dissolved in 20 mL EtOAc and washed 
with two 10 mL portions of NH4Cl, two 10 Na2CO3 and one 20 mL portion of brine. The organic 
layer was dried over anhydrous MgSO4, filtered and the solvent removed in vacuo to give 919 mg 
of 171 as a white solid (0.20 mM; 91%). 
 Rf: 0.45 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, chloroform-d) ppm 1.42 (s, 9H, CH3 
Boc), 1.45 (s, 9H, CH3 tert-butyl), 2.01 (m, J=8.10 Hz, 2H, CH-CH2-CH cyclobutane), 2.09 - 2.21 (m, 
2H, CH-CH2-CH cyclobutane), 2.60 - 2.80 (m, 2H, CH2-CH2-CH2 cyclobutane), 3.66 (ABdd, J=9.23, 
3.20 Hz, 1H, CH2 serine), 3.89 (ABdd, J=9.40, 3.20 Hz, 1H, CH2 serine), 4.41 - 4.60 (ABq, 2H, CH2 
benzyl), 4.64 (dt, J=8.10, 3.11 Hz, 1H, CH serine), 7.26 - 7.35 (m, 5H, CH benzyl). 13C NMR (75 MHZ, 
chloroform-d)  ppm 16.18, 28.32, 28.74, 31.75, 56.67, 60.12, 70.21, 73.35, 80.41, 83.15, 126.53, 
128.62, 129.37, 139.20, 156.02, 170.43, 177.28. υmax (thin film, cm
-1): 3436, 3308, 2979, 1728, 
1495, 1634, 1392, 1290, 1253, 1155, 1084, 846. [α]D
25 (CHCl3; c = 0.0097): + 4.20. MS: C24H36N2O6, 
m/z (ES+) 449.27 [M+H]+. HRMS: Calculated C24H37N2O6 449.2652, found 449.2638. MP:  74.2˚C 
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(S)-2-(1-aminocyclobutanecarboxamido)-3-(benzyloxy)propanoic acid (172).  
H
N
O
OH
O
O
H2N
 
 171 (143 mg, 0.32 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 99 mg of 172 as a 
white solid in formate salt form (0.29 mM; 92%). 
 1H NMR (300 MHz, methanol-d4)  ppm 1.90 - 2.49 (m, 5H, CH2-CH2-CH2  cyclobutane, CH2-
CH-CH2 cyclobutane), 2.55 - 2.74 (m, 1H, CH2-CH-CH2 cyclobutane), 3.72 - 3.97 (m, 2H, CH2 serine), 
4.05 - 4.15 (m, 1H, CH serine), 4.46 - 4.66 (m, 2H, CH2-benzyl), 7.27 - 7.45 (m, 4H, CH benzyl), 8.34 
- 8.46 (m, 1H, NH serine). 13C NMR (75 MHz, methanol-d4) ppm 15.18, 16.51, 32.27, 54.48, 
57.63, 74.08, 74.51, 128.95, 129.40, 129.56, 139.51, 165.03, 171.64. υmax (thin film, cm
-1): 2944, 
1655, 1520, 1385, 1076, 695. MS: C15H20N2O4, m/z (ES
+) 293.15 [M+H]+. HRMS: Calculated 
C15H21N2O4 293.1501, found 293.1508. 
 
 
 
 
 
191 
 
(S)-tert-butyl 2-(1-(tert-butoxycarbonyl)cyclobutanecarboxamido)-3-hydroxypropanoate (173). 
H
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 171 (700 mg, 1.56 mM) was dissolved in 5 mL MeOH. 10% Pd/C (100 mg) was added and 
the suspension stirred under a hydrogen atmosphere at room temperature for 24 hours. The 
reaction mixture was filtered through a Celite® bed and the organic solvent removed in vacuo. 554 
mg of 173 was obtained as a white solid (1.54 mM, 99%). 
 Rf: 0.19 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, methanol-d4) ppm 1.46, (s, 9H, CH3 
Boc),  1.49 (s, 9H, CH3 tert-butyl),  1.87 - 2.05 (m, 2H, CH-CH2-CH  cyclobutane),  2.07 - 2.23 (m, 2H, 
CH-CH2-CH  cyclobutane),  2.64 (m, 2H, CH-CH2-CH  cyclobutane), 3.84 (m, J=3.58 Hz, 2H, ABq, 2H, 
CH2 serine), 4.35 (br. s., 1H, CH serine). 
13C NMR (75 MHz, methanol-d4) ppm 16.21, 28.34, 
28.79, 31.84, 32.75, 56.67, 60.14, 62.98, 80.92, 83.11, 175.03, 170.83, 176.34. υmax (thin film, cm
-
1): 3306, 2978, 1679, 1416, 1290, 1253, 1156, 1079, 845. [α]D
25 (CHCl3; c = 0.0048): + 15.32. MS: 
C17H30N2O6, m/z (ES
+) 359.22 [M+H]+. HRMS: Calculated C17H31N2O6 359.2182, found 359.2183. 
MP: 125.4˚C 
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(S)-2-(1-aminocyclobutanecarboxamido)-3-hydroxypropanoic acid (154). 
H
N
OH
OH
O
O
H2N
 
 173 (79 mg, 0.22 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 51 mg of 154 as a 
white solid in formate salt form (0.21 mM; 94%). 
 1H NMR (300 MHz, methanol-d4)  ppm 1.92 - 2.51 (m, 4H, CH2-CH2-CH2  cyclobutane), 
2.58 - 2.72 (m, 1H, CH2-CH-CH2 cyclobutane), 2.74 - 2.86 (m, 1H, CH2-CH-CH2 cyclobutane), 3.71 - 
3.99 (m, 2H, CH2 serine), 4.55 (m, 1H, CH serine), 8.25 (br. s., 1H, NH serine). 
13C NMR (75 MHz, 
methanol-d4) ppm 15.15, 16.43, 28.28, 55.10, 56.69, 63.03, 163.87, 176.05. υmax (thin film, cm
-1): 
3243, 2952, 1658, 1393, 759,495. MS: C8H14N2O4, m/z (ES
+) 203.10 [M+H+]. HRMS: Calculated 
C8H15N2O4 203.10, found 203.1032. 
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(S)-2-(1-(tert-butoxycarbonylcyclobutanecarboxamido)-3-((R)-2-(4-
isobutylphenyl)propanoyloxy)propanoic acid tert-butyl ester (174). 
H
N
O
O
O
O
N
H
O
O
O
 
 Ibuprofen (77) (208 mg, 1.01 mM), DCC (229 mg, 1.11 mM) and DMAP (123 mg, 1.01 mM) 
were dissolved in 5 mL anhydrous DCM under a nitrogen atmosphere at 0˚C and left to stir for 30 
minutes. 173 (380 mg, 1.06 mM) in 2 mL anhydrous DCM was added and reaction mixture stirred 
at room temperature for 72 hours. The solution was filtered and the solvent removed in vacuo. 
The resultant white solid was purified by flash column chromatography (a gradient of 2:8 to 7:3 
EtOAc: pet ether) to give 422 mg of 174 as a colourless oil (0.77 mM, 76%). 
 Rf: 0.63 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, methanol-d4) ppm 0.91 (d, J=6.6, 6H, 
Ibu-CH(CH3)2), 1.42 (s, 9H, CH3-Boc), 1.44 (Ibu-CH3), 1.46  (m, 9H, CH3 tert-butyl), 1.78 - 2.02 (m, 
3H, CH2 cyclobutane, Ibu-CH(CH3)2), 2.03-2.19 (m, 2H, CH2 cyclobutane), 2.47 (d, J=7.2 Hz, 2H, Ibu-
CH2CH), 2.57 - 2.72 (m, 2H, CH2  cyclobutane), 3.72 (q, J=7.16 Hz, 1H, Ibu-CHCH3) 4.38 - 4.55 (m, 
3H, CH2 serine, CH serine), 7.07 - 7.22 (m, 4H, Ibu-CH aromatic). 
13C NMR (75 MHz, methanol-d4)  
ppm 16.12, 19.20, 22.82, 28.21, 28.80, 31.52, 31.95, 46.05, 46.25, 54.13, 60.02, 64.78, 80.88, 
83.68, 128.36, 130.52, 139.03, 141.81, 156.95, 169.40, 175.70. υmax (thin film, cm
-1): 3303, 2974, 
1731, 1679, 1506, 1246, 1153, 845. MS: C30H46N2O7, m/z (ES
+) 574.34 [M+H]+. HRMS: Calculated 
C30H47N2O7 547.3383, found 547.3385. 
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(S)-2-(1-aminocyclobutanecarboxamido)-3-((R)-2-(4-isobutylphenyl)propanoyloxy)propanoic 
acid (175). 
H
N
O
OH
O
O
H2N
O
 
 174 (104 mg, 0.19 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 53 mg of 175 as a 
white solid in formate salt form (0.12 mM; 64%). 
 1H NMR (300 MHz, methanol-d4)  ppm 0.90 (d, J=6.6, 6H, Ibu-CH(CH3)2), 1.44 (d, J=7, 3H, 
(Ibu-CH3), 1.84 (dt, J=13.61, 6.66 Hz, 1H, Ibu-CH(CH3)2), 1.93-2.16 (m, 2H, CH2 cyclobutane), 2.19-
2.32 (m, 2H, CH2 cyclobutane), 2.44 (d, J=7 Hz, 2H, Ibu-CH2CH), 2.63 (m, 2H, CH2 cyclobutane), 
3.76 (q, J=6.84 Hz, 1H, Ibu-CHCH3), 4.40 - 4.62 (m, 3H, CH2 serine, CH serine), 7.04 - 7.27 (m, 4H, 
Ibu-CH aromatic), 8.41 (br. s., 1H, NH serine). 
13C NMR (300 MHz, METHANOL-d4)  ppm 15.22, 
18.72, 22.77, 30.51, 31.49, 46.04, 46.08, 53.23, 59.46, 65.66, 128.34, 130.44, 139.26, 141.78, 
176.37. υmax (thin film, cm
-1): 2953, 1732, 1662, 1393, 1164, 738, 495. MS: C21H30N2O5, m/z (ES
+) 
391.22 [M+H]+. HRMS: Calculated C21H31N2O5 391.2233, found 391.2239. 
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6.6.5. Homocycloleucine carrier (section 3.1). 
(S)-tert-butyl 3-(benzyloxy)-2-(1-(tert-butoxycarbonyl)cyclohexanecarboxamido)propanoate 
(177). 
H
N
O
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O
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 1-(tert-butoxycarbonyl)cyclohexanecarboxylic acid (176) (600 mg; 2.47 mM) and 50 (563 
mg; 2.24 mM) were dissolved in 5 mL anhydrous DMF under nitrogen  atmosphere at 0˚C. DIPEA 
(781 μL; 4.48 mM) was added dropwise and the reaction stirred for 10 minutes prior to the 
dropwise addition of DPPA (531 μL; 2.47 mM). The solution was stirred at 0˚C for 72 hours after 
which the solvent was removed in vacuo. The residue was dissolved in 20 mL EtOAc and washed 
with two 10 mL portions of NH4Cl, two 10 mL portions of Na2CO3 and one 20 mL portion of brine. 
The organic layer was dried over anhydrous MgSO4, filtered and the solvent removed in vacuo to 
give 1.029 g of 177 as a white solid (0.97 mM; 97%). 
 Rf: 0.55 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, methanol-d4)  ppm 1.22 - 1.37 (m, 2H, 
CH2-CH2-CH2-CH2-CH2 cyclohexane), 1.43 (s, 9H, CH3 Boc), 1.46 (s, 9H, CH3 tert-butyl), 1.59 (br. s., 
4H, CH2-CH2-CH2-CH2-CH2 cyclohexane), 1.76 (m, J=3.77 Hz, 2H, CH-CH2-CH2-CH2-CH cyclohexane), 
1.98 - 2.15 (m, 2H, CH-CH2-CH2-CH2-CH cyclohexane), 3.66 (m, J=9.42, 1H, CH2 serine), 3.66 (m, 
J=9.42, 1H, CH2 serine), 4.42 - 4.59 (m, 3H, CH serine, CH2-benzyl) 6.89 (s, 1H, NH 
homocycloleucine), 7.24 - 7.36 (m, 5H CH aromatic), 7.52 - 7.61 (m, 1H NH serine). 13C NMR (75 
MHz, methanol-d4) 
 
 ppm 22.37, 26.50, 28.28, 28.80, 32.53, 33.53, 54.72, 60.57, 71.06, 74.38, 
80.58, 83.21, 128.87, 129.39, 139.17, 156.67, 170.58, 177.70. υmax (thin film, cm
-1): 3403-3294, 
2975-2853, 1669, 1506, 1364, 1246, 1096, 754, 592. [α]D
25 (CHCl3; c = 0.0062): + 4.53. MS: 
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C26H40N2O6, m/z (ES
+) 477.30 [M+H+]. HRMS: Calculated C26H41N2O6 477.2965, found 477.2971. 
MP: 75.6˚C 
(S)-2-(1-aminocyclohexanecarboxamido)-3-(benzyloxy)propanoic acid (178). 
H
N
O
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 177 (155 mg, 0.33 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 117 mg of 178 as a 
white solid in formate salt form (0.32 mM; 98%). 
 1H NMR (300 MHz, methanol-d4)  ppm 1.43 - 1.91 (m, 8H, CH2 cyclohexane), 2.06 - 2.28 
(m, 2H, CH2 cyclohexane), 3.74 - 3.97 (m, 2H, CH2 serine), 4.52 - 4.58 (m, 3H, CH serine, CH2 
benzyl), 6.94 - 7.63 (m, 5H, CH aromatic), 8.37 - 8.47 (br. s., 1H, NH serine). 13C NMR (75 MHz, 
methanol-d4) 
 ppm 22.02, 22.09, 25.28, 32.30, 33.22, 50.80, 61.17, 71.49, 74.02, 128.70, 128.95, 
129.36, 139.54, 171.77. υmax (thin film, cm
-1): 3294, 2926, 2857, 1516, 1361, 1100, 734, 667, 572. 
MS: C17H24N2O4, m/z (ES
+) 321.18 [M+H]+. HRMS: Calculated C17H25N2O4 321.1814, found 
321.1817. 
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(S)-tert-butyl 2-(1-(tert-butoxycarbonyl)cyclohexanecarboxamido)-3-hydroxypropanoate (179). 
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 177 (732 mg, 1.54 mM) was dissolved in 5 mL MeOH. 10% Pd/C (100 mg) was added and 
the suspension stirred under a hydrogen atmosphere at room temperature for 24 hours. The 
reaction mixture was filtered through a Celite® bed and the organic solvent removed in vacuo. 587 
mg of 179 was obtained as a white solid (1.52 mM, 99%). 
 Rf: 0.41 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, methanol-d4)  ppm 1.21 - 1.40 (m, 2H, 
CH2-CH2-CH2-CH2-CH2 cyclohexane), 1.43 - 1.47 (m, 9H, CH3 Boc), 1.49 (s, 9H, CH3 tert-butyl), 1.63 
(m, 4H, CH2-CH2-CH2-CH2-CH2 cyclohexane), 1.77 (m, J=13.37, 3.01 Hz, 2H, CH-CH2-CH2-CH2-CH 
cyclohexane), 2.00 (br. s., 2H, CH-CH2-CH2-CH2-CH cyclohexane), 3.83 (ABq, J=3.96 Hz, 2H, CH2 
serine), 4.28 - 4.39 (m, 1H, CH serine), 6.84 - 6.93 (m, 1H, NH homocycloleucine) 7.58 (d, J=7.54 
Hz, 1H, NH serine). 13C NMR (75 MHz, methanol-d4) 
 
 ppm 22.40, 26.50, 28.27, 28.78, 32.78, 
33.40, 56.60, 60.50, 62.94, 80.69,  83.11, 156.84, 170.87, 177.78. υmax (thin film, cm
-1): 3406, 3336, 
2976-2898, 1684, 1507, 1157, 1073, 845, 568. [α]D
25 (CHCl3; c = 0.0041): + 15.42. MS: C19H34N2O6, 
m/z (ES+) 387.25 [M+H]+. HRMS: Calculated C19H35N2O6 387.2495, found 387.2497. MP: 119.5˚C 
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(S)-2-(1-aminocyclohexanecarboxamido)-3-hydroxypropanoic acid (156). 
H
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 179 (70 mg, 0.18 mM) was dissolved 5 mL 97% formic acid and refluxed at 100°C for three 
hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. The 
residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass wool 
and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 49 mg of 156 as a white 
solid in formate salt form (0.18 mM; 98%). 
 1H NMR (300 MHz, methanol-d4)  ppm 1.37 - 1.96 (m, 8H, CH2 cyclohexane), 1.98 - 2.15 
(m, 2H, CH2 cyclohexane), 3.89 (d, J=4.90, 2H, CH2 serine), 4.35 - 4.42 (m, 1H, CH serine). 
13C NMR 
(75 MHz, methanol-d4) 
 
 ppm 21.95, 25.30, 32.51, 32.91, 51.14, 61.33, 63.34, 172.25. υmax (thin 
film, cm-1): 2934, 1591, 1397, 719, 630, 533. MS: C10H18N2O4, m/z (ES
+) 231.13 [M+H+]. HRMS: 
Calculated C10H19N2O4 231.1345, found 231.1351. 
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(S)-2-(1-(tert-butoxycarbonylcyclohexanecarboxamido)-3-((R)-2-(4-
isobutylphenyl)propanoyloxy)propanoic acid tert-butyl ester (180). 
H
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O
 
 Ibuprofen (77) (229 mg, 1.16 mM), DCC (252 mg, 1.22 mM) and DMAP (135 mg, 1.11 mM) 
were dissolved in 5 mL anhydrous DCM under a nitrogen atmosphere at 0˚C and left to stir for 30 
minutes. 179 (450 mg, 1.16 mM) in 2 mL anhydrous DCM was added and reaction mixture stirred 
at room temperature for 72 hours. The solution was filtered and the solvent removed in vacuo. 
The resultant white solid was purified by flash column chromatography (a gradient of 2:8 to 7:3 
EtOAc: pet ether) to give 543 mg of 180 as a colourless oil (0.94 mM, 85%). 
 Rf: 0.74 (EtOAc:Pet ether 4:6). 
1H NMR (300 MHz, methanol-d4)  ppm 0.85 (d, J=6.6 Hz, 
6H, Ibu-CH(CH3)2), 1.22 - 1.30 (m, 2H, CH2-CH2-CH2-CH2-CH2 cyclohexane), 1.31-1.42 (m, 21H, CH3 
Boc, CH3 tert-butyl, Ibu-CH3), 1.45-1.69 (m, 4H, CH2 cyclohexane), 1.78 (dq, J=13.49, 6.81 Hz, 2H, 
CH-CH2-CH2-CH2-CH cyclohexane), 1.96 (d, J=10.7 Hz, 2H, CH-CH2-CH2-CH2-CH cyclohexane), 2.41 
(d, J=7.2 Hz, 2H, Ibu-CH2CH), 3.66 (q, J=7.16 Hz, 1H, Ibu-CHCH3), 4.32 (m, 2H, CH2 serine), 4.44 (m, 
1H, CH serine), 7.02 - 7.17 (m, 4H, Ibu-CH aromatic), 7.55 (br. s., 1H, NH serine). 13C NMR (75 MHz, 
methanol-d4) 
 ppm 19.01, 22.36, 22.47, 22.78, 26.47, 28.21, 28.83, 31.54, 46.08, 46.19, 54.02, 
61.18, 64.01, 80.66, 83.72, 128.41, 130.50, 138.99, 141.81, 169.54, 175.73. υmax (thin film, cm
-1): 
3419, 2931, 2867, 1736, 1367, 1151, 845, 668, 444. MS: C32H50N2O7, m/z (ES
+) 575.37 [M+H]+. 
HRMS: Calculated C32H51N2O7 575.3696, found 575.3701. 
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(S)-2-(1-aminocyclohexanecarboxamido)-3-((R)-2-(4-isobutylphenyl)propanoyloxy)propanoic 
acid (181). 
H
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 180 (193 mg, 0.34 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 147 mg of 181 as a 
white solid in formate salt form (0.32 mM; 94%). 
 1H NMR (300 MHz, methanol-d4)  ppm 0.91 (d, J=6.59 Hz, 6H, Ibu-CH(CH3)2), 1.32 - 1.92 
(m, 11H, CH2 cyclohexane, Ibu-CH3), 1.94 - 2.15 (m, 2H, CH-CH2-CH2-CH2-CH cyclohexane), 2.46 (d, 
J=7.16 Hz, 3H, Ibu-CH3), 3.65 - 3.80 (m, 1H, Ibu-CHCH3), 4.34 - 4.61 (m, 3H, CH2 serine, CH serine), 
6.94 - 7.35, (m, 4H, Ibu-CH aromatic). 
13C NMR (75 MHz, methanol-d4) 
 ppm 19.27, 22.14, 26.29, 
22.76, 31.52, 32.29, 33.87, 46.02, 46.10, 54.16, 60.43, 65.38, 128.39, 130.41, 138.83, 155.86, 
170.71, 177.25. υmax (thin film, cm
-1): 3307, 2933, 2866, 1579, 1507, 1396, 1169, 578. MS: 
C23H34N2O5, m/z (ES
+) 419.25 [M+H]+. HRMS: Calculated C23H35N2O5 419.2546, found 419.2547. 
201 
 
6.7 Synthesis of gemcitabine prodrugs (section 4.3.1) 
(S)-tert-butyl 2-((S)-2-(tert-butoxycarbonyl)propanethioamido)-4-(1-((2R,4R,5R)-3,3-difluoro-4-
hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-ylamino)-4-
oxobutanoaten (195). 
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 Gemcitabine (184) (200 mg, 1.16 mM), 57 (286 mg; 0.76 mM), DCC (172 mg, 0.84 mM) 
and DMAP (93 mg, 0.76 mM) were dissolved in 5 mL anhydrous DCM under a nitrogen 
atmosphere at 0˚C and stirred at room temperature for 72 hours. The solution was filtered and 
the solvent removed in vacuo. The resultant white solid was purified by flash column 
chromatography (a gradient of 3:7 to 4:1; EtOAc/pet ether) to give 338 mg of 195 as a cream solid 
(0.54 mM, 72%). 
 Rf: 0.31 (EtOAc:Pet ether 6:4). 
1H NMR (300 MHZ, methanol-d4)  ppm 1.35 (s, 3H, CH3 
alanine), 1.39 (s, 9H, CH3 Boc), 1.42 (s, 9H, CH3 tert-butyl), 3.12 (t, J=4.71 Hz, 2H, CH2 aspartate), 
3.77 (m, 1H, CH2-tetrahydrofuran 6), 3.87 - 3.98 (m, 2H, tetrahydrofuran 4, CH2-tetrahydrofuran 
6), 4.26 (td, J=12.15, 8.48 Hz, 1H, tetrahydrofuran 5), 4.34 - 4.45 (m, 1H,CH alanine), 5.31 (t, 
J=5.65 Hz,  1H, CH aspartate), 6.28 (m, J=7.16 Hz, 1H, tetrahydrofuran 3), 7.48 (d, J=7.54 Hz, 1H, 
cytosine 2), 8.38 (d, J=7.53 Hz, 1H, cytosine 1). 13C NMR (75 MHZ, methanol-d4)  ppm 20.30, 
26.62, 27.19, 27.99, 29.18, 37.00, 53.30, 54.03, 56.25, 58.64, 68.22, 68.52, 68.83, 79.17, 81.25, 
82.18, 82.25, 96.75, 118.93, 122.37, 144.53, 155.77, 156.03, 163.06, 168.53, 170.55, 206.16, 
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208.59. υmax (thin film, cm
-1): 3242, 2977, 2930, 1659, 1488, 1367, 1315, 1246, 1152, 1052, 785. 
MS: C25H37F2N5O9S, m/z (ES
+) 622.24 [M+H]+. HRMS: Calculated C25H38F2N5O9S 622.2358, found 
622.2362. MP: 119.3˚C 
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(S)-2-((S)-2-aminopropanethioamido)-4-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-
(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-ylamino)-4-oxobutanoic 
acid (194). 
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 195 (200 mg, 0.32 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 160 mg of 194 as a 
white solid in formate salt form (0.31 mM; 97%). 
 1H NMR (300 MHZ, methanol-d4)  ppm 1.42 (s, 3H, CH3 alanine), 3.26 (m, 2H, , CH2 
aspartate), 3.73 (dd, J=12.43, 3.01 Hz, 1H, CH2-tetrahydrofuran 6), 3.81 - 3.93 (m, 2H, 
tetrahydrofuran 4, CH2-tetrahydrofuran 6), 4.03 - 4.10 (m, 1H, CH2-tetrahydrofuran 6), 4.11 - 4.31 
(m, 1H, tetrahydrofuran 5), 4.38 - 4.50 (m, 1H, CH alanine), 5.20 - 5.36 (m, 1H, CH aspartate), 6.08 
- 6.25 (m, 2H, tetrahydrofuran 3), 7.56 (d, 1H, J=7.54 Hz, cytosine 2), 8.43 (d, J=7.54 Hz, 1H, 
cytosine 1). 13C NMR (75 MHZ, water-d2)  ppm 59.21, 68.81, 69.11, 80.23, 93.13, 141.82, 157.86, 
164.40. υmax (thin film, cm
-1): 3195, 1727, 1651, 1614, 1378, 1198, 1072, 892, 609. MS: 
C16H21F2N5O7S, m/z (ES
+) 466.12 [M+H]+. HRMS: Calculated C16H22F2N5O7S 466.1208, found 
466.1204. 
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(S)-4-((2R,3R,5R)-5-(4-amino-2-oxopyrimi 
din-1(2H)-yl)-4,4-difluoro-3-hydroxy-tetra 
hydrofuran-2-yl)methyl-1-tert-butyl-2-((S)-
2-tert-butoxycarbonylpropanethioamido) 
succinate (196).  
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4-amino-1-((2R,4R,5R)-4-(1-tert-butyl-2-((S)-
2-tert-butoxycarbonylpropanethioamido) 
succinate)-5-(methoxy)-(1-tert-butyl-2-((S)-
2-tert-butoxycarbonylpropanethioamido)  
succinate)-3,3-difluoro-tetrahydrofuran-2-
yl)pyrimidin-2(1H)-one (197). 
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 57 (200 mg; 0.76 mM) and HATU (318 mg; 0.84 mM) were dissolved in 5 mL anhydrous 
DMF under a nitrogen atmosphere at 0˚C. DIPEA (132 μL; 0.76 mM) was added dropwise and the 
solution stirred for 1 hour. Gemcitabine (184) (286 mg; 0.76 mM) dissolved in 2 mL anhydrous 
DMF was added and the solution stirred at room temperature for three days. The solvent was 
removed in vacuo and the residue purified by flash column chromatography (a gradient of 2:8 to 
7:3 EtOAc: pet ether) to give 16 mg of 196 as a cream solid (0.03 mM; 3%), 21 mg of 197 as a 
yellow oil (0.02 mM; 3%) and 245 mg of 195 as a cream solid (0.40 mM, 52%). 
And 
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(S)-4-((2R,3R,5R)-5-(4-amino-2-oxopyrimi din-1(2H)-yl)-4,4-difluoro-3-hydroxy-tetra hydrofuran-
2-yl)methyl-1-tert-butyl-2-((S)-2-tert-butoxycarbonylpropanethioamido) succinate (196). 
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 Rf: 0.27 (EtOAc: pet ether 6:4). 
1H NMR (300 MHZ, methanol-d4)  ppm1.34 (d, J=7.16 Hz, 
2H, CH3 alanine), 1.37 - 1.43 (m, 18H, CH3 Boc, CH3 tert-butyl), 3.01 (d, J=6.03 Hz, 2H, CH2 
aspartate), 4.08 (br. s., 1H, tetrahydrofuran 4), 4.13 - 4.28 (m, 1H, tetrahydrofuran 5), 4.33 - 4.52 
(m, 3H, CH2-tetrahydrofuran 6, CH alanine), 5.27 (t, J=6.03 Hz, 1H, CH aspartate), 5.94 (d, J=7.54 
Hz, 2H, cytosine 1), 6.21 (t, J=8.67 Hz, 2H, tetrahydrofuran 3), 7.56 (d, J=7.54 Hz, 2H, cytosine 2). 
13C NMR (75 MHZ, methanol-d4)  ppm 20.34, 26.61, 27.18, 34.44, 54.28, 56.28, 56.34, 62.18, 
77.88, 79.24, 82.42, 95.34, 121.99, 141.12, 155.78, 156.14, 166.05, 168.37, 169.73, 206.59. υmax 
(thin film, cm-1): 3337, 2978, 2933, 1731, 1065, 1504, 1368, 1153, 1038, 758, 629. MS: 
C25H37F2N5O9S, m/z (ES
+) 622.24 [M+H]+. HRMS: Calculated C25H38F2N5O9S 622.2358, found 
622.2357. MP: 123.5˚C                    
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4-amino-1-((2R,4R,5R)-4-(1-tert-butyl-2-((S)-2-tert-butoxycarbonylpropanethioamido)succinate) 
-5-(methoxy)-(1-tert-butyl-2-((S)-2-tert-butoxycarbonylpropanethioamido)succinate)-3,3-
difluoro-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (197). 
OO
F N
N
O
NH2
F
N
H
H
N
S
O
O
O
O
O
O
NH
HN
S
O
O
O
O
O
1
2
3
4
5
6
 
 Rf: 0.52 (EtOAc: pet ether 6:4). 
1H NMR (300 MHZ, methanol-d4)  ppm 1.34 (dd, J=6.78, 
2.26 Hz, 6H, CH3 alanine, CH3 alanine), 1.37 - 1.45 (m, 36H, CH3 Boc, CH3 Boc, CH3 tert-butyl, CH3 
tert-butyl), 3.00 (d, J=5.65 Hz, 2H, CH2 aspartate), 3.02 - 3.24 (m, 2H, CH2 aspartate), 4.33 - 4.48 
(m, 6H, tetrahydrofuran 5, CH2-tetrahydrofuran 6, CH alanine, CH alanine), 5.27 (q, J=5.90 Hz, 2H, 
CH aspartate, CH aspartate), 5.33 - 5.45 (m, 1H, tetrahydrofuran 4), 5.94 (d, J=7.54 Hz, 1H, 
cytosine 1), 6.27 (t, J=8.10 Hz, 1H, tetrahydrofuran 3), 7.58 (d, J=7.54 Hz, 1H, cytosine 2). 13C NMR 
(75 MHZ, methanol-d4)  ppm 20.41, 26.57, 26.64, 27.20, 33.96, 34.46, 53.95, 54.27, 56.32, 79.19, 
82.43, 82.55, 95.46, 155.73, 155.90, 166.06, 168.11, 168.37, 168.81, 169.71. υmax (thin film, cm
-1): 
3339, 2977, 2933, 1731, 1650, 1504, 1393, 1367, 1152, 1085, 1050, 783. MS: C41H63F2N7O14S2, m/z 
(ES+) 980.39 [M+H]+. HRMS: Calculated C41H64F2N7O14S2 980.3921, found 980.3922. 
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 (S)-4-(((2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-difluoro-3-hydroxy-tetrahydrofuran-
2-yl)methoxy)-2-((S)-2-aminopropanethioamido)-4-oxobutanoic acid (193). 
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 196 (13 mg, 0.02 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 10 mg of 193 as a 
white solid in formate salt form (0.02 mM; 96%). 
 1H NMR (300 MHZ, methanol-d4)  ppm  1.50 (d, J=6.78 Hz, 3H, CH3 alanine),  3.04 (m, 
J=5.27 Hz, 2H, CH2 aspartate), 4.03 (m, 1H, tetrahydrofuran 4),  4.24 (m, 1H, tetrahydrofuran 5),  
4.32 - 4.45 (m, 3H, CH2-tetrahydrofuran 6, CH alanine), 5.10 (m, J=7.16 Hz, 1H, CH aspartate),  
5.92 (d, J=7.54 Hz, 1H, cytosine 1), 6.18 (q, J=8.67 Hz, 2H, tetrahydrofuran 3), 7.58 (d, J=7.91 Hz, 
1H, cytosine 2). 13C NMR (75 MHZ, water-d2)  ppm 66.23, 68.84, 69.16, 69.33, 80.23, 84.13, 
84.56, 96.21, 118.65, 123.16, 142.36, 154.31, 164.29. υmax (thin film, cm
-1): 3270, 2977, 2928, 
1659, 1488, 1367, 1315, 1245, 1151, 1054, 785. MS: C16H21F2N5O7S, m/z (ES
+) 466.12 [M+H]+. 
HRMS: Calculated C16H22F2N5O7S 466.1208, found 466.1215. 
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4-amino-1-((2R,4R,5R)-4-(2-((S)-2-aminopropanethioamido)-4-oxobutanoic acid)-5-(methoxy)-
(2-((S)-2-aminopropanethioamido)-4-oxobutanoicacid)-3,3-difluoro-tetrahydrofuran-2-yl) 
pyrimidin-2(1H)-one (198). 
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 197 (17 mg, 0.02 mM) was dissolved in 5 mL 97% formic acid and refluxed at 100°C for 
three hours. The reaction was cooled to room temperature and the formic acid removed in vacuo. 
The residue was taken up in 5 mL distilled water, filtered through a pipette plugged with glass 
wool and extracted with 2 mL Et2O. The aqueous layer was lyophilised to give 12 mg of 198 as a 
white solid in formate salt form (0.02 mM; 97%). 
 1H NMR (300 MHZ, water-d2)  ppm  1.44 (dd, J=6.69, 2.54 Hz, 6H, CH3 alanine, CH3 
alanine),  2.84 - 3.11 (m, 4H, CH2 aspartate, CH2 aspartate), 4.14 - 4.26 (m, 2H, CH2-
tetrahydrofuran 6) 4.28 - 4.47 (m, 4H, tetrahydrofuran 5, CH alanine, CH alanine),  4.85 - 4.98 (m, 
2H, CH aspartate, CH aspartate),  5.20 - 5.35 (m, 1H, tetrahydrofuran 4), 5.97 (d, J=7.91 Hz, 1H, 
cytosine 1), 6.14 (t, J=6.40 Hz, 1H, tetrahydrofuran 3), 7.54 (d, J=7.16 Hz, 1H, cytosine 2). 13C NMR 
(75 MHZ, water-d2)  ppm 66.27, 68.51, 68.56, 68.72, 68.84, 69.16, 69.33, 80.17, 84.14, 84.62, 
95.93, 118.42, 122.86, 142.29, 154.28, 154.37, 164.26, 164.31. υmax (thin film, cm
-1): 3340, 2977, 
2931, 1645, 1494, 1366, 1282, 1246, 1149, 1047, 842. MS: C23H31F2N7O10S2, m/z (ES
+) 668.16 
[M+H]+. HRMS: Calculated C23H32F2N7O10S2 668.1620, found 168.1625. 
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